U.S. patent application number 12/914475 was filed with the patent office on 2011-02-17 for heterocyclic janus kinase 3 inhibitors.
This patent application is currently assigned to Astellas Pharma Inc.. Invention is credited to Hisao Hamaguchi, Keiko Hatanaka, Yasuyuki Higashi, Takayuki INOUE, Shigeki Kunikawa, Koichiro Mukoyoshi, Kazuo Nakai, Yutaka Nakajima, Hiroshi Sasaki, Shohei Shirakami, Fumie Takahashi, Akira Tanaka.
Application Number | 20110039822 12/914475 |
Document ID | / |
Family ID | 37944023 |
Filed Date | 2011-02-17 |
United States Patent
Application |
20110039822 |
Kind Code |
A1 |
INOUE; Takayuki ; et
al. |
February 17, 2011 |
HETEROCYCLIC JANUS KINASE 3 INHIBITORS
Abstract
The present invention provides a compound having an excellent
JAK3 inhibition activity and being useful as an active ingredient
of an agent for treating and/or preventing various immune diseases
including autoimmune diseases, inflammatory diseases, and allergic
diseases. As a result of studies on a novel condensed heterocyclic
derivative, the inventors have found that a compound having a
cross-linked structure has an excellent JAK3 inhibition activity,
and have completed the present invention. In other words, it is
verified that the compound according to the present invention has
an inhibition activity against JAK3 and is thus useful as an active
ingredient of an agent for treating or preventing diseases caused
by undesirable cytokine signal transmission (e.g., rejection during
organ/tissue transplantation, autoimmune diseases, multiple
sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic
dermatitis, Alzheimer's disease, and atherosclerotic disease), or
diseases caused by abnormal cytokine signal transmission (e.g.,
cancer and leukemia).
Inventors: |
INOUE; Takayuki; (Tokyo,
JP) ; Tanaka; Akira; (Tokyo, JP) ; Nakai;
Kazuo; (Tokyo, JP) ; Sasaki; Hiroshi; (Tokyo,
JP) ; Takahashi; Fumie; (Tokyo, JP) ;
Shirakami; Shohei; (Tokyo, JP) ; Hatanaka; Keiko;
(Tokyo, JP) ; Nakajima; Yutaka; (Tokyo, JP)
; Mukoyoshi; Koichiro; (Tokyo, JP) ; Hamaguchi;
Hisao; (Tokyo, JP) ; Kunikawa; Shigeki;
(Tokyo, JP) ; Higashi; Yasuyuki; (Tokyo,
JP) |
Correspondence
Address: |
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, L.L.P.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US
|
Assignee: |
Astellas Pharma Inc.
Chuo-ku
JP
|
Family ID: |
37944023 |
Appl. No.: |
12/914475 |
Filed: |
October 28, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12065234 |
Feb 28, 2008 |
|
|
|
PCT/JP2006/326327 |
Dec 25, 2006 |
|
|
|
12914475 |
|
|
|
|
Current U.S.
Class: |
514/210.18 ;
514/228.5; 514/232.8; 514/253.04; 514/275; 514/293; 514/300;
514/303; 544/105; 544/126; 544/331; 544/362; 544/58.2; 546/113;
546/118; 546/82 |
Current CPC
Class: |
A61P 17/06 20180101;
A61P 37/06 20180101; A61P 35/00 20180101; C07D 471/14 20130101;
C07D 519/00 20130101; A61P 37/00 20180101; A61P 35/02 20180101;
A61P 17/00 20180101; A61P 11/00 20180101; A61P 11/06 20180101; A61P
43/00 20180101; C07D 471/04 20130101; A61P 25/28 20180101; A61P
37/08 20180101; A61P 25/00 20180101; A61P 19/02 20180101; A61P
29/00 20180101; C07D 451/04 20130101 |
Class at
Publication: |
514/210.18 ;
546/113; 546/82; 544/362; 546/118; 544/331; 544/126; 544/58.2;
544/105; 514/300; 514/293; 514/253.04; 514/303; 514/275; 514/232.8;
514/228.5 |
International
Class: |
A61K 31/437 20060101
A61K031/437; C07D 471/04 20060101 C07D471/04; C07D 471/14 20060101
C07D471/14; A61K 31/496 20060101 A61K031/496; A61K 31/506 20060101
A61K031/506; A61K 31/5377 20060101 A61K031/5377; A61K 31/541
20060101 A61K031/541; A61P 17/06 20060101 A61P017/06; A61P 19/02
20060101 A61P019/02; A61P 37/00 20060101 A61P037/00; A61P 37/06
20060101 A61P037/06 |
Foreign Application Data
Date |
Code |
Application Number |
Dec 28, 2005 |
JP |
2005 378858 |
Claims
1. A condensed pyridine compound represented by formula (I), or a
pharmaceutically acceptable salt thereof: ##STR00866## wherein X is
N or CR.sup.3, M is (CH.sub.2).sub.m; m is 0 or 1, R.sup.1 is --H
or lower alkyl which may be substituted, R.sup.2 is --H or lower
alkyl which may be substituted, R.sup.3 is --H, halogen, or lower
alkyl which may be substituted, R.sup.41 is --H or heteroaryl which
may be substituted, R.sup.42 is polycyclic bridged cyclic
hydrocarbon having three rings or aza-bridged cyclic hydrocarbon,
each of which may be substituted, R.sup.5 is a group selected from
the group consisting of cyano, acyl, acylamino, lower alkyl, lower
alkenyl, --O-lower alkyl, 5- or 6-membered heterocycloalkyl, 5- or
6-membered heterocycloalkenyl, and 5-membered heteroaryl, each of
which may be substituted, provided that when R.sup.5 is 5-membered
heteroaryl, X is --CR.sup.3, or R.sup.41 and R.sup.5 may be linked
via a specific functional group to form bivalent group selected
from: ##STR00867## wherein R.sup.A is --H or acyl which may be
substituted, wherein "which may be substituted" in definitions of
R.sup.1, R.sup.2, R.sup.3, R.sup.41, R.sup.42 and R.sup.5,
consisting of the groups described in items (a) to (g), (a)
halogen; (b) --OH, --O--R.sup.Z, --O-phenyl, --OCO--R.sup.Z,
--OCONH--R.sup.Z, oxo (.dbd.O); (c) --SH, --S--R.sup.Z, --S-phenyl,
--S-heteroaryl, --SO--R.sup.Z, --SO-phenyl, --SO-heteroaryl,
--SO.sub.3H, --SO.sub.2--R.sup.Z, --SO.sub.2-phenyl,
--SO.sub.2-heteroaryl, sulfamoyl which may be substituted with one
or two R.sup.Z groups; (d) amino which may be substituted with one
or two R.sup.Z groups, --NHCO--R.sup.Z, --NHCO-phenyl,
--NHCO.sub.2--R.sup.Z, --NHCONH.sub.2, --NHCONH--R.sup.Z,
--NHSO.sub.2-phenyl, --NHSO.sub.2NH.sub.2, --NO.sub.2,
.dbd.N--O--R.sup.Z; (e) --CHO, --CO--R.sup.Z, --CO.sub.2H,
--CO.sub.2--R.sup.Z, carbamoyl which may be substituted with one or
two R.sup.Z groups, --CO-cyclic amino, --COCO--R.sup.Z, cyano; (f)
R.sup.Z; and (g) phenyl which may be substituted with one or more
groups selected from the substituents described in the above items
(a) to (f), 5- or 6-membered heterocycloalkyl, or 5- or 6-membered
heteroaryl; wherein R.sup.Z is cyano; --OH; and lower alkyl which
may be substituted with one to three groups selected from the group
consisting of --O-lower alkyl, --NH-lower alkyl, --CONH-lower
alkyl, 5- or 6-membered heterocycloalkyl, and 5- or 6-membered
heteroaryl.
2. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein R.sup.1 is --H or lower alkyl
which may be substituted with a group selected from the group
consisting of mono- or di-lower alkylamino and --O-lower alkyl,
R.sup.2 is --H or lower alkyl, R.sup.3 is --H or lower alkyl
substituted with a group selected from the group consisting of
halogen, mono- or di-lower alkylamino, and cyclic amino, R.sup.41
is --H or heteroaryl which may be substituted with cyano, R.sup.42
is polycyclic bridged cyclic hydrocarbon having three rings or
aza-bridged cyclic hydrocarbon, each of which may be substituted,
R.sup.5 is a group selected from the group consisting of cyano,
lower alkylcarbonyl, lower alkyloxycarbonyl, hydroxycarbonyl,
formyl, amidinooxycarbonyl, guanidinooxycarbonyl, guanidino,
carbamoyl, --C (.dbd.O)-5- or -6-membered heterocycloalkyl,
--C(.dbd.O)-5- or -6-membered heteroaryl, lower alkyl, lower
alkenyl, --O-lower alkyl, 5- or 6-membered heterocycloalkyl, and
5-membered heteroaryl, each of which may be substituted, provided
that when R.sup.5 is 5-membered heteroaryl, X is --CR.sup.3.
3. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein R.sup.42 is adamantyl or tropanyl,
each of which may be substituted.
4. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein R.sup.5 is carbamoyl, 5-membered
heteroaryl, lower alkylcarbonyl, each of which may be substituted
with NH.sub.2, hydroxymethyl or OH; or R.sup.41 and R.sup.5 may be
linked via a specific functional group to form (I-A); or R.sup.41
and R.sup.5 may be linked via a specific functional group to form
(I-B); or R.sup.41 and R.sup.5 may be linked via a specific
functional group to form (I-C), wherein R.sup.A is
--C(.dbd.O)--C(.dbd.O)NH-lower alkyl which may be substituted with
lower alkyloxy.
5. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein R.sup.5 is oxadiazole or
thiadiazole, each of which may be substituted.
6. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein R.sup.42 is polycyclic bridged
cyclic hydrocarbon having three rings and which may be
substituted.
7. The compound according to claim 6, or a pharmaceutical
acceptable salt thereof, wherein R.sup.42 is adamantyl which may be
substituted.
8. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein R.sup.42 is aza-bridged cyclic
hydrocarbon having three rings and which may be substituted.
9. The compound according to claim 8, or a pharmaceutical
acceptable salt thereof, wherein R.sup.42 is tropanyl which may be
substituted.
10. The compound according to claim 1, or a pharmaceutical
acceptable salt thereof, wherein X in the formula (I) is CH,
R.sup.1 is --H, R.sup.2 is --H or CH.sub.3, R.sup.41 is --H,
R.sup.42 is adamantyl or tropanyl and each of which may be
substituted with OH, R.sup.5 is carbamoyl which may be substituted
or --C(.dbd.O)-lower alkyl which may be substituted by OH.
11. The compound according to claim 10, or a pharmaceutical
acceptable salt thereof, wherein R.sup.5 is --CONH.sub.2 or
hydroxyacetyl.
12. A pharmaceutical composition comprising a compound according to
claim 1, or a pharmaceutical acceptable salt thereof, and a
pharmaceutically acceptable carrier or excipient.
13. A method of inhibiting janus kinase 3 activity in a patient
with diseases or conditions caused by undesirable cytokine signal
translations mediated by janus kinase 3, comprising administering
to said patient a compound according to claim 1, or a
pharmaceutical acceptable salt thereof.
14. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering an effective amount of a
compound according to claim 1, or a pharmaceutical acceptable salt
thereof, to said human being or animal in need thereof.
15. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises administering
an effective amount of a compound according to claim 1, or a
pharmaceutical acceptable salt thereof, to said human being or
animal in need thereof.
16. The method of claim 15, wherein said autoimmune disease is
rheumatoid arthritis.
17. The method of claim 15, wherein the autoimmune disease is
psoriasis.
18. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a compound, a stereoisomer
or a mixture of stereoisomers thereof, or a pharmaceutically
acceptable salt thereof, of a compound selected from the group
consisting of: ##STR00868## ##STR00869## ##STR00870## ##STR00871##
##STR00872## ##STR00873##
19. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a compound selected from the group consisting
of: ##STR00874## ##STR00875## ##STR00876## ##STR00877##
##STR00878## ##STR00879##
20. The method of claim 19, wherein said autoimmune disease is
rheumatoid arthritis.
21. The method of claim 19, wherein the autoimmune disease is
psoriasis.
22. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00880##
23. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00881##
24. The method of claim 23, wherein said autoimmune disease is
rheumatoid arthritis.
25. The method of claim 23, wherein the autoimmune disease is
psoriasis.
26. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00882##
27. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00883##
28. The method of claim 27, wherein said autoimmune disease is
rheumatoid arthritis.
29. The method of claim 27, wherein the autoimmune disease is
psoriasis.
30. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00884##
31. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00885##
32. The method of claim 31, wherein said autoimmune disease is
rheumatoid arthritis.
33. The method of claim 31, wherein the autoimmune disease is
psoriasis.
34. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00886##
35. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00887##
36. The method of claim 35, wherein said autoimmune disease is
rheumatoid arthritis.
37. The method of claim 35, wherein the autoimmune disease is
psoriasis.
38. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00888##
39. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00889##
40. The method of claim 39, wherein said autoimmune disease is
rheumatoid arthritis.
41. The method of claim 39, wherein the autoimmune disease is
psoriasis.
42. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00890##
43. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00891##
44. The method of claim 43, wherein said autoimmune disease is
rheumatoid arthritis.
45. The method of claim 43, wherein the autoimmune disease is
psoriasis.
46. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00892##
47. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00893##
48. The method of claim 47, wherein said autoimmune disease is
rheumatoid arthritis.
49. The method of claim 47, wherein the autoimmune disease is
psoriasis.
50. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00894##
51. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00895##
52. The method of claim 51, wherein said autoimmune disease is
rheumatoid arthritis.
53. The method of claim 51, wherein the autoimmune disease is
psoriasis.
54. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00896##
55. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00897##
56. The method of claim 55, wherein said autoimmune disease is
rheumatoid arthritis.
57. The method of claim 55, wherein the autoimmune disease is
psoriasis.
58. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00898##
59. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00899##
60. The method of claim 59, wherein said autoimmune disease is
rheumatoid arthritis.
61. The method of claim 59, wherein the autoimmune disease is
psoriasis.
62. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00900##
63. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00901##
64. The method of claim 63, wherein said autoimmune disease is
rheumatoid arthritis.
65. The method of claim 63, wherein the autoimmune disease is
psoriasis.
66. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00902##
67. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00903##
68. The method of claim 67, wherein said autoimmune disease is
rheumatoid arthritis.
69. The method of claim 67, wherein the autoimmune disease is
psoriasis.
70. A method for treating a rejection during organ/tissue
transplantation in a human being or animal in need thereof, wherein
said method comprises administering to said human being or animal
in need thereof an effective amount of a pharmaceutically
acceptable salt form of a compound having the formula:
##STR00904##
71. A method for treating an autoimmune disease in a human being or
animal in need thereof, wherein said method comprises
administrating to said human being or animal in need thereof an
effective amount of a pharmaceutically acceptable salt form of a
compound having the formula: ##STR00905##
72. The method of claim 71, wherein said autoimmune disease is
rheumatoid arthritis.
73. The method of claim 71, wherein the autoimmune disease is
psoriasis.
Description
[0001] The present invention relates to a novel condensed
heterocyclic compound and to a medicament containing the compound
as an active ingredient, and more particularly, to an immune
disease treating agent.
BACKGROUND ART
[0002] Janus kinase 3 (hereafter referred to as JAK3) is a family
of protein kinases. Although kinases in this family, other than
JAK3, are expressed in a wide range of tissues, JAK3 is expressed
locally in hematopoietic cells. This does not contradict the fact
that JAK3 plays an important role in signal transmission via
various receptors, such as interleukin (hereafter referred to as
IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21 by noncovalent
association with the common .gamma. chain (refer to nonpatent
literature 1 and nonpatent literature 2).
[0003] In XSCID (X-linked severe combined immunodeficiency) patient
populations, JAK3 protein level lowers or a genetic defect is found
in the common .gamma. chain. It is indicated that this problem
occurs because immunosuppression blocks JAK3-dependent signaling
pathways (refer to nonpatent literature 3 and nonpatent literature
4). Animal experiments have shown that JAK3 not only plays an
important role in maturation of B-lymphocytes and T-lymphocytes but
also in maintaining the function of T-cells. Hence, it is expected
that diseases involving proliferative abnormality of T-cells, such
as rejection during organ/tissue transplantation and autoimmune
diseases, can be treated by controlling immune response through
this mechanism.
[0004] On the other hand, a pyrrolopyridine derivative (patent
literature 1) represented by formula (A) or (B) or an
imidazopyridine derivative (refer to patent literature 2) is known
as a compound having JAK3 inhibition activity.
##STR00001##
(For the symbols in the formulas, refer to the corresponding patent
publications.)
[0005] Furthermore, a pyrrolopyrimidine derivative (refer to patent
literature 3, patent literature 4, patent literature 5, and patent
literature 6) represented by formula (C) is also known as a
compound having JAK3 inhibition activity.
##STR00002##
(For the symbols in the formula, refer to the corresponding patent
publications.)
[0006] Still further, a pyrrolopyridine derivative (refer to patent
literature 7) represented by formula (D) is also known as a
compound having JAK3 inhibition activity.
##STR00003##
(For the symbols in the formula, refer to the corresponding patent
publication.)
[0007] However, in any literature, the compound according to the
present invention is not disclosed specifically.
[Nonpatent literature 1] J. J. O'shea et al, Cell, Vol. 109
(suppl.), 5121, 2002 [Nonpatent literature 2] K. Ozaki et al,
Science, Vol. 298, p. 1630, 2002 [Nonpatent literature 3] P. Macchi
et al, Nature, Vol. 377, p. 65, 1995 [Nonpatent literature 4] S. M.
Russell et al, Science, Vol. 270, p. 797, 1995 [Patent literature
1] WO 2004/099205 [Patent literature 2] WO 2004/099204 [Patent
literature 3] WO 99/065908 [Patent literature 4] WO 99/065909
[Patent literature 5] WO 01/042246 [Patent literature 6] WO
02/000661 [Patent literature 7] WO 2006/069080
DISCLOSURE OF THE INVENTION
Problem to be Solved by the Invention
[0008] As a result of intensive studies with an object of providing
a useful pharmaceutical composition having JAK3 inhibition
activity, the inventors have found that a novel condensed
heterocyclic compound has an excellent JAK3 inhibition activity,
and have completed the present invention.
[0009] More specifically, the present invention provides a novel
condensed heterocyclic compound represented by the following
formula (I) or pharmaceutically acceptable salts thereof, and a
pharmaceutical composition containing the compound, more
particularly, a pharmaceutical composition serving as an agent for
treating and/or preventing autoimmune diseases, inflammatory
diseases, and allergic diseases.
[0010] The condensed heterocyclic compound is a condensed pyridine
compound represented by the following formula (I):
##STR00004##
wherein
[0011] X is N or CR.sup.3,
[0012] M is (CH.sub.2).sub.m; m is 0 or 1,
[0013] R.sup.1 is --H or lower alkyl which may be substituted,
[0014] R.sup.2 is --H or lower alkyl which may be substituted,
[0015] R.sup.3 is --H, halogen, or lower alkyl which may be
substituted,
[0016] R.sup.41 is --H or heteroaryl which may be substituted,
[0017] R.sup.42 is a bridged ring group which may be
substituted,
[0018] R.sup.5 is a group selected from the group consisting of
halogen, cyano, acyl, acylamino, lower alkyl, lower alkenyl,
--O-lower alkyl, 5- or 6-membered heterocycloalkyl, 5- or
6-membered heterocycloalkenyl, and 5-membered heteroaryl, each of
which may be substituted,
[0019] provided that when R.sup.5 is 5-membered heteroaryl, X is
--CR.sup.3,
[0020] or R.sup.41 and R.sup.5 may be linked via a specific
functional group to form bivalent groups shown below:
##STR00005##
[0021] wherein R.sup.A is --H or acyl which may be substituted, or
pharmaceutically acceptable salts thereof.
EFFECT OF THE INVENTION
[0022] The compound according to the present invention has JAK3
inhibition activity and is thus useful as an active ingredient of
an agent for treating and/or preventing diseases caused by
undesirable cytokine signal transmission (e.g., rejection during
organ/tissue transplantation, autoimmune diseases, asthma, atopic
dermatitis, Alzheimer's disease, and atherosclerotic disease), or
diseases caused by abnormal cytokine signal transmission (e.g.,
cancer and leukemia).
BEST MODES FOR CARRYING OUT THE INVENTION
[0023] The compound according to the present invention represented
by the formula (I) is characterized in its chemical structure that
the compound has a cross-linked amine and also has a skeleton in
which 5- and 6-membered heterocycles are condensed, just as in
1H-pyrrolo[2,3-b]pyridine, 1H-imidazo[4,5-b]pyridine, or
pyrazolo[1,5-a]pyrimidine, and is further characterized in
pharmacology that the compound has a JAK3 inhibition activity.
[0024] The present invention is described below in detail.
[0025] The term "alkyl" in this specification is a straight or
branched monovalent group.
[0026] The term "lower alkyl" in the specification is a
C.sub.1-C.sub.6 straight or branched alkyl and may include, such as
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl,
n-pentyl, neopentyl, and n-hexyl, preferably methyl, ethyl,
n-propyl, isopropyl, and isobutyl, and particularly preferably
methyl and ethyl.
[0027] The term "lower alkenyl" in the specification is
C.sub.2-C.sub.6 straight or branched alkenyl having a double bond
at each possible site, and may include, such as ethenyl (vinyl),
1-propenyl, 2-propenyl(allyl), 1-methylethen-1-yl, 1-buten-1-yl,
2-buten-1-yl, 3-buten-1-yl, 1-methyl-1-propen-1-yl,
2-methyl-1-propen-1-yl, 1-methyl-2-propen-1-yl, and
2-methyl-2-propen-1-yl, preferably 1-methyl-2-propen-1-yl.
[0028] The term "halogen" means fluoro, chloro, bromo, and iodo,
preferably fluoro.
[0029] The term "cycloalkyl" is a C.sub.3-C.sub.8 monovalent
nonaromatic carbocyclic group, and may partially have unsaturated
bonds or may be condensed with a benzene ring. However, bridged
cycloc hydrocarbons are excluded. Cycloalkyl may include, such as
cyclopropyl, cyclobutyl, cyclohexyl, cycloheptyl, cyclooctyl,
cyclobutenyl, cyclohexenyl, cyclooctadienyl, indanyl, and
tetrahydronaphthyl, preferably cyclohexyl.
[0030] The term "heterocycloalkyl" is a 5- to 6-membered
nonaromatic saturated heterocycle which may have one or more
identical or different hetero atoms selected from the group
consisting of nitrogen atoms, oxygen atoms, and sulfur atoms which
may be oxidized. Heterocycloalkyl may be partially unsaturated or
may be condensed with a benzene ring. However, aza-bridged cyclic
hydrocarbons are excluded. Heterocycloalkyl may include, such as
aziridinyl, azetidinyl, pyrrolizinyl, piperidinyl, homopiperidinyl,
morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl,
tetrahydrothiophenyl, dihydrooxazolyl, tetrahydropyranyl,
tetrahydrothiopyranyl, indolynyl, tetrahydroquinolyl,
tetrahydroisoquinolyl, and benzoxazinyl, preferably
dihydrooxazolyl, oxadiazolyl, oxadiazolanyl, and furanyl.
[0031] The term "heterocycloalkenyl" is partially substituted
"heterocycloalkyl".
[0032] The term "cyclic amino" is, among groups defined in
"heterocycloalkyl" a monovalent 3- to 8-membered nonaromatic cyclic
amine which has at least one nitrogen atom, and may have one or
more identical or different hetero atoms selected from the group
consisting of nitrogen atoms, oxygen atoms, and sulfur atoms which
may be oxidized, wherein at least one nitrogen atom has a bond.
However, aza-bridged cyclic hydrocarbons are excluded. The "Cyclic
amino" may include, such as aziridino, azetidino, pyrrolidino,
piperidino, homopiperidino, morpholino, thiomorpholino, and
piperazino.
[0033] The term "aryl" is an aromatic hydrocarbon group and may
include, phenyl, naphthyl, and indenyl, preferably C.sub.6-C.sub.10
aryl, and more preferably phenyl.
[0034] The term "heteroaryl" is a monovalent 5- or 6-membered
aromatic heterocyclic group having one or more identical or
different hetero atoms selected from the group consisting of
nitrogen, oxygen and sulfur atoms, and may be condensed with a
benzene ring. "Heteroaryl" may include, such as pyridyl, pyrazinyl,
pyrimidinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolyl,
oxazolyl, thiazolyl, thienyl, furyl, oxadiazolyl, thiadiazolyl,
quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indolyl,
indazolyl, quinoxalyl, and quinazolyl, preferably pyridazinyl,
pyridyl, pyrazinyl, thiazolyl, pyrazolyl, and thioxazolyl.
[0035] The term "bridged ring group" means "bridged cyclic
hydrocarbon" and "aza-bridged cyclic hydrocarbon".
[0036] The term "bridged cyclic hydrocarbon" is a saturated or
unsaturated, bicyclic or polycyclic bridged hydrocarbon group
having two or three C.sub.3-C.sub.10 cycloalkyl rings. Non bridged
cycloalkyls are excluded. Bicyclic or polycyclic C.sub.4-C.sub.16
bridged hydrocarbon groups are particularly preferable. Bridged
cyclic hydrocarbon may include, such as bicyclo[2.1.1]hexyl,
bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[4.3.1]decyl,
bicyclo[3.3.1]nonyl, bornyl, bornenyl, norbornyl, norbornenyl,
6,6-dimethylbicyclo[3.1.1]heptyl, tricyclobutyl, and adamantyl,
preferably adamantyl or bicyclo[2.2.1]heptyl.
[0037] The term "aza-bridged cyclic hydrocarbon" is a saturated or
unsaturated, bicyclic or polycyclic bridged hydrocarbon group in
which at least one of atoms constituting a ring is a nitrogen atom.
Non bridged heterocycloalkyls are excluded. Bicyclic or polycyclic
C.sub.4-C.sub.16 aza-bridged hydrocarbon groups are particularly
preferable. The term "aza-bridged cyclic hydrocarbon" may include,
such as azanorbornyl, quinuclidinyl, isoquinuclidinyl, tropanyl,
azabicyclo[3.2.1]octanyl, azabicyclo[2.2.1]heptanyl,
2-azabicyclo[3.2.1]octanyl, azabicyclo[3.2.1]octanyl,
azabicyclo[3.2.2]nonanyl, azabicyclo[3.3.0]nonanyl, and
azabicyclo[3.3.1]nonanyl, preferably tropanyl,
2-oxa-5-azabicyclo[2.2.1]hept-5-yl.
[0038] The term "acyl" means --C(=0)-lower alkyl,
--C(=0)-cycloalkyl, --C(=0)-heterocycloalkyl, --C(=0)-aryl,
--C(=0)-heteroaryl, carbamoyl, lower alkylcarbamoyl, --C(=0)-C
(=0)-NH-lower alkyl, cycloalkylcarbamoyl,
heterocycloalkylcarbamoyl, arylcarbamoyl, and heteroarylcarbamoyl.
The term "lower alkyl," "cycloalkyl," "heterocycloalkyl," "aryl"
and "heteroaryl" have the above-mentioned meanings.
[0039] X in the formula (I) is preferably CH.
[0040] R.sup.1 in the formula (I) is preferably --H. R.sup.2 in the
formula (I) is preferably --H or CH.sub.3, and more preferably
--H.
[0041] R.sup.41 in the formula (I) is preferably --H.
[0042] Furthermore, R.sup.42 in the formula (I) is preferably
adamantyl or tropanyl, each of which may be substituted with
OH.
[0043] Still further, R.sup.5 in the formula (I) is preferably
carbamoyl which may be substituted or --C(.dbd.O)-lower alkyl which
may have OH more preferably --CONH.sub.2 or hydroxyacetyl. As
another embodiment, R.sup.41 and R.sup.5 are bonded via a specific
functional group to form a cyclic structure described above,
preferably formula (I-C).
[0044] As substituents which are allowed to be used for "which may
be substituted" of R.sup.1, R.sup.2, R.sup.3, R.sup.41, R.sup.42
and/or R.sup.5, the following groups described in items (a) to (g)
are included: [0045] (a) Halogen [0046] (b) --OH, --O--R.sup.Z,
--O-phenyl, --OCO--R.sup.Z, --OCONH--R.sup.Z, oxo (.dbd.O); [0047]
(c) --SH, --S--R.sup.Z, --S-phenyl, --S-heteroaryl, --SO--R.sup.Z,
--SO-phenyl, --SO-heteroaryl, --SO.sub.3H, --SO.sub.2--R.sup.Z,
--SO.sub.2-phenyl, --SO.sub.2-heteroaryl, sulfamoyl which may be
substituted with one or two R.sup.Z groups. [0048] (d) Amino which
may be substituted with one or two R.sup.Z groups, --NHCO--R.sup.Z,
--NHCO-phenyl, --NHCO.sub.2--R.sup.Z, --NHCONH.sub.2,
--NHCONH--R.sup.Z, --NHSO.sub.2--R.sup.0, --NHSO.sub.2-phenyl,
--NHSO.sub.2NH.sub.2, --NO.sub.2, .dbd.N--O--R.sup.Z; [0049] (e)
--CHO, --CO--R.sup.Z, --CO.sub.2H, --CO.sub.2--R.sup.Z, carbamoyl
which may be substituted with one or two R.sup.Z groups,
--CO-cyclic amino, --COCO--R.sup.Z, cyano; [0050] (f) R.sup.Z
[0051] (g) Phenyl which may be substituted with one or more groups
selected from the substituents described in the above items (a) to
(f), 5- or 6-membered heterocycloalkyl, 5- or 6-membered
heteroaryl, 5- or 6-membered heterocycloaryl.
[0052] R.sup.Z in the above items (a) to (g) may include "cyano;
--OH; and lower alkyl which may be substituted with one to three
groups selected from the group consisting of --O-lower alkyl,
--NH-lower alkyl, --CONH-lower alkyl, 5- or 6-membered
heterocycloalkyl, and 5- or 6-membered heteroaryl."
[0053] The compound according to the present invention may include
geometric isomers and tautomeric isomers depending on the type of
constituent. In addition, the compound according to the present
invention may have asymmetric carbon atoms. All of the isomers,
including separated isomers and mixtures thereof, are included
within the scope of the present invention. Furthermore, labeled
compounds, that is, compounds obtained by substituting one or more
atoms of the compound according to the present invention with
radioactive or nonradioactive isotopes are also included in the
scope of the present invention.
[0054] Furthermore, the pharmaceutically acceptable prodrug of the
compound of the present invention is also included in the scope of
the present invention. The pharmaceutically acceptable prodrug is a
compound having a group that can be converted into amino group,
hydroxyl group, carboxyl group, etc. through solvolysis or under
physiological conditions. The groups described in Prog. Med., Vol.
5, p. 2157-2161, 1985 and "Iyakuhin No Kaihatsu (Development of
Medicines)" (Hirokawa Pub. Co., 1990), Vol. 7, Molecular Design, p.
163-198 are taken as examples of groups forming such prodrugs.
[0055] The compound represented by the formula (I) may form acid or
base addition salts. These salts should only be pharmaceutically
acceptable salts. More specifically, the salts may include an acid
addition salt with an inorganic acid (e.g., hydrochloric acid,
hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, and
phosphoric acid), and an acid addition salt with an organic acid
(e.g., formic acid, acetic acid, propionic acid, oxalic acid,
malonic acid, succinic acid, fumaric acid, maleic acid, lactic
acid, malic acid, tartaric acid, citric acid, methanesulfonic acid,
ethanesulfonic acid, aspartic acid, and glutamic acid); a salt with
an inorganic base (e.g., sodium, potassium, magnesium, calcium, and
aluminum), and a salt with an organic base (e.g., methylamine,
ethylamine, ethanolamine, lysine, and ornithine); an ammonium salt;
and the like.
[0056] Still further, various hydrates, solvates, and crystalline
polymorphic forms of the compound represented by the formula (I)
and salts thereof are also included in the scope of the present
invention.
Process
[0057] The compound according to the present invention can be
produced using the characteristics based on the basic skeleton or
the type of substituent thereof and by applying various known
synthesis methods. During the production, protecting the relevant
functional group with a suitable protective group or replacing the
relevant functional group with a group that can be easily converted
into the functional group at the stage of a starting substance or
an intermediate may occasionally be effective depending on the type
of the functional group in production technology. This kind of
functional group may include, for example, amino group, hydroxyl
group, and carboxyl group. The protective group for such a
functional group may include, for example, the protective groups
described in "Protective Groups in Organic Synthesis (3rd. Ed,
1999)" written by T. W. Greene and P. G. Wuts, and one of these
should only be selected and used as necessary depending on reaction
conditions. In this kind of method, the desired component can be
obtained by introducing the protective group, by carrying out
reaction and by eliminating the protective group as necessary, or
by converting the group into a desired group.
[0058] In addition, the prodrug of the compound according to the
present invention can be produced by introducing a specific group
or by carrying out reaction using the obtained compound represented
by the formula (I) at the stage of a starting substance or an
intermediate, just as in the case of the above-mentioned protective
group. The reaction can be carried out using methods known to those
skilled in the art, such as ordinary esterification, amidation, and
dehydration.
[0059] The abbreviations used in the specification are as
follows:
Pr: Preparation number; Ex: Example number; Structure: chemical
structure; Rf-Syn: the number of an Example to which reference was
made (the number indicates that the relevant compound was produced
according to a production method similar to that for producing the
compound described in the Example designated by the number.); HPLC:
high performance liquid chromatography; TLC: thin layer
chromatography; Rf: rate of flow value; Data: NMR data and/or MS
data; 1H-NMR: .sup.1H-nuclear magnetic resonance; MS: mass
spectrometry; (M+H)+:(M+H).sup.+; (M+Na)+:(M+Na).sup.+;
(M-H)-:(M-H).sup.-.
<First Process>
##STR00006##
[0060] [wherein R.sup.1, R.sup.2, R.sup.41, R.sup.42, R.sup.5, M
and X are as defined above, and Lv is a leaving group.]
[0061] In this process, the compound represented by the formula
(I-a) and having a leaving group is reacted with the amine
represented by the formula (I-b) to produce the compound according
to the present invention represented by the formula (I). The
leaving group Lv may include halogen (e.g., chloro and bromo);
sulfonyloxy (e.g., methanesulfonyloxy, ethanesulfonyloxy,
benzenesulfonyloxy, p-toluenesulfonyloxy,
p-nitrobenzenesulfonyloxy, and trifluorometanesulfonyloxy);
etc.
[0062] In Step 1, the leaving group Lv of the compound represented
by the formula (I-a) is substituted with amine. This reaction is
carried out under atmospheric pressure or under pressure in the
absence of a solvent or in the presence of a suitable solvent.
[0063] The solvent may include, for example, aromatic hydrocarbons
(e.g., toluene and xylene); ketones (e.g., acetone and methyl ethyl
ketone); ethers (e.g., diethylether, tetrahydrofuran(THF), dioxane,
and diethoxyethane); alcohols (e.g., methanol (MeOH), ethanol
(EtOH), 2-propanol (i-PrOH), and 1-butanol (n-BuOH)); halogenated
hydrocarbons (e.g., dichloromethane, 1,2-dichloroethane,
chloroform, and carbon tetrachloride); acetonitrile; aprotic
solvents (e.g., dimethylformamide (DMF),
1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone (NMP), and
dimethylsulfoxide (DMSO)); water; or a mixture of these. It is
preferable that the reaction is carried out in the presence of a
base, and the base may include, for example, alkaline carbonates
(e.g., sodium carbonate and potassium carbonate); alkaline
hydrogencarbonates (e.g., sodium hydrogencarbonate and potassium
hydrogencarbonate); alkoxides (e.g., sodium methoxide, sodium
ethoxide, and potassium t-butoxide); tertiary amines (e.g.,
triethylamine, tributylamine, and diisopropylethylamine); organic
bases (e.g., 1,8-diazabicyclo[5.4.0]undeca-7-ene, pyridine, and
lutidine). However, an excess amount of the compound (I-b) can also
be used. Although the reaction temperature differs depending on the
type of a starting compound and reaction conditions, the reaction
can usually be carried out at a temperature approximately ranging
from ambient temperature to the refluxing temperature of a solvent.
The reaction can also usually be carried out in the presence of a
base, such as sodium hydroxide and sodium carbonate, in an organic
solvent inert to the reaction, such as N,N-dimethylformamide and
N,N-dimethylacetamide, under ambient temperature to heating. In
addition, the amine represented by the formula (I-b) can also be
used as a salt thereof for the reaction.
[0064] Furthermore, microwave irradiation can also be carried out
under heating. Still further, the reaction can also be carried out
by a coupling reaction using a phosphorus reagent, such as
2-(di-t-butylphosphino)biphenyl, and a palladium catalyst, such as
palladium acetate, in the presence of a base, such as cesium
carbonate.
[0065] For the reaction, it is possible to use the methods
described in the Preparations) or the Example(s) of the present
specification or methods similar to those. The compound represented
by the formula (I-a) can thus be produced using known methods,
methods obvious to those skilled in the art, or the methods
described in the reference examples or the Examples of the present
specification or methods similar to those.
<Second Process>
##STR00007##
[0066] [wherein R.sup.1, R.sup.2, R.sup.41, R.sup.42, R.sup.5, M
and Lv are as defined forgoing.]
[0067] In this process, the nitropyridine compound represented by
the formula (2-a) is reacted with the amine represented by the
formula (2-b), and the leaving group at the second position is
substituted with the amine to derive the aminonitropyridine
compound represented by the formula (2-c). The derived compound is
used to produce the compound according to the present invention
represented by the formula (I-2).
[0068] The method used in Step 1 of the first process can be
incorporated in Step 2-1. The amine represented by the formula
(2-b) can also be used as a salt thereof for the reaction.
[0069] In Step 2-2 in the case that --R.sup.2 is --H, an imidazole
ring can be constructed by reacting an orthoformate, such as ethyl
orthoformate, in the presence of an acid catalyst. It is desirable
that the nitro group should be reduced before the orthoformate is
used for the reaction. Furthermore, the method to be used in the
case that the compound represented by the formula (I-2) wherein
--R.sup.2 is not --H is synthesized may include, for example, the
method in which the amino group of the compound represented by the
formula (2-c) is acylated in advance, the method in which
tetraalkylorthocarbonate or alkylisothiocyanate is used instead of
the orthoformate, and the method in which carboxylic acid or
carboxylic anhydride is reacted with a strong acid, such as
sulfonic acid. These actions can be carried out in a solvent inert
to the reactions or in the absence of a solvent, under ambient
temperature to heating or under heating and refluxing.
<Third Process>
##STR00008##
[0070] [wherein R.sup.1, R.sup.2, R.sup.42, X, and M are as defined
forgoing.]
[0071] In this process, the compound according to the present
invention represented by the formula (3-a) and having a carboxyl
group is used as a starting compound to produce the compound
according to the present invention represented by the formula
(I-3).
[0072] In Step 3, the carboxyl group of the compound represented by
the formula (3-a) is reacted with an azidation agent, such as
diphenylphosphoryl azide (DPPA) and sodium azide, to construct an
imidazolone ring according to the so-called Curtius rearrangement
reaction. It is advantageous that the reaction is carried out in
the presence of a base.
[0073] Usually, triethylamine, pyridine, etc. can be used as a
base, and the reaction can be carried out under ambient temperature
to heating or under heating and refluxing.
<Fourth Process>
##STR00009##
[0074] [wherein R.sup.1, R.sup.2, R.sup.42, M, X and Lv are as
defined forgoing.]
[0075] In this process, the carboxylic compound represented by the
formula (4-a) is reacted with the hydrazine derivative represented
by the formula (4-b) to obtain the hydrazide represented by the
formula (4-c). From the hydrazide, the compound according to the
present invention represented by the formula (I-4) is produced.
[0076] Step 4-1 can be carried out similarly to the reaction in
which the compound represented by the formula (4-a) and the
compound represented by the formula (4-b) are condensed by
amidation. The compound (4-a) can be used as a free acid for the
reaction, and the reactive derivative thereof can also be used for
the reaction. The reactive derivative of the compound (4-a) may
include an acid halide (e.g., acid chloride and acid bromide); an
ordinary ester (e.g., methyl ester, ethyl ester, and benzyl ester);
acid azide; an activated ester with N-hydroxybenzotriazole (HOBt),
p-nitrophenyl, or N-hydroxysuccinimide); a symmetric acid
anhydride; a mixed acid anhydride with a halocarboxylic acid alkyl
ester (e.g., alkyl halide carbonate), pivaloyl halide,
p-toluenesulfonic acid chloride, etc.; and a mixed acid anhydride,
such as a phosphoric acid-type mixed acid anhydride obtained by
reaction with diphenylphosphoryl chloride or N-methylmorpholine;
etc.
[0077] When the compound (4-a) is reacted in the form of a free
acid or reacted without isolating the activated ester, it is
preferable to use a condensing agent, such as
dicyclohexyl-carbodiimide (DCC), 1,1'-carbonylbis-1H-imidazole
(CDI), diphenylphosphoryl azide (DPPA), diethyphosphoryl
cyanide(DEPC), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDCI HCl).
[0078] The reaction is carried out in an organic solvent inert to
the reaction, such as halogenated hydrocarbons, aromatic
hydrocarbons, ethers, esters (e.g., ethyl acetate), acetonitrile,
DMF, and DMSO, under cooling, under cooling to ambient temperature,
or under ambient temperature to heating, although the conditions
differ depending on the reactive derivative or the condensing agent
to be used.
[0079] In order to smoothly advance the reaction, it is
occasionally advantageous that an excess amount of the compound
(4-b) is used for the reaction or the reaction is carried out in
the presence of a base, such as N-methylmorpholine, trimethylamine,
triethylamine, diisopropylethylamine, N,N-dimethylaniline,
pyridine, 4-(N,N-dimethylamino)pyridine, picoline, and lutidine.
Pyridine can also be used as a solvent.
[0080] The method used in Step 1 of the first process can be
incorporated in Step 4-2.
<Fifth Process>
##STR00010## ##STR00011##
[0081] [wherein R.sup.1, R.sup.2, R.sup.41, R.sup.42 and M are as
defined above, R' is suitable substituent. The carboxylic acid
represented by the formula (5-f) is a marketed product or can be
prepared using a marketed product.]
[0082] In step 5-2, step 5-4 and step 5-6, a reaction for
constructing an oxadiazole ring at R.sup.5 is carried out.
[0083] In Step 5-1, a reaction for synthesizing an acid hydrazide
from the carboxylic acid represented by the formula (5-a) is
carried out. Furthermore, the intermediate represented by the
formula (5-c) can also be synthesized from the carboxylic acid
represented by the formula (5-a). The reaction in Step 4-1 can be
incorporated in each of these reactions.
[0084] In Step 5-2, Step 5-4, and step 5-6, a reaction for
constructing an oxadiazole ring is carried out under ambient
temperature to heating. An organic base may be added to advance the
reaction.
[0085] In Step 5-5, the aromatic nitrile compound represented by
the formula (5-d) is reacted with hydroxylamine to obtain
hydroxyamidine represented by the formula (5-e). The obtained
hydroxyamidine is reacted with the carboxylic acid represented by
the formula (5-f) to produce the compound according to the present
invention represented by the formula (I-53).
[0086] In Step 5-5, the reaction with free hydroxylamine or
hydroxylamine hydrochloride is carried out in the presence of a
base, whereby the hydroxyamidine represented by the formula (5-e)
can be produced.
[0087] The reaction can be carried out in a solvent inert to the
reaction. The solvent may include, for example, alcohols (e.g.,
methanol (MeOH), ethanol (EtOH), and 2-propanol (iPrOH)); aromatic
hydrocarbons (e.g., toluene and xylene); ethers (e.g.,
diethylether, tetrahydrofuran (THF), dioxane, and diethoxyethane);
halogenated hydrocarbons (e.g., dichloromethane,
1,2-dichloroethane, chloroform, and carbon tetrachloride); aprotic
solvents (e.g., DMF, 1,3-dimethyl-2-imidazolidinone, and DMSO);
water; or a mixture of these. Usually, alcohols are used for the
reaction. In the case that hydroxylamine hydrochloride is used for
the reaction as described above, it is preferable that the reaction
is carried out in the presence of a base, and the base may include,
for example, alkaline carbonates (e.g., sodium carbonate and
potassium carbonate); alkaline hydrogencarbonates (e.g., sodium
hydrogencarbonate and potassium hydrogencarbonate); alkoxides
(e.g., sodium methoxide, sodium ethoxide, and potassium
t-butoxide); tertiary amines (e.g., triethylamine and
diisopropylethylamine); and organic bases (e.g.,
1,8-diazabicyclo[5.4.0]undeca-7-ene, pyridine, and lutidine).
Although the reaction temperature differs depending on the type of
a starting compound and reaction conditions, the reaction can
usually be carried out at a temperature approximately ranging from
ambient temperature to the refluxing temperature of a solvent. The
reaction can usually be carried out in the presence of a base, such
as sodium carbonate, in an organic solvent inert to the reaction,
such as methanol, under ambient temperature to heating.
[0088] Step 5-6 consists of two stages: acylation of hydroxyamidine
and subsequent cyclization. The intermediate producing method in
Step 4-1 can be incorporated in the acylation in the first stage.
However, the reaction is usually carried out under ambient
temperature to heating, or under heating and refluxing. The
cyclization in the second stage can be carried out by isolating and
purifying an acyl and by heating the acyl in an organic solvent
inert to the reaction, such as ethanol and dioxane, in the presence
or absence of a base. The base may include an inorganic base, such
as sodium acetate, or an organic base, such as
diisopropylethylamine. The reaction consisting of the two stages
can be carried out by one operation by performing ordinary
acylation and then by directly heating the reaction mixture or by
carrying out reaction under microwave irradiation.
[0089] The solvent may include, for example, aromatics (e.g.,
toluene, xylene, and pyridine); ethers (e.g., diethylether,
tetrahydrofuran, dioxane, and diethoxyethane); halogenated
hydrocarbons (e.g., dichloromethane, 1,2-dichloroethane,
chloroform, and carbon tetrachloride); acetonitrile; aprotic
solvents (e.g., DMF, N,N-dimethylacetamide (DMA),
1,3-dimethyl-2-imidazolidinone, N-methylpyrrolidone (NMP), and
DMSO)); water; or a mixture of these. Although the reaction
temperature differs depending on the type of a starting compound
and reaction conditions, the reaction can be carried out under
ambient temperature to heating.
<Sixth Process>
##STR00012##
[0090] [wherein R.sup.1, R.sup.2, R.sup.42, M, m and Lv are as
defined above; R'' is suitable substituent.]
[0091] In Step 6, in the case that the compound represented by the
formula (6-a) is reacted with the primary amine represented by the
formula (6-b), after ipso substitution, the oxadiazole ring is
opened to construct an aminopyrazolone ring. The reaction
conditions described in Step 1 can be incorporated herein as the
reaction conditions. The reaction can be carrying out under ambient
temperature to refluxing temperature.
[0092] In addition, some of the compounds represented by the
formula (I) can also be produced from the compound according to the
present invention produced as described above by appropriately
combining processes usually used by those skilled in the art, such
as known alkylation, acylation, substitution, oxidation, reduction,
hydrolysis, deprotection, halogenation, and Mannich reaction. For
example, when the compound according to the present invention
wherein --R.sup.5 is --CO.sub.2H is produced from the compound
according to the present invention wherein R.sup.5 is lower
alkyloxycarbonyl, hydrolysis can be used referring to the method
described in "Jikken Kagaku Koza (Courses in Experimental
Chemistry) (5th Ed., 2003)." Moreover, when the compound according
to the present invention wherein R.sup.5 is halogen is produced
from the compound according to the present invention wherein both
R.sup.3 and R.sup.5 are --H, halogenation can be used referring to
the method described in "Jikken Kagaku Koza (Courses in
Experimental Chemistry) (5th Ed., 2003)." Still further, when the
compound according to the present invention wherein R.sup.3 is a
lower alkyl substituted with a group selected from the group
consisting of mono (lower alkyl)amino, di(lower alkyl)amino, and
cyclic amino is produced from the compound according to the present
invention wherein R.sup.3 is --H, the Mannich reaction can be used
referring to the methods described in "Jikken Kagaku Koza (Courses
in Experimental Chemistry) (5th Ed., 2003)"; C. Mannich et al.,
Arch. Pharm., 1912, Vol. 250, p. 647; J. H. Brewster et al., Org.
React., 1953, Vol. 7, p. 99; F. F. Blicke, Org. React., 1942, Vol.
1, p. 303; K. W. Merz et al., Pharmazie, 1956, Vol. 11, p. 505;
etc.
[0093] The processes capable of being usually used by those skilled
in the art are not only used for the compound according to the
present invention but can also be used for intermediates formed
during production. The processes can also advance to subsequent
processes.
[0094] The compound produced as described above is in a free form
or subjected to salt-forming processing using a conventional method
and isolated and purified as a salt thereof. The isolation and
purification are carried out by performing ordinary chemical
operations, such as extraction, concentration, evaporation,
crystallization, filtration, recrystallization, and various types
of chromatography.
[0095] Various types of isomers can be isolated by utilizing the
difference in physicochemical properties between the isomers using
a conventional method. For example, a racemic mixture can be
converted into an optically pure isomer using a general racemic
resolution method, such as the method in which the racemic mixture
is converted into a diastereomer salt with a general
optically-active acid, such as tartaric acid, and subjected to
optical resolution. Furthermore, the diastereo mixture can be
separated by fractional crystallization or various types of
chromatography, for example. Still further, the optically-active
compound can also be produced using a suitable optically-active
material.
[0096] The pharmacological activity of the compound according to
the present invention was verified by carrying out the following
test.
Test Example 1
JAK3 Inhibition Test
[0097] The JAK3 inhibition test was performed as described below
according to the method of Okimoto et al.
(1) Preparation of Human JAK3
[0098] Purified human JAK3 kinase domain was purchased from Carna
Biosciences, Inc. (Kobe, Japan). This is obtained as described
below. His-tag (41 kDa) was attached to the N-terminal of the
796-1124 (C-terminal) fragment of the human JAK3 protein (accession
number #NM.sub.--000215), expressed using baculovirus expression
system, and then purified using Ni-NTA affinity column
chromatography.
(2) Measurement of JAK3 Activity
[0099] As substrates, Biotin-Lyn-Substrate-2 (Biotin-XEQED EPEGF
YFEWL EPE, X=.epsilon.-Acp (PEPTIDE INSTITUTE, INC., Osaka, Japan)
and ATP were used. As an assay buffer, 15 mM Tris-HCl pH 7.5
containing 0.01% Tween 20 and 2 mM DTT was used. Normally, 20 .mu.L
of a substrate solution (an assay buffer containing 627 nM
Biotin-Lyn-Substrate-2, 20 .mu.M ATP, and 25 mM MgCl.sub.2), an
assay buffer containing 10 .mu.L of a substance to be tested, and
20 .mu.L of an enzyme solution were added to a microplate, and
stirred sufficiently.
[0100] After incubation at ambient temperature for one hour, the
plate was washed with a cleaning buffer (50 mM Tris-HCl pH 7.5, 150
mM NaCl, 0.02% Tween 20), and a blocking buffer (a cleaning buffer
containing 0.1% bovine serum albumin) was added to the plate. After
incubation at ambient temperature for 30 minutes, the blocking
buffer was removed, and an HRP-PY-20 solution (obtained by diluting
HRP-PY-20 solution with the blocking buffer 500 times) was added.
After incubation at ambient temperature for 30 minutes, the plate
was washed four times, and a TMB substrate solution (Sigma) was
added to the plate. After incubation at ambient temperature for
four minutes, 1M sulfuric acid was added to stop the reaction.
Enzyme activity was measured as absorbance at 450 nm. The efficacy
of the test compound as a JAK3 inhibitor was expressed as an
IC.sub.50 value.
[0101] The IC.sub.50 values described below are results obtained in
the test.
[0102] The results of those tests are shown in the Table 1. Table
1: JAK3 inhibitory activity of the compound of the present
invention.
TABLE-US-00001 TABLE 1 Ex IC.sub.50 (nM) Ex IC.sub.50 (nM) 29 2.3
379 1.2 32 1.9 384 0.28 33 2.1 405 0.65 34 0.17 426 2.3 121 1.1 434
0.86 122 0.43 484 0.31 133 4.4 498 1.3 143 0.69 543 0.33
[0103] It is verified that the compound according to the present
invention has inhibition activity against JAK3 and is useful as an
active ingredient of an agent for treating or preventing diseases
caused by undesirable cytokine signal transmission (e.g., rejection
during organ/tissue transplantation, autoimmune diseases, asthma,
atopic dermatitis, Alzheimer's disease, and atherosclerotic
disease), or diseases caused by abnormal cytokine signal
transmission (e.g., cancer and leukemia).
[0104] In addition, on the basis of the JAK3 inhibition activity,
the compound according to the present invention is useful for
treating and/or preventing the following diseases.
[0105] The pharmaceutical composition of the present invention
comprising JAK3 inhibitor such as the compound (I) is useful as a
therapeutic or prophylactic agent for diseases or conditions caused
by undesirable cytokine signal transduction, such as rejection
reaction in organ/tissue transplantation, autoimmune diseases,
asthma, atopic dermatitis, Alzheimer's disease, atherosclerosis,
tumors, myelomas, and leukemia as exemplified below:
rejection reactions by transplantation of organs or tissues such as
the heart, kidney, liver, bone marrow, skin, cornea, lung,
pancreas, islet, small intestine, limb, muscle, nerve,
intervertebral disc, trachea, myoblast, cartilage, etc.; and
graft-versus-host reactions following bone marrow transplantation;
autoimmune diseases such as rheumatoid arthritis, systemic lupus,
erythematosus, Hashimoto's thyroiditis, multiple sclerosis,
myasthenia gravis, type I diabetes and complications from diabetes,
etc.
[0106] Furthermore, pharmaceutical preparations of the JAK3
inhibitor, such as the compound (I), are useful for the therapy or
prophylaxis of the following diseases.
[0107] Inflammatory or hyperproliferative skin diseases or
cutaneous manifestations of immunologically-mediated diseases
(e.g., psoriasis, atopic dermatitis, contact dermatitis, eczematoid
dermatitis, seborrheic dermatitis, lichen planus, pemphigus,
bullous penphigoid, epidermolysis bullosa, urticaria, angioedema,
vasculitides, erythema, dermal eosinophilia, lupus erythematosus,
acne, alopecia greata, etc.);
autoimmune diseases of the eye (e.g., keratoconjunctivitis, vernal
conjunctivitis, uveitis associated with Behcet's disease,
keratitis, herpetic keratitis, conical keratitis, corneal
epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren's
ulcer, scleritis, Grave's ophthalmopathy, Vogt-Koyanagi-Harada
syndrome, keratoconjunctivitis sicca (dry eye), phlyctenule,
iridocyclitis, sarcoidosis, endocrine ophthalmopathy, etc.);
reversible obstructive airways diseases [asthma (e.g., bronchial
asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust
asthma, etc.), particularly chronic or inveterate asthma (e.g.,
late asthma, airway hyper-responsiveness, etc.), bronchitis, etc.];
mucosal or vascular inflammations (e.g., gastric ulcer, ischemic or
thrombotic vascular injury, ischemic bowel diseases, enteritis,
necrotizing enterocolitis, intestinal damages associated with
thermal burns, leukotriene B4-mediated diseases, etc.); intestinal
inflammations/allergies (e.g., coeliac diseases, proctitis,
eosinophilic gastroenteritis, mastocytosis, Crohn's disease,
ulcerative colitis, etc.); food-related allergic diseases with
symptomatic manifestation remote from the gastrointestinal tract
(e.g., migrain, rhinitis, eczema, etc.); autoimmune diseases and
inflammatory conditions (e.g., primary mucosal edema, autoimmune
atrophic gastritis, premature menopause, male sterility, juvenile
diabetes mellitus, pemphigus vulgaris, pemphigoid, sympathetic
ophthalmitis, lens-induced uveitis, idiopathic leukopenia, active
chronic hepatitis, idiopathic cirrhosis, discoid lupus
erythematosus, autoimmune orchitis, arthritis (e.g., arthritis
deformans, etc.), polychondritis, etc.); allergic
conjunctivitis.
[0108] Therefore, the pharmaceutical composition of the present
invention is useful for the therapy and prophylaxis of liver
diseases [e.g., immunogenic diseases (e.g., chronic autoimmune
liver diseases such as autoimmune hepatic diseases, primary biliary
cirrhosis, sclerosing cholangitis, etc.), partial liver resection,
acute liver necrosis (e.g., necrosis caused by toxins, viral
hepatitis, shock, anoxia, etc.), hepatitis B, non-A/non-B
hepatitis, hepatocirrhosis, hepatic failure (e.g., fulminant
hepatitis, late-onset hepatitis, "acute-on-chronic" liver failure
(acute liver failure on chronic liver diseases, etc.), etc.),
etc.]. Pharmaceutical preparations of the JAK3 inhibitor, such as
the compound (I), either from alone or in combination with one or
more additional agents which may include but are not limited to
cyclosporin A, tacrolimus, sirolimus, everolimus, micophenolate
(e.g. Cellcept.RTM., Myfortic.RTM., etc.), azathioprine, brequinar,
leflunomide, sphingosine-1-phosphate receptor agonist (e.g.
fingolimod, KRP-203, etc.), LEA-29Y, anti-IL-2 receptor antibody
(e.g. daclizumab, etc.), anti-CD3 antibody (e.g. OKT3, etc.),
Anti-T cell immunogloblin (e.g. AtGam, etc.) aspirin, CD28-B7
blocking molecules (e.g. Belatacept, Abatacept, etc.), CD40-CD154
blocking molecules (e.g. Anti-CD40 antibody, etc.), protein kinase
C inhibitor (e.g. AEB-071, etc.), acetaminophen, ibuprofen,
naproxen, piroxicam, and anti inflammatory steroid (e.g.
prednisolone or dexamethasone) may be administrated as part of the
same or separate dosage forms, via the same or different routes of
administration, and on the same or different administration
schedules according to standard pharmaceutical practice.
[0109] The pharmaceutical composition containing one or two or more
kinds of the compound represented by the formula (I) or
pharmaceutically acceptable salts thereof as an active ingredient
can be prepared using carriers, excipients, and other additives
usually used for pharmaceutical preparation.
[0110] Therapeutic administration can be accomplished either by
oral administration via tablets, pills, capsules, granules,
powders, solutions, etc., or parenteral administration via
intravenous or intramascular injections, suppositories, transdermal
agents, transnasal agents, inhalers, etc. The dose of the compound
is determined appropriately in consideration of the symptoms, age,
sex, and the like of each patient to be treated. Usually, in the
case of oral administration, a daily dose of approximately 0.001 to
100 mg/kg of the compound can be administered one or two to four
times per day for an adult patient. When intravenous administration
is required depending on symptoms, a dose of 0.0001 to 10 mg/kg of
the compound can usually be administered one to multiple times per
day for an adult patient. In the case of inhalation, a dose of
0.0001 to 1 mg/kg of the compound can usually be administered one
to multiple times per day for an adult patient.
[0111] The solid composition for use in the oral administration
according to the present invention is used in the form of tablets,
powders, granules, etc. In such a solid composition, one or more
active ingredients are mixed with at least one inactive excipient,
such as lactose, mannitol, glucose, hydroxypropyl cellulose,
microcrystalline cellulose, starch, polyvinyl pyrrolidone, and
magnesium aluminometasilicate. According to a usual method, the
composition may contain inactive additives, such as a lubricant
(e.g., magnesium stearate), a disintegrating agent (e.g.,
carboxymethyl starch sodium), and a solubilization assisting agent.
If necessary, tablets or pills may be coated with sugar or a film
of a gastric or enteric coating substance.
[0112] The liquid composition for oral administration contains
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups, or elixirs, and also contains a generally used inert
diluent, such as purified water or ethanol. In addition to the
inert diluent, the composition may also contain auxiliary agents,
such as a solubilization assisting agent, a moistening agent, and a
suspending agent, as well as sweeteners, flavors, aromatics, and
antiseptics.
[0113] The injections for parenteral administration contain aseptic
aqueous or non-aqueous solutions, suspensions, or emulsions. The
diluent for use in the aqueous solutions may include, for example,
distilled water for injection use and physiological saline. The
diluent for use in the non-aqueous solutions may include, for
example, propylene glycol, polyethylene glycol, plant oil (e.g.,
olive oil), alcohol (e.g., ethanol), and polysorbate 80 (official
name). Such a composition may further contain additive agents, such
as a tonicity agent, an antiseptic, a moistening agent, an
emulsifying agent, a dispersing agent, a stabilizing agent, and a
solubilization assisting agent. These compositions are sterilized
by filtration through a bacteria retaining filter, blending of a
germicide, or irradiation. Furthermore, they may also be produced
in the form of sterile solid compositions and dissolved or
suspended in sterile water or a sterile solvent for injection use
prior to their use.
[0114] The transmucosal agents, such as inhalers and transnasal
agents, are used in the form of solid, liquid or semisolid and can
be produced according to conventional known methods. For example,
excipients (e.g., lactose and starch), pH adjusters, antiseptics,
surface active agents, lubricants, stabilizers, thickeners, etc.
may also be added as necessary. For administration, suitable
devices for inhalation or insufflation can be used. For example,
using known devices and sprayers, such as measuring inhalation
devices, the compound can be administered independently or in the
form of prescribed mixture powders. Furthermore, the compound
combined with pharmaceutically acceptable carriers can also be
administered in the form of solutions or suspensions. Dry powder
inhalers and the like may be devices for single or multiple
administrations, and dry powders or capsules containing powders can
also be used. Still further, the devices may be in the form of a
pressure aerosol spray or the like that uses a suitable ejection
agent, such as chlorofluoroalkane or hydrofluoroalkane, or a
suitable gas, such as carbon dioxide.
[0115] The drug for external use may include ointments, plasters,
creams, jellies, patches, sprays, lotions, eye-drops, eye
ointments, etc. The drug contains generally used ointment bases,
lotion bases, aqueous or non-aqueous solutions, suspensions,
emulsions, etc. The ointment bases or lotion bases may include, for
example, polyethylene glycol, carboxyvinal polymer, white Vaseline,
bleached bee wax, polyoxyethylene hydrogenated castor oil, glyceryl
monostearate, stearyl alcohol, cetyl alcohol, lauromacrogol, and
sorbitan sesquioleate.
Examples
[0116] Although the present invention is described below
specifically by way of Examples, the present invention is not
limited by these Examples at all. Starting compounds being used in
Examples include novel substances, and the methods for producing
such starting compounds from known compounds are described by way
of Preparations.
Preparation 1
[0117] The compounds in Preparations 1-1 to 1-25 shown in the
following table were produced by using the corresponding starting
compounds according to the method similar to that described in
Example 1.
TABLE-US-00002 TABLE 2 Pr Structure 1-1 ##STR00013## 1-2
##STR00014## 1-3 ##STR00015## 1-4 ##STR00016## 1-5 ##STR00017## 1-6
##STR00018## 1-7 ##STR00019## 1-8 ##STR00020## 1-9 ##STR00021##
1-10 ##STR00022## 1-11 ##STR00023## 1-12 ##STR00024## 1-13
##STR00025## 1-14 ##STR00026## 1-15 ##STR00027## 1-16 ##STR00028##
1-17 ##STR00029## 1-18 ##STR00030## 1-19 ##STR00031## 1-20
##STR00032## 1-21 ##STR00033## 1-22 ##STR00034## 1-23 ##STR00035##
1-24 ##STR00036## 1-25 ##STR00037##
TABLE-US-00003 TABLE 3 Pr Data 1-1 MS: 342 (M + H) + 1-2 MS: 342 (M
+ H) + 1-3 MS: 460 (M + H) + 1-4 MS: 370 (M + H) + 1-5 MS: 370 (M +
H) + 1-6 MS: 358 (M + H) + 1-7 1H-NMR (400 MHz, d6-DMSO) .delta.:
1.32 (3H, t, J = 7.0 Hz), 1.43 (9H, s), 1.73-1.87 (2H, m),
1.90-2.08 (4H, m), 2.18-2.33 (2H, m), 4.08-4.18 (2H, m), 4.28 (2H,
q, J = 7.0 Hz), 4.37-4.47 (1H, m), 6.52-6.57 (1H, m), 7.13-7.18
(1H, m), 8.56 (1H, s), 9.39 (1H, d, J = 7.6 Hz), 11.67 (1H, s). MS:
415 (M + H) + 1-8 1H-NMR (400 MHz, d6-DMSO) .delta.: 0.32 (3H, t, J
= 7.1 Hz), 0.48-3.13 (14H, m), 4.26 (2H, q, J = 7.1 Hz), 4.68 (1H,
s), 6.71-6.72 (1H, m), 7.23-7.24 (1H, m), 8.60 (1H, s), 9.34 (1H,
s), 11.69 (1H, s). MS: 356 (M + H) + 1-9 1H-NMR (400 MHz, d6-DMSO)
.delta.: 0.32 (3H, t, J = 7.1 Hz), 0.40-0.47 (2H, m), 1.95-2.17
(11H, m), 0.80-0.83 (1H, m), 4.26 (2H, q, J = 7.1 Hz), 4.73 (1H, d,
J = 2.9 Hz), 6.76 (1H, dd, J = 2.4 Hz, 3.5 Hz), 7.22 (1H, dd, J =
2.6 Hz, 3.3 Hz), 8.60 (1H, s), 9.33 (1H, s), 11.68 (1H, s). MS: 356
(M + H) + 1-10 MS: 372 (M + H) + 1-11 MS: 471 (M + H) + 1-12 MS:
481 (M + H) + 1-13 MS: 405 (M + H) + 1-14 MS: 484 (M + H) + 1-15
MS: 484 (M + H) + 1-16 MS: 517 (M + H) + 1-17 MS: 445 (M + H) +
1-18 MS: 445 (M + H) + 1-19 MS: 300 (M + H) + 1-20 MS: 342 (M + H)
+ 1-21 MS: 354 (M + H) + 1-22 MS: 356 (M + H) + 1-23 MS: 342 (M +
H) + 1-24 1H-NMR (400 MHz, d6-DMSO) .delta.: 1.35 (3H, t, J = 7.1
Hz), 1.68-1.77 (6H, m), 2.10-2.18 (9H, m), 4.26 (2H, q, J = 7.1
Hz), 6.75 (1H, d, J = 3.6 Hz), 7.22 (1H, d, J = 3.4 Hz), 8.60 (1H,
s), 9.34 (1H, s), 11.67 (1H, s). MS: 340 (M + H) + 1-25 1H-NMR (400
MHz, d6-DMSO) .delta.: 1.32 (3H, t, J = 7.1 Hz), 1.61-2.07 (16H,
m), 4.29 (2H, q, J = 7.1 Hz), 4.48 (1H, d, J = 3.5 Hz), 7.18 (1H,
d, J = 3.2 Hz), 9.36 (1H, d, J = 8.0 Hz), 11.67 (1H, s). MS: 340 (M
+ H) +
Preparation 2
[0118] To glycinamide hydrochloride (34 mg) were added a solution
of ethyl
3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-oxadiazole-5-carboxylate
(60 mg) in 1-methyl-2-pyrrolidone (0.6 ml) and
1,8-diazabicyclo[5.4.0]undec-7-ene (0.092 ml), and the mixture was
stirred at 70.degree. C. for 1 hour. After being left to cool, the
reaction solution was directly purified by preparative HPLC (10 mM
NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=90:10 to 20:80). The
active fraction was concentrated and dried to hardness to obtain
3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-N-methyl-1,2,4-oxadiazole-5-ca-
rboxylate (23 mg) as a solid.
[0119] The compounds in Preparations 2-1 to 2-26 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 2.
TABLE-US-00004 TABLE 4 Pr Structure 2 ##STR00038## 2-1 ##STR00039##
2-2 ##STR00040## 2-3 ##STR00041## 2-4 ##STR00042## 2-5 ##STR00043##
2-6 ##STR00044## 2-7 ##STR00045## 2-8 ##STR00046## 2-9 ##STR00047##
2-10 ##STR00048## 2-11 ##STR00049## 2-12 ##STR00050## 2-13
##STR00051## 2-14 ##STR00052## 2-15 ##STR00053## 2-16 ##STR00054##
2-17 ##STR00055## 2-18 ##STR00056## 2-19 ##STR00057## 2-20
##STR00058## 2-21 ##STR00059## 2-22 ##STR00060## 2-23 ##STR00061##
2-24 ##STR00062## 2-25 ##STR00063## 2-26 ##STR00064##
TABLE-US-00005 TABLE 5 Ex MS data 2 MS: 278 (M + H) + 2-1 MS: 348
(M + H) + 2-2 MS: 334 (M + H) + 2-3 MS: 377 (M + H) + 2-4 MS: 361
(M + H) + 2-5 MS: 377 (M + H) + 2-6 MS: 357 (M + H) + 2-7 MS: 382
(M + H) + 2-8 MS: 348 (M + H) + 2-9 MS: 303 (M + H) + 2-10 MS: 332
(M + H) + 2-11 MS: 410 (M + H) + 2-12 MS: 368 (M + H) + 2-13 MS:
318 (M + H) + 2-14 MS: 346 (M + H) + 2-15 MS: 375 (M + H) + 2-16
MS: 415 (M + H) + 2-17 MS: 373 (M + H) + 2-18 MS: 322 (M + H) +
2-19 MS: 322 (M + H) + 2-20 MS: 375 (M + H) + 2-21 MS: 350 (M + H)
+ 2-22 MS: 334 (M + H) + 2-23 MS: 378 (M + H) + 2-24 MS: 378 (M +
H) + 2-25 MS: 334 (M + H) + 2-26 MS: 347 (M + H) +
Preparation 3
[0120] Benzyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (55
mg), ethyl {[(4-amino-1-adamantyl)carbonyl]amino}acetate (54 mg)
and triethylamine (80 .mu.l) were dissolved in
N-methyl-2-pyrrolidone (0.55 ml) and stirred at 180.degree. C. for
1 hour using a microwave reaction system. To the reaction solution
were added ethyl acetate and water, and the mixture was extracted
with ethyl acetate. The organic layer was washed with saturated
brine, dried over magnesium sulfate, and evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate), the obtained compound was
dissolved in dioxane (1.1 ml) and methanol (1.1 ml), 10% palladium
on carbon (50% wet) was added, and catalytic reduction was
performed for 4 hours at ambient temperature at 1 atm. Methanol,
dioxane, and 1M hydrochloric acid were added, and the precipitated
solid was dissolved and filtered to remove the catalyst. The
filtrate was concentrated under reduced pressure to obtain
4-({5-[(2-ethoxy-2-oxoethyl)carbamoyl]adamantan-2-yl}amino)-1H-pyrrolo[2,-
3-b]pyridine-5-carboxylic acid (18 mg).
TABLE-US-00006 TABLE 6 Pr Structure Data 3 ##STR00065## MS: 441 (M
+ H)+
Preparation 4
[0121] To a ethanol (3 ml) was added acetyl chloride carefully at
4.degree. C. The reaction solution was stirred at 4.degree. C. for
30 minutes. To the reaction solution were added a solution of
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rbonitrile (50 mg) in chloroform (0.5 ml) and 2M hydrochloric
acid/ethanol solution (0.5 ml) dropwise. The reaction solution was
stirred under ambient temperature for 18 hours. The reaction
solution was concentrated under reduced pressure to obtain ethyl
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboxyimidate trihydrochloride (75 mg).
TABLE-US-00007 TABLE 7 Pr Structure Data 4 ##STR00066## MS: 355 (M
- 3HCl + H)+
Preparation 5
[0122] The compounds in Preparations 5-1 to 5-32 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 3.
TABLE-US-00008 TABLE 8 Pr Structure 5-1 ##STR00067## 5-2
##STR00068## 5-3 ##STR00069## 5-4 ##STR00070## 5-5 ##STR00071## 5-6
##STR00072## 5-7 ##STR00073## 5-8 ##STR00074## 5-9 ##STR00075##
5-10 ##STR00076## 5-9 ##STR00077## 5-10 ##STR00078## 5-11
##STR00079## 5-12 ##STR00080## 5-13 ##STR00081## 5-14 ##STR00082##
5-15 ##STR00083## 5-16 ##STR00084## 5-17 ##STR00085## 5-18
##STR00086## 5-19 ##STR00087## 5-20 ##STR00088## 5-21 ##STR00089##
5-22 ##STR00090## 5-23 ##STR00091## 5-24 ##STR00092## 5-25
##STR00093## 5-26 ##STR00094## 5-27 ##STR00095## 5-28 ##STR00096##
5-29 ##STR00097## 5-30 ##STR00098## 5-31 ##STR00099## 5-32
##STR00100##
TABLE-US-00009 TABLE 9 Pr Data 5-1 MS: 272 (M + H)+ 5-2 MS: 272 (M
+ H)+ 5-3 1H-NMR (400 MHz, d6-DMSO).delta.: 1.60-2.06 (14H, m),
4.24 (1H, d, J = 7.9 Hz), 6.46 (1H, dd, J = 1.3 Hz, 3.3 Hz), 7.16
(1H, dd, J = 2.4 Hz, 3.2 Hz), 8.52 (1H, s), 9.61 (1H, s), 11.59
(1H, s), 12.33 (1H, br)MS: 312 (M + H)+ 5-4 MS: 314 (M + H)+ 5-5
1H-NMR (400 MHz, d6-DMSO).delta.: 1.67-1.75 (6H, m), 2.09-2.16 (9H,
m), 6.71 (1H, s), 7.16 (1H, s), 8.56 (1H, s), 9.76 (1H, br), 11.49
(1H, s). MS: 312 (M + H)+ 5-6 MS: 326 (M + H)+ 5-7 MS: 410 (M +
Na)+ 5-8 MS: 329 (M + H)+ 5-9 MS: 479 (M + H)+ 5-10 5-11 MS: 475 (M
+ Na)+ 5-12 5-13 MS: 409 (M + Na)+ 5-14 MS: 446 (M - H)- 5-15 MS:
377 (M + H)+ 5-16 MS: 209 (M - H)- 5-17 MS: 342 (M + H)+ 5-18 MS:
330 (M + H)+ 5-19 1H-NMR (400 MHz, d6-DMSO).delta.: 1.43 (9H, s),
1.70-1.88 (2H, m), 1.88-2.09 (4H, m), 2.14-2.33 (2H, m), 4.05-4.20
(2H, m), 4.34-4.46 (1H, m), 6.48-6.58 (1H, m), 7.09-7.17 (1H, m),
8.52 (1H, s), 9.67 (1H, d, J = 6.2 Hz), 11.62 (1H, s), 12.45 (1H,
br). MS: 387 (M + H)+ 5-20 MS: 463 (M + Na)+ 5-21 MS: 437 (M - H)-
5-22 MS: 371 (M + Na)+ 5-23 1H-NMR (400 MHz, d6-DMSO).delta.:
1.40-1.46 (2H, m), 1.96-2.15 (11H, m), 2.44-2.55 (1H, m), 3.82 (1H,
s), 4.71 (1H, s), 6.72-6.75 (1H, m), 7.19 (1H, t, J = 2.9 Hz), 8.56
(1H, s), 9.71 (1H, br), 11.57 (1H, s). MS: 328 (M + H)+ 5-24 MS:
355 (M + Na)+ 5-25 MS: 314 (M + H)+ 5-26 MS: 437 (M - H)- 5-27 MS:
261 (M + H)+ 5-28 MS: 342 (M + H)+ 5-29 MS: 314 (M + H)+ 5-30
1H-NMR (400 MHz, d6-DMSO).delta.: 1.48-1.68 (6H, m), 1.98 (6H, s),
2.26 (2H, s), 4.66 (1H, s), 6.68 (1H, dd, J = 5.3 Hz, 11.4 Hz), 7.2
(1H, dd, J = 2.5 Hz, 3.0 Hz), 8.57 (1H, s), 9.70 (1H, br), 11.58
(1H, s). MS: 328 (M + H)+ 5-31 MS: 328 (M + H)+ 5-32 MS: 458 (M +
H)+
Preparation 6
[0123] To a ethyl
7-[(trans-5-hydroxyadamantan-2-yl)amino]-3H-imidazo[4,5-b]pyridine-6-carb-
oxylate (50 mg) was added 47% aqueous hydrobromic acid (0.75 ml),
and the mixture was stirred at 120.degree. C. for 1 hour using a
microwave reaction system. After the reaction solution was cooled,
the pH was adjusted to 5 with aqueous potassium carbonate, and the
obtained solid was collected by filtration and washed with water to
obtain
7-[(trans-5-bromoadamantan-2-yl)amino]-3H-imidazo[4,5-b]pyridine-6-carbox-
ylic acid (44 mg).
[0124] The compounds in Preparations 6-1 shown in the following
table were produced using the corresponding starting compounds
according to the method similar to that described in Preparation
6.
TABLE-US-00010 TABLE 10 Pr Structure Data 6 ##STR00101## MS: 391,
393 (M + H)+ 6-1 ##STR00102## MS: 391, 393 (M + H)+
Preparation 7
[0125] A mixture of ethyl
7-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-3H-imidazo[4,5-b]pyridine-6--
carboxylate (400 mg), di-t-butyl dicarbonate (203 mg),
triethylamine (130 .mu.l), dioxane (4 ml) and water (4 ml) was
stirred at ambient temperature for 1 hour. The mixture was diluted
with ethyl acetate (5 ml) and water (20 ml). The resulting
precipitate was collected by filtration (ethyl
7-{[(3-exo)-8-(tert-butoxycarbonyl)-8-azabicyclo[3.2.1]oct-3-yl]am-
ino}-3H-imidazo[4,5-b]pyridine-6-carboxylate, (200 mg)). The
filtrate was diluted with ethyl acetate (50 ml) and extracted with
ethyl acetate. The organic extracts were washed with brine, dried
over sodium sulfate and concentrated. Recrystallization from ethyl
acetate/n-hexane gave ethyl
7-{[(3-exo)-8-(tert-butoxycarbonyl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-3H-
-imidazo[4,5-b]pyridine-6-carboxylate (100 mg) as a white
solid.
[0126] The compounds in Preparations 7-1 shown in the following
table were produced using the corresponding starting compounds
according to the method similar to that described in Example
64.
TABLE-US-00011 TABLE 11 Pr Structure Data 7 ##STR00103## MS: 416 (M
+ H)+ 7-1 ##STR00104## MS: 415 (M + H)+
Preparation 8
[0127] The compounds in Preparations 8-1 to 8-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 44.
TABLE-US-00012 TABLE 12 Pr Structure Data 8-1 ##STR00105## MS: 326
(M + Na)+ 8-2 ##STR00106## MS: 326 (M + Na)+ 8-3 ##STR00107## MS:
326 (M + Na)+
Preparation 9
[0128] The compounds in Preparations 9-1 to 9-2 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 10.
TABLE-US-00013 TABLE 13 Pr Structure Data 9-1 ##STR00108## MS: 319
(M + Na)+ 9-2 ##STR00109## MS: 424 (M - H.sub.2O + H)+
Preparation 10
[0129] The compounds in Preparations 10-1 to 10-18 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 4.
TABLE-US-00014 TABLE 14 Pr Structure 10-1 ##STR00110## 10-2
##STR00111## 10-3 ##STR00112## 10-4 ##STR00113## 10-5 ##STR00114##
10-6 ##STR00115## 10-7 ##STR00116## 10-8 ##STR00117## 10-9
##STR00118## 10-10 ##STR00119## 10-11 ##STR00120## 10-12
##STR00121## 10-13 ##STR00122## 10-14 ##STR00123## 10-15
##STR00124## 10-16 ##STR00125## 10-17 ##STR00126## 10-18
##STR00127##
TABLE-US-00015 TABLE 15 Pr Data 10-1 MS: 332 (M + H)+ 10-2 MS: 246
(M + Na)+ 10-3 MS: 586 (M + H)+ 10-4 MS: 452 (M + H)+ 10-5 MS: 370
(M + Na)+ 10-6 MS: 368 (M + H)+ 10-7 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.39-1.45 (2H, m), 1.65-1.86 (8H, m), 1.94-1.97
(2H, m), 2.15-2.20 (2H, m), 3.08-3.11 (1H, m), 5.05-5.08 (1H, m),
6.55-6.57 (1H, m), 7.66-7.68 (1H, m), 8.19 (1H, s), 9.85 (1H, d, J
= 6.8 Hz), 12.20 (1H, brs). MS: 367 (M + Na)+ 10-8 MS: 232 (M +
Na)+ 10-9 MS: 427 (M + H)+ 10-10 MS: 415 (M + H)+ 10-11 MS: 233 (M
+ Na)+ 10-12 MS: 474 (M + Na)+ 10-13 MS: 462 (M + Na)+ 10-14 MS:
262 (M + Na)+ 10-15 MS: 447 (M + H)+ 10-16 10-17 MS: 232 (M + Na)+
10-18 MS: 452 (M + H)+
Preparation 11
[0130] To a solution of
4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid (350 mg) in
N,N-dimethylformamide (4 ml) were added N,N-carbonyl diimidazole
(289 mg) and glycinemethylester hydrochloride (447 mg) successively
under ambient temperature. The mixture was stirred at ambient
temperature for 2 hours. To the reaction solution was added water.
The precipitated solid was filtered, washed with water, and dried
to obtain
4-chloro-5-(1H-imidazol-1-ylcarbonyl)-1H-pyrrolo[2,3-b]pyridine
(325 mg) as a white solid.
TABLE-US-00016 TABLE 16 Pr Structure Data 11 ##STR00128## MS: 247
(M + H)+, 245 (M - H)-
Preparation 12
[0131] To a solution of
4-chloro-5-(1H-imidazol-1-ylcarbonyl)-1H-pyrrolo[2,3-b]pyridine
(300 mg) in N,N-dimethylformamide (3 ml) were added
N-ethyl-N-isopropylpropane-2-amine (0.64 ml) and glycine
methylester hydrochloride (305 mg) at ambient temperature. The
mixture was warmed immediately to 60.degree. C. and stirred at
60.degree. C. for 2 hours. After to the reaction solution was added
water, the mixture was stirred for 1 hour. The precipitated solid
was filtered, washed with water, and dried to obtain methyl
N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)carbonyl]glycinate (267
mg) as a white solid.
TABLE-US-00017 TABLE 17 Pr Structure Data 12 ##STR00129## MS: 290
(M + Na)+
Preparation 13
[0132] To a solution of benzyl
rel-[(1R,2S,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (1.3 g) in
dichloroethane (13 ml) were added trimethyloxonium
tetrafluoroborate (1.28 g), 2,6-di-t-butyl-4-methylpyridine (2.21
g). The reaction solution was refluxed for 3 hours. The reaction
solution was concentrated under reduced pressure, ethyl acetate was
added, and the insoluble matter was filtered. To the filtrate was
added water, and the mixture was extracted with ethyl acetate. The
organic layer was washed with saturated brine, dried over anhydrous
magnesium sulfate, and filtered. The filtrate was concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (n-hexane:ethyl acetate=19:1 to 7:3) to
obtain benzyl rel-[(1R,2S,3S,5s)-5-methoxyadamantan-2-yl]carbamate
(540 mg) as a colorless oily matter.
[0133] The compounds in Preparations 13-1 to 13-2 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 13.
TABLE-US-00018 TABLE 18 Pr Structure Data 13 ##STR00130## MS: 338
(M + Na)+ 13-1 ##STR00131## MS: 338 (M + Na)+ 13-2 ##STR00132## MS:
352 (M + Na)+
Preparation 14
[0134] The compounds in Preparations 14-1 to 14-6 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Examples 12 to Examples 14.
TABLE-US-00019 TABLE 19 Pr Structure 14-1 ##STR00133## 14-2
##STR00134## 14-3 ##STR00135## 14-4 ##STR00136## 14-5 ##STR00137##
14-6 ##STR00138##
TABLE-US-00020 TABLE 20 Pr Data 14-1 MS: 267 (M + H)+ 14-2 MS: 414
(M + H)+ 14-3 MS: 443 (M + H)+ 14-4 MS: 467 (M + H)+ 14-5 MS: 333
(M + Na)+ 14-6 MS: 481 (M + H)+
Preparation 15
[0135] To a solution of
(3-exo,7-endo)-7-hydroxybicyclo[3.3.1]nonan-3-carboxylic acid (700
mg) in methanol (14 ml) was added concentrated sulfuric acid (2 ml)
dropwise, and the reaction solution was refluxed for 1 hour. To the
reaction solution was added water, the mixture was extracted with
ethyl acetate. The organic layer was washed with water, saturated
aqueous sodium hydrogencarbonate, and brine, dried over magnesium
sulfate, and filtered. The filtrate was concentrated under reduced
pressure to obtain
methyl-(3-exo,7-endo)-7-hydroxybicyclo[3.3.1]nonan-3-carboxylate
(730 mg).
TABLE-US-00021 TABLE 21 Pr Structure Data 15 ##STR00139## MS: 221
(M + Na)+
Preparation 16
[0136] The compounds in Preparations 16-1 to 16-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 28.
TABLE-US-00022 TABLE 22 Pr Structure 16-1 ##STR00140## 16-2
##STR00141## 16-3 ##STR00142##
TABLE-US-00023 TABLE 23 Pr Data 16-1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.44 (9H, s), 1.77-2.39 (8H, m), 2.42 (3H, s),
4.09-4.20 (2H, m), 4.48-4.57 (1H, m), 6.61-6.66 (1H, m), 7.21-7.26
(1H, m), 8.57 (1H, s), 9.16 (1H, d, J = 7.5 Hz), 11.81 (1H, s). MS:
425 (M + H)+ 16-2 MS: 315 (M + Na)+ 16-3 MS: 425 (M + H)+
Preparation 17
[0137] The compound in Preparation 17 shown in the following table
was produced using the corresponding starting compound according to
the method similar to that described in Example 29.
TABLE-US-00024 TABLE 24 Pr Structure Data 17 ##STR00143## MS: 301
(M + Na)+
Preparation 18
[0138] The compounds in Preparations 18-1 to 18-5 shown in the
following table were produced using the corresponding starting
compound according to the method similar to that described in
Example 30.
TABLE-US-00025 TABLE 25 Pr Structure 18-1 ##STR00144## 18-2
##STR00145## 18-3 ##STR00146## 18-4 ##STR00147## 18-5
##STR00148##
TABLE-US-00026 TABLE 26 Pr Data 18-1 MS: 315 (M + Na)+ 18-2 MS: 287
(M + Na)+ 18-3 MS: 424 (M + H)+ 18-4 MS: 291 (M + Na)+ 18-5 MS: 468
(M + H)+
Preparation 19
[0139] To a solution of
4-chloro-N'-hydroxy-1H-pyrrolo[2,3-b]pyridine-5-carboxyimidamide
(100 mg) in N,N-dimethylformamide (1 ml) were added pyridine (58
.mu.l) and 2-ethylhexyl chlorocarbonate (92 .mu.l) at 4.degree. C.
The reaction solution was stirred at ambient temperature for 2
hours. To the reaction solution was added water. The precipitate
was collected by filtration and dissolved in xylene (2 ml). The
reaction solution was stirred at 160.degree. C. for 3 hours. To the
reaction solution was added water, and the precipitate was
collected by filtration to obtain
3-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,2,4-oxadiazol-5(4H)-one
(63 mg) as a white solid.
TABLE-US-00027 TABLE 27 Pr Structure Data 19 ##STR00149## MS: 235
(M - H)-
Preparation 20
[0140] To a solution of methyl
N-[(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)carbonyl]glycinate (167
mg) in chloroform (5 ml) was added diphosphorus pentoxide (886 mg)
under ambient temperature, and the mixture was refluxed for 18
hours. The reaction solution was cooled and added to saturated
aqueous sodium hydrogencarbonate. The reaction solution was
extracted with ethyl acetate. The organic layer was washed with
water. The organic layer was dried over magnesium sulfate and
filtered. The filtrate was concentrated under reduced pressure. The
residue was purified by thin-layer silica gel column chromatography
(chloroform:methanol=15:1) to obtain
4-chloro-5-(5-methoxy-1,3-oxazol-2-yl)-1H-pyrrolo[2,3-b]pyridine
(45 mg) as a yellowish white solid.
TABLE-US-00028 TABLE 28 Pr Structure Data 20 ##STR00150## MS: 250
(M + H)+
Preparation 21
[0141] To a solution of
4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbonitri-
le (150 mg) in tetrahydrofuran (3 ml) was added 1.01M
diisobutylaluminum hydride/toluene solution (1.93 ml) at
-78.degree. C. The reaction solution was stirred for 18 hours under
ambient temperature. To the reaction solution was added 1M
hydrochloric acid under ice cooling, and the mixture was stirred
for 30 minutes. The mixture was extracted with chloroform and
washed with water. The organic layer was dried over magnesium
sulfate and filtered. The filtrate was concentrated under reduced
pressure to obtain
4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbaldehy-
de (100 mg) as a pale yellow amorphous substance.
[0142] The compound in Preparation 21-1 shown in the following
table was produced using the corresponding starting compound
according to the method similar to that described in Preparation
21.
TABLE-US-00029 TABLE 29 Pr Structure Data 21 ##STR00151## MS: 312
(M + H)+ 21-1 ##STR00152## MS: 312 (M + H)+
Preparation 22
[0143] To a mixture of
6-(benzylamino)-1-(5-hydroxyadamantan-2-yl)-7-nitro-1,3-dihydro-2H-imidaz-
o[4,5-c]pyridine-2-one (68 mg) and methanol (1 ml) were added
ammonium formate (197 mg) and 50% wet 10% palladium on carbon (33
mg) at ambient temperature. The mixture was refluxed for 5 hours.
After the mixture was cooled, the catalyst was removed by
filtration. The mothr liquid was concentrated to obtain
6,7-diamino-1-(5-hydroxyadamantan-2-yl)-1,3-dihydro-2H-imidazo[4,5-c]pyri-
dine-2-one (54 mg).
[0144] The compounds in Preparations 22-1 to 22-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 22.
TABLE-US-00030 TABLE 30 Pr Structure 22 ##STR00153## 22-1
##STR00154## 22-2 ##STR00155## 22-3 ##STR00156##
TABLE-US-00031 TABLE 31 Pr Data 22 MS: 316 (M + H)+ 22-1 MS: 332 (M
+ H)+ 22-2 MS: 320 (M + H)+ 22-3 MS: 332 (M + H)+
Preparation 23
[0145] To a suspension of ethyl
6-[(3,4-dimethoxybenzyl)amino]-4-[(cis-5-hydroxy
adamantan-2-yl)amino]-5-nitronicotinate (2.73 g) in ethanol (40 ml)
was added 10% palladium on carbon (50% wet) (550 mg). In hydrogen
atmosphere, catalytic reduction was carried out at 80.degree. C.
for 5 hours. After the reaction solution was cooled to ambient
temperature, the catalyst was filtered and washed with dioxane, and
the solvent was evaporated under reduced pressure. To the residue
were added ethyl orthoformate (17 ml) and concentrated hydrochloric
acid (864 .mu.l), and the mixture was stirred at ambient
temperature for overnight. The reaction solution was neutralized
with saturated aqueous sodium hydrogencarbonate and extracted with
ethyl acetate and tetrahydrofuran. The organic layer was washed
with saturated brine, dried over magnesium sulfate, and filtered.
The filtrate was evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (chloroform:methanol)
to obtain ethyl
3-(3,4-dimethoxybenzyl)-7-[(cis-5-hydroxyadamantan-2-yl)
amino]-3H-imidazo[4,5-b]pyridine-6-carboxylate (2.17 g).
[0146] The compound in Preparation 23-1 shown in the following
table were produced using the corresponding starting compound
according to the method similar to that described in Preparation
23.
TABLE-US-00032 TABLE 32 Pr Structure Data 23 ##STR00157## MS: 507
(M + H)+ 23-1 ##STR00158## MS: 357 (M + H)+
Preparation 24
[0147] The compounds in Preparations 24-1 to 24-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 35.
TABLE-US-00033 TABLE 33 Pr Structure Data 24-1 ##STR00159## MS: 182
(M + H)+ 24-2 ##STR00160## MS: 299 (M + Na)+ 24-3 ##STR00161## MS:
273 (M + Na)+
Preparation 25
[0148] To a reaction solution of N-Boc-nortropinone (1.38 g),
benzylamine (0.803 ml) and acetic acid (0.35 ml) in dichloromethane
(10 ml) and 1,2-dichloroethane (32 ml) was added sodium
triacetoxyborohydride (1.95 g). And the mixture was stirred at
ambient temperature for 2 hours. To the reaction mixture was added
benzylamine (0.201 ml) and sodium triacetoxyborohydride (649 mg),
and the mixture was stirred at 50.degree. C. for 3.5 hours.
Furthermore, to the reaction mixture was added sodium
triacetoxyborohydride (649 mg) and the mixture was stirred at
50.degree. C. for 3 hours. The reaction solvent was evaporated
under reduced pressure. To the residue were added saturated aqueous
sodium hydrogencarbonate and 1M aqueous sodium hydroxide to
alkalify the residue. The residue was extracted with ethyl acetate.
The organic layer was washed with saturated aqueous sodium
hydrogencarbonate, water, and saturated brine, dried over anhydrous
sodium sulfate, and filtered. The filtrate was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography (chloroform:methanol) to obtain
3-(benzylamino)-8-azabicyclo[3.2.1]octane-8-carbamic acid t-butyl
ester (1.78 g) as a white solid.
[0149] The compounds in Preparations 25-1 to 25-8 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 25.
TABLE-US-00034 TABLE 34 Pr Structure 25 ##STR00162## 25-1
##STR00163## 25-2 ##STR00164## 25-3 ##STR00165## 25-4 ##STR00166##
25-5 ##STR00167## 25-6 ##STR00168## 25-7 ##STR00169## 25-8
##STR00170##
TABLE-US-00035 TABLE 35 Pr Data 25 1H-NMR (400 MHz,
CDCl.sub.3).delta.: 1.35-1.66 (3H, m), 1.45 (9H, s), 1.86-2.22 (6H,
m), 3.00 (1H, dd, J = 6.0, 6.0 Hz), 3.78 (2H, s), 4.04-4.28 (2H,
m), 7.20-7.38 (5H, m) 25-1 MS: 423, 425 (M + H)+ 25-2 MS: 383 (M +
Na)+ 25-3 MS: 357 (M + H)+ 25-4 MS: 311 (M + H)+ 25-5 MS: 320, 322
(M + H)+ 25-6 MS: 327 (M + Na)+ 25-7 MS: 258 (M + H)+ 25-8 MS: 423,
425 (M + H)+
Preparation 26
[0150] The compounds in Preparations 26-1 to 26-2 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 50.
TABLE-US-00036 TABLE 36 Pr Structure Data 26-1 ##STR00171## MS: 301
(M + Na)+ 26-2 ##STR00172## MS: 317 (M + Na)+
Preparation 27
[0151] To a solution of
rel-(1'R,3'S,5'S,7's)-5'H-spiro[1,3-dioxolane-2,2'-tricyclo[3.3.1.1.about-
.3,7.about.]decane]-5'-carboxylic acid (100 mg) in toluene (1 ml)
was added diphenylphosphate azide (99 .mu.l) and triethylamine (64
.mu.l). The mixture was stirred at 110.degree. C. for 2 hours.
After the reaction solution was cooled to ambient temperature,
water was added, and the mixture was extracted with ethyl acetate.
The organic layer was washed with brine, dried over magnesium
sulfate, and filtered. The filtrate was evaporated under reduced
pressure. The residue was dissolved in N,N-dimethylacetamide (1
ml), and potassium t-butoxide (49 mg) was added. The mixture was
stirred at ambient temperature for overnight. To the reaction
solution was added water, and the mixture was extracted with ethyl
acetate. The organic layer was washed with saturated brine, dried
over magnesium sulfate, and filtered. The filtrate was evaporated
under reduced pressure. The residue was purified by silica gel
column chromatography (n-hexane:ethyl acetate) to obtain t-butyl
rel-(1'R,3'S,5'S,7's)-5'H-spiro[1,3-dioxolane-2,2'-tricyclo[3.3.1.1.about-
.3,7.about.]decane]-5'-yl carbamate (40 mg).
[0152] The compounds in Preparations 27-1 to 27-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 27.
TABLE-US-00037 TABLE 37 Pr Structure Data 27 ##STR00173## MS: 332
(M + Na)+ 27-1 ##STR00174## MS: 455 (M + H)+ 27-2 ##STR00175## MS:
436 (M + H)+ 27-3 ##STR00176## MS: 374 (M + H)+
Preparation 28
[0153] To a concentrated sulfuric acid (175 ml) was added 70%
nitric acid (20 ml) dropwise under ice cooling, and 2-adamantamine
hydrochloride (25 g) was added slowly at 10.degree. C. or less. The
mixture was warmed to ambient temperature and stirred for 2 hours.
The reaction solution was poured into ice water, and the mixture
was neutralized with 6M aqueous sodium hydroxide and extracted with
dichloromethane four times. The organic layers were combined, dried
over anhydrous magnesium sulfate, and concentrated under reduced
pressure to obtain 4-aminoadamantan-1-ol (17.7 g).
TABLE-US-00038 TABLE 38 Pr Structure Data 28 ##STR00177## MS: 168
(M + H)+
Preparation 29
[0154] A mixture of ethyl
4-{[3-exo(hydroxymethyl)bicyclo[2.2.1]heptyl-2-exo]amino}-1H-pyrrolo[2,3--
b]pyridine-5-carboxylate (54 mg), triisopropylsilyl chloride (52
.mu.l), imidazole (17 mg), and N,N-dimethylformamide (0.3 ml) was
stirred at ambient temperature for 2 hours. The reaction solution
was diluted with ethyl acetate (20 ml) and poured into saturated
aqueous sodium hydrogencarbonate (15 ml). The mixture was extracted
with ethyl acetate (15 ml) two times, and the extract was washed
with brine (20 ml), dried over anhydrous magnesium sulfate, and
filtered. The filtrate was concentrated. The residue was purified
by silica gel column chromatography (n-hexane:ethyl acetate) to
obtain ethyl
4-{[3-exo(triisopropylsilyl)oxy]methyl}bicyclo[2.2.1]heptyl-2-exo]amino}--
1H-pyrrolo[2,3-b]pyridine-5-carboxylate (76 mg) as a pale brown
solid.
TABLE-US-00039 TABLE 39 Pr Structure Data 29 ##STR00178## MS: 486
(M + H)+
Preparation 30
[0155] To a solution of 4-chloro-2-methyl-1H-pyrrolo[2,3-b]pyridine
(0.85 g) in N,N-dimethylformamide (8.5 ml) was added 60%
oil-suspended NaH (245 mg) under nitrogen atmosphere while being
cooled in an ice water bath. The reaction solution was stirred at
ambient temperature for 1 hour and cooled again in the ice water
bath. To the reaction solution was added triisopropylsilyl chloride
(1.3 ml) slowly dropwise for 10 or more minutes. The reaction
solution was stirred for 3 hours at ambient temperature and diluted
with ethyl acetate (30 ml). The solution was washed with saturated
aqueous sodium hydrogencarbonate (30 ml) and brine (20 ml). The
solution was dehydrated with anhydrous magnesium sulfate and
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography (n-hexane) to obtain
4-chloro-2-methyl-1-(triisopropylsilyl)-pyrrolo[2,3-b]pyridine
(1.45 g) as a colorless transparent liquid.
TABLE-US-00040 TABLE 40 Pr Structure Data 30 ##STR00179## MS: 323
(M + H)+
Preparation 31
[0156] The compounds in Preparations 31-1 to 31-2 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 19.
TABLE-US-00041 TABLE 41 Pr Structure Data 31-1 ##STR00180## MS: 272
(M + H)+ 31-2 ##STR00181## MS: 287 (M + H)+
Preparation 32
[0157] A mixture of
4-chloro-2-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine
(4.73 g), potassium carbonate (6.4 g), methanol (45 ml), and water
(15 ml) was stirred at 90.degree. C. for 2 hours. After the mixture
was cooled, the obtained needle crystals were filtered and washed
with water to obtain 4-chloro-2-methyl-1H-pyrrolo[2,3-b]pyridine
(1.85 g).
TABLE-US-00042 TABLE 42 Pr Structure Data 32 ##STR00182## MS: 167
(M + H)+
Preparation 33
[0158] To a solution of benzyl
rel-[(1R,2S,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (5.5 g) in
methanol (55 ml) was added 10% palladium on carbon (50% wet) (1.1
g), and the mixture was stirred under hydrogen atmosphere at
ambient temperature for 3 hours. After 10% palladium on carbon was
removed with Celite, the filtrate was concentrated under reduced
pressure to obtain rel-(1s,3R,4S,5S)-4-adamantamine-1-ol (3.8
g).
[0159] The compounds in Preparations 33-1 to 33-11 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 33.
TABLE-US-00043 TABLE 43 Pr Structure 33 ##STR00183## 33-1
##STR00184## 33-2 ##STR00185## 33-3 ##STR00186## 33-4 ##STR00187##
33-5 ##STR00188## 33-6 ##STR00189## 33-7 ##STR00190## 33-8
##STR00191## 33-9 ##STR00192## 33-10 ##STR00193## 33-11
##STR00194##
TABLE-US-00044 TABLE 44 Pr Data Pr Data 33 MS: 168 (M + H)+ 33-1
MS: 281 (M + H)+ 33-2 MS: 168 (M + H)+ 33-3 MS: 234 (M + H)+ 33-4
MS: 182 (M + H)+ 33-5 MS: 182 (M + H)+ 33-6 MS: 170 (M + H)+ 33-7
MS: 170 (M + H)+ 33-8 MS: 196 (M + H)+ 33-9 MS: 281 (M + H)+ 33-10
MS: 170 (M + H)+ 33-11 MS: 234 (M + H)+
Preparation 34
[0160] The compounds in Preparations 34-1 to 34-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 21.
TABLE-US-00045 TABLE 45 Pr Structure Data 34-1 ##STR00195## MS: 261
(M + Na)+ 34-2 ##STR00196## MS: 171 (M + H)+ 34-3 ##STR00197## MS:
323 (M + H)+
Preparation 35
[0161] To a solution of ethyl
5-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-3-carboxylat-
e (350 mg) in ethanol (3.5 ml) was added 1M aqueous sodium
hydroxide (1.79 ml), and the reaction solution was stirred at
50.degree. C. for 3 hours. The reaction solution was cooled to
4.degree. C., and 1M hydrochloric acid was added to acidify the
solution. The mixture was extracted with a mixture of chloroform
and methanol (4:1) and washed with water. The organic layer was
dried over magnesium sulfate and then filtered. The filtrate was
concentrated under reduced pressure to obtain
4-chloro-5-(1,2,4-oxadiazole-5-yl)-1H-pyrrolo[2,3-b]pyridine (215
mg) as a white solid.
TABLE-US-00046 TABLE 46 Pr Structure Data 35 ##STR00198## MS: 219
(M - H)+
Preparation 36
[0162] t-Butyl
rel-(1'R,3'S,5'S,7's)-5'H-spiro[1,3-dioxolane-2,2'-tricyclo[3.3.1.1.about-
.3,7.about.]decane]-5'-yl carbamate (420 mg) was dissolved in
tetrahydrofuran (4.2 ml) and water (4.2 ml), para-tosylic acid
monohydrate (516 mg) was added, and the mixture was stirred at
60.degree. C. for 4 hours. The reaction solution was evaporated
under reduced pressure, and saturated aqueous sodium
hydrogencarbonate was added. The mixture was extracted with ethyl
acetate. The organic layer was washed with saturated brine, dried
over magnesium sulfate, and evaporated under reduced pressure. The
residue was purified by silica gel column chromatography
(n-hexane:ethyl acetate) to obtain t-butyl
(cis-4-oxoadamantan-1-yl)carbamate (120 mg).
[0163] The compound in Preparation 36-1 shown in the following
table was produced using the corresponding starting compound
according to the method similar to that described in Preparation
36.
TABLE-US-00047 TABLE 47 Pr Structure Data 36 ##STR00199## MS: 288
(M + H)+ 36-1 ##STR00200## MS: 220 (M + H)+
Preparation 37
[0164] To a reaction solution of
2-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl]-1H-isoindole-1,3(2H)-dione
(1.4 g) in tetrahydrofuran (28 ml) and ethanol (28 ml) was added
80% aqueous hydrazine monohydrate (1.1 ml), and the mixture was
refluxed for 3 hours. After the reaction solution was cooled to
ambient temperature, insoluble matter was removed by filtration.
The filtrate was concentrated under reduced pressure to reduce the
amount of the solvent. To the residue was added dichloromethane,
and the mixture was washed with 1M aqueous sodium hydroxide, dried
over anhydrous magnesium sulfate, and evaporated under reduced
pressure. To the residue was added methanol, the mixture was
converted into hydrochloride by adding 4M hydrochloric acid/dioxane
solution, concentrated under reduced pressure and dried to hardness
to obtain (1R,2R,4S)-bicyclo[2.2.1]heptane-2-amine hydrochloride
(0.6 g).
[0165] The compound in Preparation 37-1 shown in the following
table was produced using the corresponding starting compound
according to the method similar to that described in Preparation
37.
TABLE-US-00048 TABLE 48 Pr Structure Data 37 ##STR00201## MS: 112
(M + H)+ 37-1 ##STR00202## MS: 198 (M + H)+
Preparation 38
[0166] To a suspension of methyl
(2-{[4-chloro-6-(methylamino)-5-vinylpyridine-3-yl]carbonyl}hydrazino)(ox-
o)acetate (450 mg) in tetrahydrofuran (7 ml) and dioxane (7 ml) was
added diphosphorus pentasulfide (383 mg) under cooling in an ice
bath. After the mixture was stirred at ambient temperature for 5
hours. To the reaction mixture was added tetrahydrofuran (10 ml)
and diphosphorus pentasulfide (190 mg). After the mixture was
stirred at ambient temperature for 2 hours, water was added to the
reaction solution, and the pH was adjusted to approximately 10 with
aqueous sodium hydroxide, and the solution was extracted with ethyl
acetate. The organic layer was dried over magnesium sulfate and
filtered. The filtrate was concentrated under reduced pressure. The
residue was purified by silica gel chramatography
(chloroform:methanol) to obtain
methyl-5-(4-chloro-1H-pyrrolo[2,3,b]pyridine-5-yl)-1,3,4-thiadiazole-2-ca-
rboxylate (90 mg).
TABLE-US-00049 TABLE 49 Pr Structure Data 38 ##STR00203## MS: 317
(M + H)+
Preparation 39
[0167] The compounds in Preparations 39-1 to 39-4 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 45.
TABLE-US-00050 TABLE 50 Pr Structure Data 39 ##STR00204## MS: 304
(M + H)+, 326 (M + Na)+ 39-1 ##STR00205## MS: 316 (M + Na)+ 39-2
##STR00206## MS: 330 (M + Na)+ 39-3 ##STR00207## MS: 356 (M + Na)+
39-4 ##STR00208## MS: 356 (M + Na)+
Preparation 40
[0168] To a reaction solution of
4-Chloro-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine (2.26 g)
in tetrahydrofuran (16 ml) was added sec-butyllithium (14.6 ml)
dropwise in nitrogen atmosphere at -78.degree. C. After the mixture
was stirred at the same temperature for 30 minutes, a solution of
benzyl chloroformate (2.1 ml) in tetrahydrofuran (16 ml) was added
dropwise to the reaction mixture at -78.degree. C. Furthermore, the
reaction solution was stirred at -78.degree. C. for 15 minutes,
neutralized with saturated aqueous ammonium chloride (12 ml), and
extracted with ethyl acetate. The organic layer was washed with
saturated brine, dried over magnesium sulfate, and evaporated under
reduced pressure. The residue was dissolved in tetrahydrofuran (17
ml), 1M tetrabutylammonium fluoride/tetrahydrofuran solution (16.9
ml) was added, and the mixture was stirred at ambient temperature
for 3 hours. To the reaction solution were added ethyl acetate and
water, the mixture was extracted with ethyl acetate. The organic
layer was washed with saturated brine, dried over magnesium
sulfate, and evaporated under reduced pressure. The residue was
purified by silica gel column chromatography (n-hexane:ethyl
acetate) to obtain benzyl
4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylate (690 mg).
[0169] The compounds in Preparations 40-1 to 40-3 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 40.
TABLE-US-00051 TABLE 51 Pr Structure 40 ##STR00209## 40-1
##STR00210## 40-2 ##STR00211## 40-3 ##STR00212##
TABLE-US-00052 TABLE 52 Pr Data 40 1H-NMR (d6-DMSO).delta.: 5.40
(2H, s), 6.6 (1H, d, J = 1.8 Hz), 7.35-7.39 (3H, m), 7.41-7.45 (2H,
m), 7.71 (1H, d, J = 3.5 Hz), 8.75 (1H, s), 12.42 (1H, br). MS:
(+): 297 40-1 MS: 279 (M + Na)+ 40-2 MS: 247 (M + H)+ 40-3 MS: 285
(M - H)-
Preparation 41
[0170] Into a 100 ml metal sealed tube were put a stirring rod,
ethyl
4-{[(3-exo)8-benzyl-8-azabicyclo[3.2.1]oct-3-yl]amino}-6-chloro-5-nicotin-
ic acid ester (1.5 g), 28% aqueous ammonia (4.6 ml), and ethanol
(7.5 ml). The tube was closed and stirred at 90.degree. C. for 2
hours. After being cooled, the reaction solution was diluted with
methanol (20 ml) and evaporated under reduced pressure. The residue
was recrystallized from ethyl acetate-methanol to obtain ethyl
6-amino-4-{[(3-exo)8-benzyl-8-azabicyclo[3.2.1]oct-3-yl]amino}-5-nicotini-
c acid ester (1.3 g) as a yellow solid.
[0171] The compound in Preparation 41-1 shown in the following
table was produced using the corresponding starting compound
according to the method similar to that described in Preparation
41.
TABLE-US-00053 TABLE 53 Pr Structure Data 41 ##STR00213## MS: 426
(M + H)+ 41-1 ##STR00214## MS: 361 (M + H)+ 41-1 ##STR00215## MS:
361 (M + H)+
Preparation 42
[0172] The compounds in Preparations 42-1 to 42-26 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Example 7.
TABLE-US-00054 TABLE 54 Pr Structure 42-1 ##STR00216## 42-2
##STR00217## 42-3 ##STR00218## 42-4 ##STR00219## 42-5 ##STR00220##
42-6 ##STR00221## 42-7 ##STR00222## 42-8 ##STR00223## 42-9
##STR00224## 42-10 ##STR00225## 42-11 ##STR00226## 42-12
##STR00227## 42-13 ##STR00228## 42-14 ##STR00229## 42-15
##STR00230## 42-16 ##STR00231## 42-17 ##STR00232## 42-18
##STR00233## 42-19 ##STR00234## 42-20 ##STR00235## 42-21
##STR00236## 42-22 ##STR00237## 42-23 ##STR00238## 42-24
##STR00239## 42-25 ##STR00240## 42-26 ##STR00241##
TABLE-US-00055 TABLE 55 Pr Data 42-1 MS: 348 (M + H)+ 42-2 MS: 377
(M + H)+ 42-3 MS: 316 (M + Na)+ 42-4 MS: 370 (M + H)+ 42-5 MS: 384
(M + Na)+ 42-6 MS: 335 (M + H)+ 42-7 MS: 375 (M + H)+ 42-8 MS: 322
(M + H)+ 42-9 MS: 308 (M + H)+ 42-10 MS: 314 (M + Na)+ 42-11 MS:
384 (M + Na)+ 42-12 MS: 286 (M + Na)+ 42-13 MS: 384 (M + Na)+ 42-14
MS: 358 (M + Na)+ 42-15 MS: 358 (M + Na)+ 42-16 MS: 398 (M + Na)+
42-17 MS: 404 (M + Na)+ 42-18 MS: 412 (M + Na)+ 42-19 MS: 398 (M +
Na)+ 42-20 MS: 286 (M + Na)+ 42-21 MS: 418 (M + Na)+, 394 (M - H)-
42-22 MS: 300 (M + Na)+ 42-23 MS: 369 (M + Na)+ 42-24 MS: 286 (M +
Na)+ 42-25 MS: 346 (M + H)+ 42-26 MS: 322 (M + H)+, 344 (M + Na)+,
320 (M - H)-
Preparation 43
[0173] The compound in Preparation 43 shown in the following table
was produced using the corresponding starting compound according to
the method similar to that described in Example 41.
TABLE-US-00056 TABLE 56 Pr Structure Data 43 ##STR00242## MS: 264
(M + H)+
Preparation 44
[0174] To a solution of 4-aminoadamantan-1-ol (8.9 g) in
tetrahydrofuran (89 ml) were added benzyloxycarbonyl chloride (7.6
ml) and 1M aqueous sodium hydroxide (53.4 ml) dropwise successively
under ice cooling, and the mixture was stirred for 3 hours under
ice cooling. The reaction solution was poured into aqueous
potassium hydrogensulfate, and the mixture was extracted with ethyl
acetate. The organic layer was washed with saturated brine, dried
over anhydrous magnesium sulfate, and evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate=1:1 to 1:3) to obtain benzyl
rel-[(1R,2S,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (6.2 g) and
benzyl rel-[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]carbamate (5.3
g).
TABLE-US-00057 TABLE 57 Pr Structure Data 44 ##STR00243## MS: 324
(M + Na)+ 324 (M + Na)+ ##STR00244##
Preparation 45
[0175] To a solution of (1R,2S,4S)-bicyclo[2.2.1]heptane-2-ol (1.0
g) in tetrahydrofuran (10 ml) were added phthalimide (1.4 g) and
triphenylphosphine (2.6 g), and diethylazodicarboxylate (1.5 ml)
dropwise under ice cooling. The mixture was warmed to ambient
temperature and stirred for 24 hours. The reaction solution was
concentrated under reduced pressure, and the residue was purified
by silica gel column chromatography (n-hexane:ethyl acetate)=100:0
to 95:5) to obtain
2-[(1R,2R,4S)-bicyclo[2.2.1]kept-2-yl]-1H-isoindole-1,3(2H)-dione
(1.4 g) as a colorless solid.
[0176] The compound in Preparation 45-1 shown in the following
table was produced using the corresponding starting compound
according to the method similar to that described in Preparation
45.
TABLE-US-00058 TABLE 58 Pr Structure Data 45 ##STR00245## MS: 264
(M + Na)+ 45-1 ##STR00246## MS: 350 (M + Na)+
Preparation 46
[0177] A mixture of ethyl
6-chloro-4-{[5-methoxyadamantan-2-yl]amino}-5-nicotinic acid ester
(635 mg), benzylamine (253 .mu.l), diisopropylethylamine (270
.mu.l), and 2-propanol (3 ml) was subjected to microwave
irradiation under nitrogen atmosphere and heated at 90.degree. C.
for 30 minutes. After being cooled, the reaction solution was
diluted with ethyl acetate (20 ml) and poured into 1/2 saturated
aqueous ammonia chloride (20 ml). The mixture was extracted with
ethyl acetate (20 ml) two times, washed with brine (30 ml),
dehydrated with anhydrous magnesium sulfate, and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate) to obtain ethyl
6-benzylamino-4-{[5-methoxyadamantan-2-yl]amino}-5-nicotinic acid
ester (550 mg) as an orange solid.
[0178] The compounds in Preparations 46-1 to 46-2 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 46.
TABLE-US-00059 TABLE 59 Pr Structure Data 46 ##STR00247## trans MS:
481 (M + H)+ 46-1 ##STR00248## diastereomer of 46-2 cis or trans
unknown MS: 481 (M + H)+ 46-2 ##STR00249## diastereomer of 46-1 cis
or trans unknown MS: 481 (M + H)+
Preparation 47
[0179] A solution of
4-chloro-2-methyl-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine
(525 mg) in tetrahydrofuran (10 ml) was cooled to -78.degree. C.
under nitrogen atmosphere, and to the reaction mixture was added
0.99M sec-butyllithium/cyclohexane solution (4.1 ml) dropwise.
After the mixture was stirred at -78.degree. C., ethyl
chlorocarbonate (389 .mu.l) was added dropwise. The reaction
solution was stirred at -78.degree. C. for 30 minutes, saturated
aqueous ammonium chloride (20 ml) was added, and the temperature
was returned to ambient temperature. The reaction solution was
transferred into a separating funnel and extracted with ethyl
acetate. The organic layer was washed with brine, dried over
anhydrous magnesium sulfate, filtered, and evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography (n-hexane) to obtain ethyl
4-chloro-2-methyl-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carbo-
xylate (645 mg) as a colorless viscous liquid.
[0180] The compound in Preparation 47-1 shown in the following
table was produced using the corresponding starting compound
according to the method similar to that described in Preparation
47.
TABLE-US-00060 TABLE 60 Pr Structure Data 47 ##STR00250## MS: 417
(M + Na)+ 47-1 ##STR00251##
Preparation 48
[0181] A mixture of ethyl 4,6-dichloro-5-nitronicotinic acid ester
(1 g), 2-adamantamine hydrochloride (708 mg), diisopropylethylamine
(1.3 ml), and 2-propanol (4 ml) was subjected to microwave
irradiation under nitrogen atmosphere, and heated at 90.degree. C.
for 10 minutes. After being cooled, the reaction solution was
diluted with ethyl acetate (20 ml), and poured into 1/2 saturated
aqueous ammonium chloride (20 ml). The mixture was extracted with
ethyl acetate (20 ml) two times, washed with brine (30 ml),
dehydrated with anhydrous magnesium sulfate, and evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography (n-hexane:ethyl acetate) to obtain ethyl
4-(2-adamantylamino)-6-chloro-5-nicotinic acid ester (1.23 g) as an
orange solid.
[0182] The compounds in Preparations 48-1 to 48-5 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 48.
TABLE-US-00061 TABLE 61 Pr Structure 48 ##STR00252## 48-1
##STR00253## cis-trans mix 48-2 ##STR00254## trans 48-3
##STR00255## 48-4 ##STR00256## cis/trans mix 48-5 ##STR00257## cis
or trans unknown
TABLE-US-00062 TABLE 62 Pr Data 48 MS: 380 (M + H)+ 48-1 MS: 396 (M
+ H)+ 48-2 MS: 410 (M + H)+ 48-3 MS: 445 (M + H)+ 48-4 MS: 377 (M +
H)+ 48-5 MS: 410 (M + H)+
Preparation 49
[0183] A mixture of ethyl 4,6-dichloro-5-nitronicotinic acid ester
(333 mg), 4-amino-1-adamantanol (200 mg), diisopropylethylamine
(219 .mu.l), and isopropylalcohol (1 ml) was subjected to microwave
irradiation under nitrogen atmosphere and heated at 90.degree. C.
for 10 minutes. After the mixture was cooled, benzylamine (157
.mu.l) was added to the reaction solution, the mixture was
subjected to microwave irradiation again and heated at 90.degree.
C. for 10 minutes. After being cooled, the reaction solution was
diluted with ethyl acetate (20 ml), poured into 1/2 saturated
aqueous ammonium chloride (20 ml), extracted with ethyl acetate (20
ml) two times, washed with brine (30 ml), dried over anhydrous
magnesium sulfate, and filtered. The filtrate was evaporated under
reduced pressure. The residue was purified by silica gel column
chromatography (chloroform:methanol) to obtain ethyl
6-(benzylamino)-4-[(5-hydroxy-2-adamantyl)amino]-nicotinic acid
ester (515 mg) as an orange solid.
[0184] The compounds in Preparations 49-1 to 49-5 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 49.
TABLE-US-00063 TABLE 63 Pr Structure 49 ##STR00258## cis/trans mix
49-1 ##STR00259## cis/trans mix 49-2 ##STR00260## cis or trans
unknown 49-3 ##STR00261## cis 49-4 ##STR00262## trans 49-5
##STR00263## cis
TABLE-US-00064 TABLE 64 Pr Data 49 MS: 467 (M + H)+ 49-1 MS: 469 (M
+ H)+ 49-2 MS: 476 (M + H)+ 49-3 MS: 467 (M + H)+ 49-4 49-5 MS: 527
(M + H)+
Preparation 50
[0185] The compound in Preparation 50 shown in the following table
was produced using the corresponding starting compound according to
the method similar to that described in Example 10.
TABLE-US-00065 TABLE 65 Pr Structure 50 ##STR00264##
Preparation 51
[0186] The compound in Preparation 51 shown in the following table
was produced using the corresponding starting compound according to
the method similar to that described in Example 28.
TABLE-US-00066 TABLE 66 Pr Structure Data 51 ##STR00265## MS: 211
(M + H)+
Preparation 52
[0187] 10% Palladium on carbon (50% wet) (40 mg) was added to a
solution of benzyl
4-[(5-carbamoyladamantan-2-yl)amino]-1H-pyrrolo-[2,3-b]pyridine-
-5-carboxylate (183 mg) in methanol (5 ml) and 1,4-dioxane (5 ml),
and hydrogenated under hydrogen atmosphere for 5 hours. Resulting
precipitates were dissolved by tetrahydrofuran and filtered out the
catalysts. The filtrates were evaporated in vacuo to give
4-[(5-carbamoyladamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxyl-
ic acid (117 mg).
[0188] The compounds in Preparations 52-1 to 52-17 shown in the
following table were produced using the corresponding starting
compounds according to the method similar to that described in
Preparation 52.
TABLE-US-00067 TABLE 67 Pr Structure 52-1 ##STR00266## diastereomer
of 52-14 cis or trans unknown 52-2 ##STR00267## cis/trans mix 52-3
##STR00268## 52-4 ##STR00269## cis/trans mix 52-5 ##STR00270## 52-6
##STR00271## 52-7 ##STR00272## cis or trans unknown 52-8
##STR00273## cis or trans unknown 52-9 ##STR00274## cis or trans
unknown 52-10 ##STR00275## cis/trans mix 52-11 ##STR00276## 52-12
##STR00277## diastereomer of 53-17 cis or trans unknown 52-13
##STR00278## cis or trans unknown 52-14 ##STR00279## diastereomer
of 53-1 cis or trans unknown 52-15 ##STR00280## 52-16 ##STR00281##
52-17 ##STR00282## diastereomer of 53-12 cis or trans unknown
TABLE-US-00068 TABLE 68 Pr Data 52-1 MS: 355 (M + H)+ 52-2 MS: 370
(M + H)+ 52-3 MS: 168 (M + H)+. 52-4 MS: 267 (M + H)+ 52-5 MS: 316
(M + H)+ 52-6 MS: 313 (M - H)- 52-7 MS: 390, 392 (M + H)+ 52-8 MS:
230, 232 (M + H)+ 52-9 MS: 381 (M + H)+ 52-10 MS: 221 (M + H)+
52-11 MS: 284 (M + H)+ 52-12 MS: 394 (M + H)+ 52-13 MS: 427 (M +
H)+ 52-14 MS: 355 (M + H)+ 52-15 MS: 168 (M + H)+. 52-16 1H-NMR
(400 MHz, CDCl.sub.3).delta.: 1.46 (9H, s), 1.61-2.29 (10H, m),
3.33 (1H, dd, J = 6.2, 6.2 Hz), 4.06-4.29 (2H, m) MS: 227 (M + H)+
52-17 MS: 394 (M + H)+
Preparation 53
[0189] The compound in Preparation 53-1 to 53-4 shown in the
following table was produced using the corresponding starting
compound according to the method similar to that described in
Example 16.
TABLE-US-00069 TABLE 69 Pr Structure 53-1 ##STR00283## 53-2
##STR00284## cis/trans mix 53-3 ##STR00285## 53-4 ##STR00286##
trans
TABLE-US-00070 TABLE 70 Pr Structure 53-1 MS: 143 (M - H)- 53-2 MS:
430 (M + Na)+ 53-3 MS: 176 (M - H)- 53-4 MS: 372, 374 (M + H)+
Example 1
[0190] To a solution of
5-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-methyl-1,3,4-oxadiazole-2-c-
arboxamide (18 mg) in 1-methyl-2-pyrrolidone (0.18 ml) were added
N,N-dibutyl-1-butaneamine (0.046 ml) and
cis-(1S,3R,4R,5S)-4-aminoadamantan-1-ol (32.5 mg) under ambient
temperature. The mixture was heated immediately to 150.degree. C.
and stirred for 2 hours. After the disappearance of the starting
compound was ascertained, the residue was purified by silica gel
column chromatography (chloroform:methanol=97:3 to 85:15) to obtain
cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]-
pyridine-5-yl)-N-methyl-1,3,4-oxadiazole-2-carboxamide (19.8 mg) as
a white solid.
Example 2
[0191] To
1-[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methaneamine (61
mg) were added a solution of
4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (39 mg) in
1-methyl-2-pyrrolidone (0.6 ml), triethylamine (0.056 ml), and
sodium iodide (3 mg), and the mixture was stirred at 130.degree. C.
for 17 hours. After the reaction mixture was left to cool, to the
reaction mixture were added N,N-dimethylformamide (0.3 ml) and
water (0.1 ml), and the reaction mixture was dissolved. The
reaction mixture was directly purified by preparative HPLC (10
mM-NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=98:2 to 30:70).
The active fraction was concentrated and dried to hardness to
obtain
4-({[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}amino)-1H-pyrr-
olo[2,3-b]pyridine-5-carboxamide (33.5 mg) as a solid.
Example 3
[0192] To a suspension methyl
4-(2-oxo-3,6-dihydropyrazolo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adaman-
tan-1-carboxy late (40 mg) in methanol (0.4 ml) and dioxane (0.4
ml) was added 1M aqueous sodium hydroxide (0.22 ml), and the
suspension was refluxed for 2 hours. The reaction solution was
cooled to ambient temperature, the pH was adjusted to 5 with 1M
aqueous hydrochloric acid and pH 4 buffer solution, and the
reaction solution was evaporated under reduced pressure. The
obtained solid was collected by filtration and washed with water to
obtain
4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamant-
an-1-carboxylic acid (32 mg).
Example 4
[0193]
4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)a-
damantan-1-carboxylic acid (50 mg) was suspended in N,N-dimethyl
formamide (1 ml). To the suspension were added aminoacetonitrile
hydrochloride (17 mg), 1-hydroxybenzotriazole (28 mg),
diisopropylethylamine (62 .mu.l), and
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (41
mg) successively, and the mixture was stirred overnight at ambient
temperature. To the reaction solution were added ethyl acetate and
water, and the organic layer was extracted. The organic layer was
washed with saturated brine, dried over magnesium sulfate, and
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography (chloroform:methanol) to obtain
N-(cyanomethyl)-4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine--
1(2H)-yl)adamantan-1-carboxamide (23 mg).
Example 5
[0194] To a solution of 3-methylbenzoic acid (22.4 mg) in
1-methyl-2-pyrrolidone (0.6 ml) were added
4-[(3-exo-8-azabicyclo[3.2.1]oct-3-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5--
carboxamide (42.8 mg) and 1-hydroxybenzotriazole (22.3 mg).
Furthermore, 1M
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/1-methyl-2-pyrrolidone
solution (0.225 ml) was added, and the mixture was stirred for 4
hours at 50.degree. C. After being cooled, the reaction solution
was directly purified by preparative HPLC system (10
mM-NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=98:2 to 30:70).
The active fraction was concentrated and dried to hardness to
obtain
4-{[(3-exo)-8-(3-methylbenzoyl)-8-azabicyclo[3.2.1]oct-3-yl)amino]}-1H-py-
rrolo[2,3-b]pyridine-5-carboxamide (34.8 mg) as a solid.
Example 6
[0195] To a solution of 2-aminoethanol (18.6 mg) in
1-methyl-2-pyrrolidone (0.6 ml) were added
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (41 mg) and 1-hydroxybenzotriazole (18.6
mg). Furthermore,
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide/1-methyl-2-pyrrolidone
solution (0.188 ml) was added, and the mixture was stirred for 6
hours at 60.degree. C. After being cooled, the reaction solution
was directly purified by preparative HPLC (10
mM-NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=98:2 to 30:70).
The active fraction was concentrated and dried to hardness to
obtain
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-N-(2-hydroxyethyl)-1H-pyrrolo[-
2,3-b]pyridine-5-carboxamide (22.9 mg) as a solid.
Example 7
[0196] To a solution of ethyl
3-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-
-yl)-1,2,4-oxadiazole-5-carboxylate (25 mg) in
1-methyl-2-pyrrolidone (0.25 ml) was added 2-piperazin-1-ylethanol
(8.5 mg) under ambient temperature. The mixture was immediately
warmed to 50.degree. C. and stirred for 0.5 hour. After the
disappearance of the starting compound was ascertained, the residue
was purified by silica gel column chromatography
(chloroform:methanol=96:4 to 87:13) to obtain
cis-(1s,3R,4R,5S)-4-{[5-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}-1-
,2,4-oxadiazole-3-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol
(22.6 mg) as a yellowish white solid.
Example 8
[0197] To a solution of methylamine hydrochloride (4.7 mg) in
1-methyl-2-pyrrolidone (0.3 ml) were added ethyl
cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]-
pyridine-5-yl)-1,2,4-oxadiazole-5-carboxylate (14.8 mg) and
diisopropylamine (0.0183 ml), and the mixture was stirred for 6
hours at 90.degree. C. After being cooled, the reaction solution
was directly purified by preparative HPLC system (10
mM-NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=90:10 to 20:80).
The active fraction was concentrated and dried to hardness to
obtain
5-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-
-yl)-N-methyl-1,2,4-oxadiazole-3-carboxamide (6.74 mg) as a
solid.
Example 9
[0198] To a solution of
cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]-
pyridine-5-yl)-N-piperidine-4-yl-1,2,4-oxadiazole-3-carboxamide
dihydrochloride (20 mg) in 1-methyl-2-pyrrolidone (0.25 ml) were
added N-ethyl-N-isopropylpropan-2-amine (0.025 ml) and acetic
anhydride (0.043 ml) under ambient temperature, and the mixture was
stirred for 1 hour. The residue was purified by silica gel column
chromatography (chloroform:methanol=99:1 to 89:11) to obtain
cis-N-(1-acetylpiperidine-4-yl)-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-
-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-yl)-1,2,4-oxadiazole-3-carboxamide
(7.8 mg) as a yellowish white solid.
Example 10
[0199] To
1-(5-aminoadamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b-
]pyridine-2 (1H)-one dihydrochloride (15 mg) were added
dichloromethane-methanol and saturated aqueous sodium
hydrogencarbonate, and the organic layer was extracted. The organic
layer was dried over magnesium sulfate and filtered. The filtrate
was evaporated under reduced pressure. The residue was suspended in
dichloromethane (7.5 ml), and triethylamine (13 .mu.l) and
propanoyl chloride (4 .mu.l) were added. The mixture was stirred
overnight at ambient temperature. The reaction solution was
purified by NH silica gel column chromatography
(chloroform:methanol) to obtain
N-[4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adam-
antan-1-yl]propanamide (2 mg).
Example 11
[0200] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (30 mg) in N,N-dimethylformamide (0.21 ml)
were added N,N'-carbonyl diimidazole (22.3 mg) and 2M
dimethylamine/methanol solution (0.183 ml) successively under
ambient temperature. The mixture was stirred at ambient temperature
for 18 hours. Water was added to the reaction solution, and the
reaction solution was filtered. The solid residue was washed with
water and dried. The residue was purified by thin-layer silica gel
column chromatography (chloroform:methanol=10:1) to obtain methyl
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylate (18 mg) as a yellowish white solid.
Example 12
[0201] To a suspension of
rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (25 mg) in N,N-dimethylformamide (0.4 ml)
were added potassium carbonate (15.8 mg) and 1-chloroacetone
(0.0073 ml), and the mixture was stirred at ambient temperature for
5 hours. The reaction solution was diluted with ethyl acetate,
washed with water and saturated brine, dried over anhydrous sodium
sulfate, and filtered. The filtrate was evaporated under reduced
pressure. The residue was purified by silica gel column
chromatography (chloroform:methanol) to obtain
rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid 2-oxopropyl ester (20.8 mg) as a white
solid.
Example 13
[0202] To a suspension of
rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (45 mg), acetamide oxime (25.5 mg), and
1-hydroxybenzotriazole (27.9 mg) in N,N-dimethylformamide (1.08 ml)
were added triethylamine (0.077 ml) and
N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride
(39.5 mg). The mixture was stirred for 2 hours at 60.degree. C. The
reaction solution was diluted with chloroform and ethanol, washed
with saturated brine, dried over anhydrous sodium sulfate, and
filtered. The filtrate was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography
(chloroform:methanol) to obtain
rel-(1Z)-N'-{[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrol-
o[2,3-b]pyridine-5-yl)carbonyl]oxy}ethanimidamide (38.9 mg) as
white powder.
Example 14
[0203] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (30 mg) in N,N-dimethylformamide (0.9 ml)
were added N,N'-carbonyldiimidazole (83 mg),
N-ethyl-N-isopropylpropane-2-amine (0.018 ml), and carbonic
acid-guanidine (1:2) (82.5 mg) successively under ambient
temperature. Furthermore, after 1-methyl-2-pyrrolidone (0.3 ml) was
added, the mixture was immediately warmed to 60.degree. C. and
stirred for 5 hours. The mixture was evaporated under reduced
pressure and dried. The residue was purified by basic thin-layer
silica gel column chromatography (chloroform:methanol=6:1) to
obtain
cis-N-(diaminomethylene)-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-
-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (18.1 mg) as a yellowish
white solid.
Example 15
[0204] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (80 mg) in 1-methyl-2-pyrrolidone (0.8 ml)
were added (O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate) (HATU) (139 mg),
N-ethyl-N-isopropylpropane-2-amine (0.17 ml), and hydrazine
carboxamide hydrochloride (32.7 mg) successively under ambient
temperature. The mixture was stirred for 3 hours at ambient
temperature. To the reaction solution were added ethyl acetate and
diisopropyl ether, and the mixture was filtered. The solid residue
was washed with ethyl acetate-diisopropyl ether and dried to obtain
cis-2-[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b-
]pyridine-5-yl)carbonyl]hydrazinecarboxamide (90 mg) as a yellowish
white solid.
Example 16
[0205]
4-(2-Oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)a-
damantan-1-carboxamide (70 mg) was suspended in
N,N-dimethylformamide (1 ml), and 2,4,6-trichloro-1,3,5-triazine
(37 mg) was added under ice cooling. The mixture was stirred at
ambient temperature for 4 hours. To the reaction solution was added
saturated aqueous sodium hydrogencarbonate, and the obtained solid
was collected by filtration, washed with water and ethyl acetate to
obtain
4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adamant-
an-1-carbonitrile (30 mg).
Example 17
[0206] To a solution of
5-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-
-yl)-1,2,4-oxadiazole-3-carboxamide (30 mg) in tetrahydrofuran (1
ml) were added pyridine (37 .mu.l) and trifluoroacetic anhydride
(64 .mu.l) under ice cooling, and the reaction solution was stirred
under ambient temperature for 30 minutes. Water was added to the
reaction solution, and the precipitate was collected by filtration
and dissolved in tetrahydrofuran (1 ml). To the reaction solution
was added 1M aqueous sodium hydroxide (0.114 ml) under ice cooling,
and the reaction solution was stirred for 1 hour under ambient
temperature. The reaction solution was extracted with chloroform
and washed with water. The organic layer was dried over magnesium
sulfate and filtered. The filtrate was concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (chloroform:methanol=100:0 to 90:10) to obtain
5-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-
-yl)-1,2,4-oxadiazole-3-carbonitrile (5 mg) as a white solid.
Example 18
[0207] t-Butyl
[4-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-yl)adaman-
tan-1-yl]carbamate (118 mg) was suspended in dioxane (1.2 ml). 4M
hydrochloric acid/dioxane (0.7 ml) was added, and the mixture was
stirred overnight at ambient temperature. To the reaction solution
was added ethyl acetate, and the obtained solid was collected by
filtration and washed with ethyl acetate to obtain
1-(5-adamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H-
)-one dihydrochloride (108 mg).
Example 19
[0208] To
3-(3,4-dimethoxybenzyl)-N-(4-fluorobenzyl)-7-{(5-hydroxyadamanta-
n-2-yl)amino}-3H-imidazo[4,5-b]pyridine-6-carboxamide (170 mg) was
added trifluoroacetic acid (1.7 ml), and the mixture was stirred at
ambient temperature for overnight. The reaction solution was
neutralized with saturated aqueous sodium hydrogencarbonate and
extracted with ethyl acetate and tetrahydrofuran. The organic layer
was washed with saturated brine, dried over magnesium sulfate, and
filtered. The filtrate was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography
(chloroform:methanol) to obtain
N-(4-fluorobenzyl)-7-{(5-hydroxyadamantan-2-yl)amino}-3H-imidazo[4,5-b]py-
ridine-6-carboxamide (31 mg).
Example 20
[0209] To a solution of
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-N-(tetrahydro-2H-pyran-2-yloxy-
)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (35 mg) in ethanol (0.525
ml) was added 2M hydrochloric acid/ethanol solution (0.205 ml)
under ambient temperature. The reaction solution was stirred under
ambient temperature for 2 hours. To the reaction solution was added
ethyl acetate, and the precipitate was collected by filtration to
obtain
N-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxamide hydrochloride (18 mg) as a white solid.
Example 21
[0210] To a solution of
3-{[(triisopropylsilyl)oxy]methyl}bicyclo[2.2.1]hept-2-yl]-3,6-dihydroimi-
dazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (45 mg) in
tetrahydrofuran (0.15 ml) was added 1M
tetrabutylammoniumfluoride/tetrahydrofuran solution (297 .mu.l),
and the mixture was stirred overnight at ambient temperature. The
reaction solution was evaporated under reduced pressure. The
residue was purified by silica gel column chromatography (ethyl
acetate:methanol) to obtain
1-[3-(hydroxymethyl)bicyclo[2.2.1]hept-2-yl]-3,6-dihydroimidazo[4,5-d]pyr-
rolo[2,3-b]pyridine-2(1H)-one (14.8 mg) as a white solid. To a
solution of
rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carbohydrazide in 1-methyl-2-pyrrolidone (1 ml) were added
triethyl orthoformate (340 .mu.l) and p-toluene sulfonic acid
monohydrate (5.6 mg). After stirring at 120.degree. C. for 30
minutes, triethyl orthoformate (340 .mu.l) and p-toluene sulfonic
acid monohydrate (5.6 mg) were added. After the mixture was stirred
at 120.degree. C. for 40 minutes, the reaction solution was
extracted with 20% chloroform/methanol solution, and washed with
saturated aqueous sodium bicarbonate. The organic layer was dried
over magnesium sulfate and filtered. The filtrate was evaporated
under reduced pressure. The residue was purified by silica gel
chromatography (chloroform:methanol) to obtain
rel-(1s,3R,4R,5S)-4-{[1-(diethoxymethyl)-5-(1,3,4-oxazole-2-yl)-1H-pyrrol-
o[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (28 mg) and
rel-(1s,3R,4R,5S)-4-{[5-(1,3,4-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4--
yl]amino}adamantan-1-ol (70 mg).
Example 22
[0211] The cis-trans mixture of
N-(cyanomethyl)-4-(2-oxo-3,6-dihydropyrazolo[4,5-d]pyrrolo[2,3-b]pyridine-
-1(2H)-yl)adamantan-1-carboxylate was separated by HPLC (aqueous
(NH.sub.4)HCO.sub.3-aqueous ammonia (pH=9.2):acetonitrile) to
obtain a fraction (8 mg) having a peak with a short retention time
and another fraction (15 mg) having a peak with a long retention
time.
Example 23
[0212]
4-(Adamantan-1-ylamino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid
(17 mg) and triethylamine (15 .mu.l) were dissolved in dioxane (0.5
ml). To the mixture was added diphenylphosphoryl azide (DPPA) (18
.mu.l) at 120.degree. C. under stirring. The mixture was stirred at
the same temperature for 2 hours and cooled to ambient temperature.
The obtained solid was collected by filtration and washed with
acetonitrile to obtain
(adamantan-1-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-on-
e (11 mg).
Example 24
[0213] To a mixture of
5,6-diamino-4-{cis-5-hydroxyl-2-adamantyl]amino}-N-methylnicotinamide
(9 mg) and triethyl orthoformate (0.15 ml) was added concentrated
hydrochloric acid (5 .mu.l), and the mixture was heated at
90.degree. C. for 3 hours. After being cooled, the reaction
solution was diluted with ethyl acetate (10 ml), and saturated
aqueous sodium hydrogencarbonate (10 ml) was added. The organic
layer was extracted, dried over magnesium sulfate, and
concentrated. The residue was purified by silica gel column
chromatography (chloroform:methanol) to obtain
7-{[cis-5-hydroxyadamantan-2-yl]amino}-N-methyl-3H-imidazo[4,5-b]pyridine-
-6-carboxyamide (0.5 mg) as a pale yellow solid.
Example 25
[0214] A mixture of acetic anhydride (897 .mu.l) and formic acid
(342 .mu.l) was stirred at 60.degree. C. for 2 hours. After the
mixture was cooled, a solution of
4-(2-adamantylamino)-6-amino-5-nicotinamide (200 mg) in
dichloromethane (1 ml) was added dropwise. The reaction mixture was
stirred at ambient temperature for 1 hour and at 50.degree. C. for
2 hours. After being cooled, the reaction mixture was evaporated
under reduced pressure. To the residue were added ethanol (2 ml),
tetrahydrofuran (1 ml), and water (1 ml). Then, iron powder (169
mg) and ammonium chloride (16 mg) were added to the mixture. The
mixture was stirred at 120.degree. C. for 6 hours. After being
cooled, the mixture was evaporated under reduced pressure. To the
residue was added saturated aqueous sodium hydroxide (10 ml), and
the mixture was extracted with ethyl acetate. The organic layer was
dried over magnesium sulfate and filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (chloroform:methanol) to obtain
7-(2-adamantylamino)-3H-imidazo[4,5-b]pyridine-6-carboxyamide (110
mg) as a white solid.
Example 26
[0215] To a mixture of isopropyl
6-(benzylamino)-4-{[cis-5-hydroxyadamantan-2-yl]amino}-5-nicotinate
(90 mg), ammonium formate (236 mg), and methanol was added 10%
palladium on carbon (50% wet) (40 mg), and the mixture was stirred
for 5 hours under refluxing. After being cooled, the reaction
mixture was filtered to remove catalyst. The filtrate was
concentrated under reduced pressure. To the residue were added
triethyl orthoformate (0.6 ml) and concentrated hydrochloric acid
(31 .mu.l), and the mixture was stirred at ambient temperature for
3 hours. After the reaction mixture was diluted with ethyl acetate
(20 ml), saturated aqueous sodium hydrogencarbonate (20 ml) was
added. The organic layer was extracted, dried over magnesium
sulfate, and filtered. The filtrate was concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (chloroform:methanol) to obtain
isopropyl-rel-7-{[(1R,2R,3S,5S)-5-hydroxyadamantan-2-yl]amino}-3H-imidazo-
[4,5-b]pyridine-6-carboxylate (45 mg) as a white solid.
Example 27
[0216] To a solution of
4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carbonitri-
le (100 mg) in methanol (3 ml) were added hydroxylamine
hydrochloride (34 mg) and sodium hydrogencarbonate (82 mg), and the
reaction solution was stirred at 90.degree. C. for 18 hours. The
reaction solution was concentrated under reduced pressure, and the
residue was purified by silica gel column chromatography
(chloroform:methanol=100:0 to 90:10) to obtain
N'-hydroxy-4-{[(2r,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-
-b]pyridine-5-carboxyimidamide (32 mg) as a white solid and to
obtain
N'-hydroxy-4-{[(2s,5r)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyri-
dine-5-carboxyimidamide (35 mg) as a white solid.
Example 28
[0217] A solution of
rel-(1Z)-N'-{[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrol-
o[2,3-b]pyridin-5-yl)carbonyl]oxy}ethanimidamide (16.2 mg) in
N,N-dimethylformamide (0.4 mL) was stirred at 160.degree. C. for 3
hours, then stirred at 165.degree. C. for 1 hour. The reaction
mixture was diluted with ethyl acetate, washed with 10% sodium
chloride aqueous solution, water (three times), and brine, dried
over magnesium sulfate, filtered and evaporated in vacuo. The
residue was purified by silica gel column chromatography
(chlcroform:methanol, 15:1) to give
rel-(1s,3R,4R,5S)-4-{[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrrolo[2,3-b]-
pyridin-4-yl]amino}adamantan-1-ol (6.0 mg) as a orange
crystals.
Example 29
[0218] To a solution of
rel-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carbohydrazide in 1-methyl-2-pyrrolidone (1 ml) were added
triethyl orthoformate (340 .mu.l) and p-toluene sulfonic acid
monohydrate (5.6 mg). After the mixture was stirred at 120.degree.
C. for 30 minutes, triethyl orthoformate (340 .mu.l) and p-toluene
sulfonic acid monohydrate (5.6 mg) were added. After the mixture
was stirred at 120.degree. C. for 40 minutes, the reaction solution
was extracted with 20% chloroform/methanol solution and washed with
saturated aqueous sodium bicarbonate. The organic layer was dried
over magnesium sulfate and filtered. The filtrate was concentrated
under reduced pressure. The residue was purified by silica gel
chromatography (chloroform:methanol) to obtain
rel-(1s,3R,4R,5S)-4-{[1-(diethoxymethyl)-5-(1,3,4-oxazole-2-yl)-
-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamantan-1-ol (28 mg) and to
obtain
rel-(1s,3R,4R,5S)-4-{[5-(1,3,4-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4--
yl]amino}adamantan-1-ol (70 mg).
Example 30
[0219] To a solution of
N'-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]py-
ridine-5-carboximidamide (45 mg) in dichloromethane (0.45 ml) were
added pyridine (32 .mu.l) and acetic anhydride (19 .mu.l). The
reaction solution was stirred under ambient temperature for 2
hours. To the reaction solution were further added pyridine (32
.mu.l) and acetic anhydride (19 .mu.l), and the reaction solution
was stirred at 60.degree. C. for 2 hours. To the reaction solution
was further added pyridine (0.5 ml), and the mixture was stirred at
90.degree. C. for 16 hours. The reaction solution was extracted
with chloroform and washed with water. The organic layer was dried
over magnesium sulfate and filtered. The filtrate was concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (chloroform:methanol=100:0 to 90:10) to
obtain
(1s,4r)-4-{[5-(5-methyl-1,2,4-oxadiazole-3-yl)-1H-pyrrolo[2,3-b]pyridine--
4-yl]amino}adamantan-1-ol (10 mg) as a white solid.
Example 31
[0220] To a solution of
N'-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]py-
ridine-5-carboxyimidamide (25 mg) in N,N-dimethylformamide (0.5 ml)
were added pyridine (9 .mu.l) and 2-ethylhexyl chlorocarbonate (14
.mu.l) under ice cooling. The reaction solution was stirred at
ambient temperature for 2 hours. To the reaction solution was added
water. The mixture was extracted with chloroform and washed with
water. The organic layer was dried over magnesium sulfate and
filtered. The filtrate was concentrated under reduced pressure. The
residue was dissolved in N,N-dimethylformamide (0.5 ml) and xylene
(0.5 ml), and the reaction solution was stirred at 150.degree. C.
for 2 hours. After the reaction solution was cooled to ambient
temperature, the precipitate was collected by filtration and washed
with a small amount of ethyl acetate to obtain
(1s,4r)-4-(3-aminopyrazolo[3,4-d]pyrrolo[2,3-b]pyridine-1(6H)-yl)adamanta-
n-1-ol (8 mg) as a white solid.
Example 32
[0221] To a solution of
3-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-(2-methoxyethyl)-1,2,4-oxad-
iazole-5-carboxamide (35 mg) in 1-methyl-2-pyrrolidone (0.35 ml)
were added N,N-dibutyl-1-butanamine (0.078 ml) and
cis-(1S,3R,4R,5S)-4-aminoadamantan-1-ol (36 mg) under ambient
temperature. The mixture was immediately heated to 190.degree. C.
and stirred for 1 hour. After the disappearance of the starting
compound was ascertained, water was added to the reaction solution,
and the solution was filtered. The solid residue was washed with
water and dried. The solid residue was purified by thin-layer
silica gel column chromatography (chloroform:methanol=12:1) to
obtain
cis-N-{1-[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]-1,6-dihydropyrazolo[3,4--
d]pyrrolo[2,3-b]pyridine-3-yl}-N'-(2-methoxyethyl)ethanediamide
(18.1 mg) as a yellowish white solid.
Example 33
[0222] To a solution of
3-(4-chloro-1H-pyrrolo[2,3-b]pyridine-5-yl)-N-methyl-1,2,4-oxadiazole-5-c-
arboxamide (14.2 mg) in 1-methyl-2-pyrrolidone (0.142 ml) were
added N,N-dibutyl-1-butanamine (0.0487 ml) and
cis-(1S,3R,4R,5S)-4-aminoadamantan-1-ol (25.7 mg). The mixture was
stirred for 100 minutes using a microwave reaction system at
200.degree. C. After being cooled, the reaction solution was
directly purified by preparative HPLC system (10 mM
NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=95:5 to 20:80). The
active fraction was concentrated to obtain
cis-N-{1-[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]-1,6-dihydropyr-
azolo[3,4-d]pyrrolo[2,3-b]pyridine-3-yl}-N'-methylethanediamide
(11.1 mg) as a solid.
Example 34
[0223] To a suspension of
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rbonitrile (60 mg) in toluene (0.6 ml) were added thiosemicarbazide
(35.5 mg) and trifluoroacetic acid (0.15 ml), and the mixture was
stirred at 70.degree. C. for 6 hours. To the mixture were further
added thiosemicarbazide (35.5 mg) and trifluoroacetic acid (0.15
ml), and the mixture was stirred at 90.degree. C. for 51 hours.
Furthermore, thiosemicarbazide (17.8 mg) was added, and the mixture
was stirred at 90.degree. C. for 48 hours. The reaction solution
was alkalified with saturated aqueous sodium hydrogencarbonate and
extracted with ethyl acetate. The organic layer was washed with
water and saturated brine, dried over anhydrous sodium sulfate, and
evaporated under reduced pressure. The residue was purified by
silica gel column chromatography (chloroform:methanol) to obtain
(1s,4r)-4-{[5-(5-amino-1,3,4-thiadiazole-2-yl)-1H-pyrrolo[2,3-b]pyridine--
4-yl]amino}adamantan-1-ol (8.3 mg) as a white solid.
Example 35
[0224] To a solution of ethyl
5-[4-(2-oxo-3,6-dihydroimidazo[2,3-b]pyridine-1(2H)-yl)adamantan-1-yl]-1,-
2,4-oxadiazole-3-carboxylate (30 mg) in tetrahydrofuran (1 ml) was
added lithium aluminum hydride (10 mg) under ice cooling, and the
mixture was stirred for 1 hour at ambient temperature. To the
reaction solution was added 1M aqueous sodium hydroxide. The
mixture was stirred for 30 minutes at ambient temperature and
extracted with chloroform. The organic layer was dried over
magnesium sulfate and filtered, and the filtrate was concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (chloroform:methanol) to obtain
1-{5-[3-(hydroxymethyl)-1,2,4-oxadiazole-5-yl]adamantan-2-yl}-3,6-dihydro-
imiazo[4,5-d]pyrrolo[2,3-b]pyridine-2(1H)-one (3 mg).
Example 36
[0225] To a solution of
4-{[(2r,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carb-
onitrile (27 mg) in ethanol (0.5 ml) were added 10% palladium on
carbon (30 mg) and 2M hydrochloric acid/ethanol solution (0.5 ml).
The reaction solution was stirred for 3 hours under hydrogen
atmosphere at 60.degree. C. The catalyst was filtered with Celite,
and the filtrate was concentrated under reduced pressure to obtain
(1s,4r)-4-{[5-(aminomethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amino}adamanta-
n-1-ol trihydrochloride (37 mg) as a white solid.
Example 37
[0226] To a solution of
1-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-
-yl)ethanone (20 mg) in tetrahydrofuran (2.5 ml) was added lithium
aluminum hydride (19.4 mg) under ambient temperature. Furthermore,
the mixture was stirred at ambient temperature for 2 hours. After
the disappearance of the starting compound was ascertained, to the
reaction solution were added water (19 .mu.l), 2M aqueous sodium
hydroxide (19 .mu.l), and water (57 .mu.l) successively. The
precipitated solid was removed by Celite filtration and washed with
tetrahydrofuran. The filtrate was concentrated under reduced
pressure and purified by thin-layer silica gel column
chromatography (chloroform:methanol=4:1) to obtain
(1s,4r)-4-{[5-(1-hydroxyethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl]amin-
o}adamantan-1-ol (9.1 mg).
Example 38
[0227] To a solution of
4-{[(3-exo)-8-(5-nitropyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1-
H-pyrrolo[2,3-b]pyridine-5-carboxamide (25 mg) in methanol (0.5 ml)
were added ammonium formate (38.6 mg) and palladium on carbon (50%
wet) (1.3 mg), and the mixture was heated for 5 hours under
refluxing. After the mixture was cooled to ambient temperature, the
insoluble matter was removed by Celite filtration and washed with
methanol. The filtrate was evaporated under reduced pressure and
purified by thin-layer silica gel column chromatography
(chloroform:methanol=4:1) to obtain
4-{[(3-exo)-8-(5-aminopyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1-
H-pyrrolo[2,3-b]pyridine-5-carboxamide (12 mg).
Example 39
[0228] To a solution of
N'-(5-bromoadamantan-2-yl)-4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carbohydr-
azide (200 mg) in 1-methyl-2-pyrrolidone (1.5 ml) was added
triethylamine (0.2 ml), and the mixture was stirred at 200.degree.
C. using a microwave reaction system for 2 hours. After the
reaction solution was cooled, water was added to the reaction
solution, and the mixture was extracted with chloroform. The
organic layer was dried over magnesium sulfate and filtered. The
filtrate was concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (chloroform:methanol)
to obtain
1-(5-bromoadamantan-2-yl)-1,6-dihydropyrazolo[3,4-d]pyrrolo[2,3-b]pyridin-
e-3(2H)-one (91 mg).
Example 40
[0229] To a suspension of
4-{[(2R,5S)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rbonitrile (50 mg) in a mixture of toluene (1.5 ml) and
N,N'-dimethylformamide (1.5 ml) were added sodium azide (105 mg)
and triethylamine hydrochloride (223 mg), and the mixture was
stirred for at 100.degree. C. for 3 hours. To the reaction mixture
was added sodium azide (210 mg) and triethylamine hydrochloride
(446 mg), and the mixture was stirred at 100.degree. C. for 3.5
hours. The reaction solution was diluted with a mixture solvent of
dichloromethane:methanol (=10:1), and the organic layer was
separated. Furthermore, the water layer was extracted with a
mixture solvent of dichloromethane: methanol (=10:1) three times.
The obtained organic layers were combined, dried over anhydrous
sodium sulfate, and filtered. The filtrate was concentrated under
reduced pressure. The residue was purified by preparative TLC
(dichloromethane: methanol=10:1) to obtain
rel-(1s,3R,4R,5S)-4-{[5-(2H-tetrazole-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-y-
l]amino}adamantan-1-ol (35 mg) as a solid.
Example 41
[0230] To
4-[(5-bromoadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-car-
boxamide (52 mg) were added ethylene cyanhydrin (250 .mu.l) and
triethylamine (56 .mu.l), and the mixture was stirred for 20
minutes using a microwave reaction system at 150.degree. C. The
reaction solution was cooled and purified by silica gel column
chromatography (chloroform:methanol). The obtained fraction was
concentrated under reduced pressure, and water was added. The
obtained solid was collected by filtration to obtain
4-{[5-(2-cyanoethoxy)adamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboxamide (16 mg).
Example 42
[0231] To a solution of
4-({5-[5-(trichloromethyl)-1,2,4-oxadiazole-3-yl]-1H-pyrrolo[2,3-b]pyridi-
ne-4-yl}amino)adamantan-1-ol (80 mg) in 1-methyl-2-pyrrolidinone
(1.6 ml) was added ethylamine/methanol solution (2.0M) (1.7 ml)
under ice cooling. The reaction solution was stirred for 5 hours
under ambient temperature. To the reaction solution were added
ethyl acetate, tetrahydrofuran, and water. The mixture was
extracted with a mixture solvent of tetrahydrofuran and ethyl
acetate, and washed with saturated brine. The organic layer was
dried over magnesium sulfate and filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
silica gel (NH silica gel) column chromatography
(chloroform:methanol=100:0 to 91:9) to obtain
4-({5-[5-(ethylamino)-1,2,4-oxadiazole-3-yl]-1H-pyrrolo[2,3-b]pyridine-4--
yl}amino)adamantan-1-ol (50 mg) as a yellow solid.
Example 43
[0232]
4-[(5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carb-
oxamide (100 mg) was dissolved in 45% aqueous HBr (0.5 ml), and the
mixture was refluxed for 1.5 hours. The reaction solution was
cooled, and the obtained solid was collected by filtration and
washed with water. The obtained solid was dissolved in
dichloromethane and methanol, and purified by silica gel column
chromatography (chloroform:methanol) to obtain
4-[5-bromoadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carbox-
amide (85 mg).
Example 44
[0233]
(5-Hydroxyadamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]py-
ridine-2(1H)-one (92 mg) was suspended in dichloromethane, and
diethyl aminosulfur trifluoride (DAST) was added. The mixture was
stirred at ambient temperature for 1 hour. The saturated aqueous
sodium hydrogencarbonate and ethyl acetate were added. The obtained
solid was collected by filtration and washed with diisopropyl
ethylether to obtain
(5-fluoroadamantan-2-yl)-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine--
2(1H)-one (34 mg).
Example 45
[0234] To a solution of
cis-(1s,3R,4R,5S)-4-{[5-(2H-tetrazole-5-yl)-1H-pyrrolo[2,3-b]pyridine-4-y-
l]amino}adamantan-1-ol (55 mg) in 1-methyl-2-pyrrolidone (0.65 ml)
were added N-ethyl-N-isopropylpropane-2-amine (0.11 ml) and
iodomethane (0.015 ml) under ambient temperature, and the mixture
was stirred at ambient temperature for 4 hours. The residue was
purified by silica gel column chromatography
(chloroform:methanol=99:1 to 90:10) to obtain
cis-(1s,3R,4R,5S)-4-{[5-(2-methyl-2H-tetrazol-5-yl)-1H-pyrrolo[2,3-b]pyri-
dine-4-yl]amino}adamantan-1-ol (19.5 mg) as a major product (having
a larger Rf value obtained by TLC (chloroform-methanol=10:1)) and
to obtain
cis-(1s,3R,4R,5S)-4-{[5-(1-methyl-1H-tetrazole-5-yl)-1H-pyrrolo[2,3-b]pyr-
idine-4-yl]amino}adamantan-1-ol (4.5 mg) as a minor product (having
a smaller Rf value obtained by TLC (chloroform-methanol=10:1)), the
major and minor products each being obtained as a yellowish white
solid.
Example 46
[0235] To a solution of 2-chloronicotinonitrile (56.7 mg) and
4-[(3-exo)-8-azabicyclo[3.2.1]oct-3-ylamino]-1H-pyrrolo[2,3-b]pyridine-5--
carboxamide (58.4 mg) in 1-methyl-2-pyrrolidone (0.6 ml) were added
triethylamine (0.057 ml) and sodium iodide (3 mg), and the mixture
was stirred for 10 hours at 130.degree. C. After the reaction
mixture was left to cool, 1-methyl-2-pyrrolidone (0.3 ml) was added
to the reaction mixture, and the reaction mixture was dissolved.
The mixture was directly purified by preparative HPLC system (10 mM
NH.sub.4HCO.sub.3+NH.sub.3 (pH=9.2):CH.sub.3CN=98:2 to 60:40). The
active fraction was concentrated and dried to hardness to obtain
4-{[(3-exo)-8-(3-cyanopyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1-
H-pyrrolo[2,3-b]pyridine-5-carboxamide (10.1 mg) as a solid.
Example 47
[0236] To a solution of
4-{[(3-exo)-8-(5-aminopyridine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1-
H-pyrrolo[2,3-b]pyridine-5-carboxamide (11 mg) in
methanol/dichloromethane was added aqueous formalin (0.022 ml), and
the mixture was stirred at ambient temperature for 0.5 hours.
Sodium triacetoxyborohydride (30.9 mg) was further added, and the
mixture was stirred for 16 hours at ambient temperature. To the
reaction solution was added saturated aqueous sodium
hydrogencarbonate, and the mixture was stirred for 30 minutes at
ambient temperature and extracted with chloroform-methanol. The
extract was concentrated, and the obtained yellow oily matter was
purified by thin-layer silica gel column chromatography
(chloroform:methanol=7:1) to obtain
4-{[(3-exo)-8-(5-(dimethylamino)pyridine-2-yl)-8-azabicyclo[3.2.1]-
oct-3-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (5.2 mg) as
a yellowish white solid.
Example 48
[0237] To a suspension of
4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-ylamino]-1H-pyrrolo[2,3-b]pyridine-5-
-carboxamide dihydrochloride (25 mg) in
1,3-dimethyl-2-imidazolidinone (0.5 ml) was added triethylamine
(0.029 ml). Furthermore, mesyl chloride (0.0059 ml) was added under
ice cooling. After the mixture was stirred for 1 hour at ambient
temperature, diluted aqueous sodium hydrogencarbonate was added,
and the mixture was stirred. The precipitated white solid was
collected by filtration, washed with water, and dried to obtain
4-{[(3-endo)-8-(methylsulfonyl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-1H-pyr-
rolo[2,3-b]pyridine-5-carboxamide (14.1 mg) as a white solid.
Example 49
[0238] To a solution of
1-[(3-exo)-8-azabicyclo[3.2.1]oct-3-yl]-3,6-dihydroimidazo[4,5-d]pyrrolo[-
2,3-b]pyridine-2(1H)-one (12 mg) in N,N-dimethylacetamide (0.48 ml)
and N,N-dimethylformamide (0.24 ml) were added
N-ethyl-N-isopropylpropane-2-amine (0.015 ml) and
6-chloronicotinonitrile (11.7 mg). The mixture was immediately
heated to 90.degree. C. and stirred for 12 hours. After the
disappearance of the starting compound was ascertained, the
reaction solution was evaporated under reduced pressure and dried.
The solid residue was purified by thin-layer silica gel column
chromatography (chloroform:methanol=8:1) to obtain
6-[(3-exo)-3-(2-oxo-3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-1(2H)-
-yl)-8-azabicyclo[3.2.1]oct-8-yl]nicotinonitrile (5.2 mg) as a
yellowish white solid.
Example 50
[0239] To a solution of ethyl
3-(4-{[(2r,5s)-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-y-
l)-1,2,4-oxadiazole-5-carboxylate (80 mg) in tetrahydrofuran (3.2
ml) was added 3M iodo(methyl)magnesium/diethy ether solution (0.315
ml) under ice cooling, and the reaction solution was stirred for 16
hours under ambient temperature. To the reaction solution was
further added 3M iodo(methyl)magnesium/diethy ether solution (0.189
ml) under ice cooling. The reaction solution was stirred under
ambient temperature for 16 hours. To the reaction solution was
added water under ice cooling, and the mixture was stirred at the
same temperature for 15 minutes. To the reaction solution were
added chloroform and saturated aqueous ammonium chloride. The
mixture was extracted with chloroform and washed with saturated
brine. The organic layer was dried over magnesium sulfate and
filtered. The filtrate was concentrated under reduced pressure. The
residue was purified by silica gel column chromatography
(chloroform:methanol=100:0 to 90:10) to obtain
rel-(1s,3R,4R,5S)-4-({5-[5-(1-hydroxy-1-methylethyl)-1,2,4-oxadiazole-3-y-
l]-1H-pyrrolo[2,3-b]pyridine-4-yl}amino)adamantan-1-ol (15 mg) as a
white solid.
Example 51
[0240] To a solution of
4-{[(3-exo)-8-(5-bromopyrimidine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl]amino}-
-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (22.2 mg) in
N,N-dimethylformamide (0.67 ml) and 1,3-dimethyl-2-imidazolidinone
(0.67 ml) were added tetrakis(triphenylphosphine)palladium (O) (5.8
mg) and dicyanozinc (17.7 mg). Reaction was carried out at
160.degree. C. using a microwave reaction system for 1 hour. To the
reaction solution was added dichloromethane, and the mixture was
filtered. The solid residue was washed with dichloromethane and
dried. The solid residue was purified by thin-layer silica gel
column chromatography (chloroform:methanol=8:1) to obtain
4-{[(3-exo)-8-(5-cyanopyrimidine-2-yl)-8-azabicyclo[3.2.1]oct-3-yl-
]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (15 mg) as a
yellowish white solid.
Example 52
[0241] To a solution of
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rbonitrile (30 mg) in tetrahydrofuran (0.6 ml) was added
diisobutylaluminum hydride (0.99M toluene solution) (0.49 ml) at
5.degree. C. The mixture was stirred for 2 hours at 5.degree. C.
and further stirred for 3 hours at ambient temperature. To the
reaction solution was added 6M aqueous hydrochloric acid (0.09 ml)
at 5.degree. C. The mixture was stirred for 0.5 hour at ambient
temperature. Solid sodium hydroxide (23.3 mg) and magnesium sulfate
were added, and the mixture was stirred for 0.5 hour at ambient
temperature. The insoluble matter was removed by Celite filtration
and washed with tetrahydrofuran. The filtrate was evaporated under
reduced pressure and purified by thin-layer silica gel column
chromatography (chloroform:methanol=9:1) to obtain
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboaldehyde (18 mg) as a yellowish white solid.
Example 53
[0242] To a solution of
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboaldehyde (20 mg) in ethanol (0.6 ml) were added pyridine (0.052
ml) and O-methylhydroxyamine hydrochloride (32.1 mg), and the
mixture was heated for 6 hours under refluxing. After being cooled
to ambient temperature, the reaction solution was evaporated under
reduced pressure, dried, and purified by thin-layer silica gel
column chromatography (chloroform:methanol=10:1) to obtain
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboaldehyde O-methyloxime (11 mg) as a yellowish white solid.
Example 54
[0243] To acetic acid (0.8 ml) were added pyrrolidine (0.013 ml)
and para-formaldehyde (5.72 mg), and the mixture was stirred for 5
minutes at 60.degree. C. To the reaction solution was added
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxamide (40.0 mg) at 60.degree. C., and the mixture was
stirred at 60.degree. C. for 2 hours. The reaction solution was
evaporated under reduced pressure, and toluene and
N-ethyl-N-isopropylpropane-2-amine were added, and the mixture was
subjected to azeotropy. The solid residue was purified by NH
thin-layer silica gel column chromatography
(chloroform:methanol=10:1) to obtain
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-3-(pyrrolidine-1-ylm-
ethyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (10.8 mg) as a
yellowish white solid.
Example 55
[0244] To a solution of
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboaldehyde (40 mg) in tetrahydrofuran (1 ml) was added methyl
(triphenylphosphoranylidene)acetate (56 mg), and the reaction
solution was stirred at 80.degree. C. for 16 hours. To the reaction
solution was further added methyl
(triphenylphosphoranylidene)acetate (43 mg), and the reaction
solution was stirred at 90.degree. C. for 3 hours. To the reaction
solution was further added methyl
(triphenylphosphoranylidene)acetate (129 mg), and the reaction
solution was stirred at 90.degree. C. for 16 hours. The reaction
solution was concentrated under reduced pressure, and the residue
was purified by silica gel column chromatography
(chloroform:methanol=100:0 to 90:10) to obtain methyl
(2E)-3-(4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyrid-
ine-5-yl)acrylate (7 mg) as a yellow solid.
Example 56
[0245] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxamide (50 mg) in N,N-dimethylformamide (0.6 ml) was
added 1-chloro-2,5-pyrrolidinedione (18.4 mg) at ambient
temperature. After the mixture was stirred at ambient temperature
for 2 hours, water was added to the reaction solution, and the
solution was filtered. The solid residue was washed with water and
dried. The solid residue was purified by thin-layer silica gel
column chromatography (chloroform:methanol=4:1) to obtain
cis-3-chloro-4-{[(1R,2R,3S,5s)-hydroxyadamantan-2-yl]amino}-1H--
pyrrolo[2,3-b]pyridine-5-carboxamide (5 mg) as a yellowish white
solid.
Example 57
[0246] To a solution of
N'-hydroxy-4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]py-
ridine-5-carboxyimidamide (30 mg) in acetic acid (0.5 ml) was added
acetic anhydride (11 .mu.l), and the reaction solution was stirred
for 30 minutes under ambient temperature. To the reaction solution
was added 10% palladium on carbon (10 mg), and the mixture was
stirred under hydrogen atmosphere at 50.degree. C. for 3 hours.
After the reaction solution was cooled to ambient temperature, the
catalyst was filtered off with Celite. The filtrate was
concentrated under reduced pressure, and the residue was washed
with acetonitrile under stirring. The precipitate was collected by
filtration to obtain
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboxyimidamide acetate (20 mg) as a yellow solid.
Example 58
[0247] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (30 mg) in 1-methyl-2-pyrrolidone (0.18 ml)
was added pyridine hydrochloride (10.6 mg) at ambient temperature.
Reaction was carried out at 200.degree. C. for 1 hour using a
microwave reaction system. To the reaction solution was added
saturated aqueous sodium hydrogencarbonate, and the mixture was
extracted with ethyl acetate and washed with water. The extract was
dried over magnesium sulfate and filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
thin-layer silica gel column chromatography
(chloroform:methanol=10:1) to obtain
cis-(1s,3R,4R,5S)-4-(1H-pyrrolo[2,3-b]pyridine-4-ylamino)adamantan-1-ol
(14.1 mg) as a yellowish white solid.
Example 59
[0248] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxylic acid (30 mg) in N,N-dimethylformamide (0.1 ml)
was added N,N'-carbonyldiimidazole (29.7 mg), and the mixture was
stirred for 0.5 hours at 60.degree. C. To the reaction mixture was
added methanesulfonamide (17.4 mg) and
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.027 ml). After being
further stirred at 60.degree. C. for 3 hours, the reaction solution
was concentrated under reduced pressure. The residue was purified
by thin-layer silica gel column chromatography
(chloroform:methanol=4:1) to obtain
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-N-(methylsulfonyl)-1-
H-pyrrolo[2,3-b]pyridine-5-carboxamide (7.8 mg) as a yellowish
white solid.
Example 60
[0249] To a solution of
cis-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyr-
idine-5-carboxamide (75 mg) in tetrahydrofuran (0.5 ml) and
methanol (0.375 ml) was added
1,1-dimethoxy-N,N-dimethylmethaneamine (1.54 ml) at ambient
temperature. After being stirred for 1 hour under heating and
refluxing, the mixture was cooled to ambient temperature and
stirred for 1 hour. The precipitated solid was collected by
filtration, washed and dried to obtain
cis-N-[(dimethylamino)methylene]-4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-y-
l]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide (70 mg) as a white
solid.
Example 61
[0250] A solution of
cis-2-[(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b-
]pyridine-5-yl)carbonyl]hydrazine carboxamide (30 mg) in a mixture
of xylene (0.45 ml) and acetic acid (0.45 ml) was stirred at
120.degree. C. for 3 hours. Furthermore, 1-methyl-2-pyrrolidone
(0.45 ml) was added, and the mixture was stirred at 150.degree. C.
for 4 hours. The reaction solution was concentrated under reduced
pressure and dried. The residue was purified by thin-layer silica
gel column chromatography (chloroform:methanol=10:1) to obtain
cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]-
pyridine-5-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one (5.6 mg) as a
product (having a higher Rf value obtained by TLC
(chloroform-methanol=10:1)) and to obtain
cis-5-(4-{[(1R,2R,3S,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrr-
olo[2,3-b]pyridine-5-yl)-1,3,4-oxadiazole-2(3H)-one (8.9 mg) as
another product (having a lower Rf value obtained by TLC
(chloroform-methanol=10:1)), these products each being obtained as
a yellowish white solid.
Example 62
[0251] To a solution of ethyl
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboxyimidate trihydrochloride (75 mg) in ethanol (1 ml) was added
1,2-ethanediamine (0.11 ml), the reaction solution was stirred at
120.degree. C. for 2 hours. The reaction solution was concentrated
under reduced pressure, and the residue was purified by NH-silica
gel column chromatography (chloroform:methanol=100:0 to 95:5) to
obtain
(1s,4r)-4-{[5-(4,5-dihydro-1H-imidazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-
-yl]amino}adamantan-1-ol (17 mg) as a white solid.
Example 63
[0252] To a solution of ethyl
4-{[(2r,5s)-5-hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-ca-
rboxyimidate trihydrochloride (150 mg) in ethanol (1.5 ml) were
added 2-aminoethanol (78 .mu.l) and triethylamine (0.225 ml), and
the reaction solution was stirred at 110.degree. C. for 2 hours.
The reaction solution was cooled to ambient temperature and
filtered, and the filtrate was concentrated under reduced pressure.
The residue was purified by silica gel column chromatography
(chloroform:methanol=100:0 to 90:10). The obtained solid was washed
with ethyl acetate under stirring and collected by filtration to
obtain
(1s,4r)-4-{[5-(4,5-dihydro-1,3-oxazole-2-yl)-1H-pyrrolo[2,3-b]pyridine-4--
yl]amino}adamantan-1-ol (5 mg) as a white solid.
Example 64
[0253]
4-[(5-Hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-carb-
onitrile (200 mg) and Raney nickel were added to ethanol (5 ml),
and the reaction solution was stirred under hydrogen atmosphere at
60.degree. C. for 8 hours. The catalyst was filtered off with
Celite. The filtrate was concentrated under reduced pressure. The
residue was dissolved in dioxane (3 ml), and 1M aqueous sodium
hydroxide (0.65 ml) was added. To the reaction solution was added
di-t-butyl dicarbonate (0.22 ml) under ambient temperature, and the
mixture was stirred for 16 hours. The reaction solution was
extracted with chloroform and washed with water. The organic layer
was dried over magnesium sulfate and filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (chloroform:methanol=100:0 to
90:10) to obtain t-butyl
({4-[(5-hydroxyadamantan-2-yl)amino]-1H-pyrrolo[2,3-b]pyridine-5-yl}methy-
l)carbamate (40 mg) as a pale yellow solid.
[0254] The compounds shown in the following Table 71 were produced
according to the above-mentioned production methods, the methods
obvious to those skilled in the art, or modified methods of these.
The tables 71 and 72 show the structures and physicochemical data
of the compounds described in these Examples and also show the
methods for producing the compounds.
TABLE-US-00071 TABLE 71 Ex Structure 1 ##STR00287## cis 2
##STR00288## 3 ##STR00289## cis/trans mix 4 ##STR00290## cis/trans
mix 5 ##STR00291## 6 ##STR00292## cis 7 ##STR00293## cis 8
##STR00294## cis 9 ##STR00295## cis 10 ##STR00296## cis/trans mix
11 ##STR00297## cis 12 ##STR00298## cis 13 ##STR00299## cis 14
##STR00300## cis 15 ##STR00301## cis 16 ##STR00302## diastereomer
of 365 cis or trans unknown 17 ##STR00303## cis 18 ##STR00304##
cis/trans mix 19 ##STR00305## cis 20 ##STR00306## cis 21
##STR00307## 22 ##STR00308## diastereomer of 382 cis or trans
unknown 23 ##STR00309## 24 ##STR00310## cis 25 ##STR00311## 26
##STR00312## cis 27 ##STR00313## cis 28 ##STR00314## cis 29
##STR00315## cis 30 ##STR00316## cis 31 ##STR00317## cis 32
##STR00318## cis 33 ##STR00319## cis 34 ##STR00320## cis 35
##STR00321## cis/trans mix 36 ##STR00322## cis 37 ##STR00323## cis
38 ##STR00324## 39 ##STR00325## cis/trans mix 40 ##STR00326## cis
41 ##STR00327## cis 42 ##STR00328## cis 43 ##STR00329## trans 44
##STR00330## cis 45 ##STR00331## cis 46 ##STR00332## 47
##STR00333## 48 ##STR00334## 49 ##STR00335## 50 ##STR00336## cis 51
##STR00337## 52 ##STR00338## cis 53 ##STR00339## cis 54
##STR00340## cis 55 ##STR00341## cis 56 ##STR00342## cis 57
##STR00343## cis 58 ##STR00344## cis 59 ##STR00345## cis 60
##STR00346## cis 61 ##STR00347## cis 62 ##STR00348## cis 63
##STR00349## cis 64 ##STR00350## cis/trans mix 65 ##STR00351## 66
##STR00352## cis/trans mix 67 ##STR00353## diastereomer of 68 cis
or trans unknown 68 ##STR00354## diastereomer of 67 cis or trans
unknown 69 ##STR00355## cis 70 ##STR00356## 71 ##STR00357## 72
##STR00358## trans 73 ##STR00359## cis 74 ##STR00360## trans 75
##STR00361## trans 76 ##STR00362## trans 77 ##STR00363## cis/trans
mix 78 ##STR00364## cis 79 ##STR00365## cis 80 ##STR00366## cis 81
##STR00367## cis 82 ##STR00368## trans 83 ##STR00369## cis 84
##STR00370## diastereomer of 85 cis or trans unknown 85
##STR00371## diastereomer of 84 cis or trans unknown 86
##STR00372## cis 87 ##STR00373## cis 88 ##STR00374## cis/trans mix
89 ##STR00375## cis/trans mix 90 ##STR00376## cis 91 ##STR00377##
92 ##STR00378## 93 ##STR00379## 94 ##STR00380## 95 ##STR00381## 96
##STR00382## cis 97 ##STR00383## cis/trans mix 98 ##STR00384## cis
99 ##STR00385## 100 ##STR00386## 101 ##STR00387## cis 102
##STR00388## trans 103 ##STR00389## cis/trans mix 104 ##STR00390##
trans 105 ##STR00391## cis 106 ##STR00392## trans 107 ##STR00393##
cis 108 ##STR00394## cis 109 ##STR00395## cis 110 ##STR00396## cis
111 ##STR00397## trans 112 ##STR00398## cis/trans mix 113
##STR00399## 114 ##STR00400## 115 ##STR00401## cis 116 ##STR00402##
cis 117 ##STR00403## 118 ##STR00404## 119 ##STR00405## cis 120
##STR00406## 121 ##STR00407## trans 122 ##STR00408## cis 123
##STR00409## cis/trans mix
124 ##STR00410## cis/trans mix 125 ##STR00411## trans 126
##STR00412## cis 127 ##STR00413## cis 128 ##STR00414## cis 129
##STR00415## cis/trans mix 130 ##STR00416## trans 131 ##STR00417##
racemate 132 ##STR00418## racemate 133 ##STR00419## 134
##STR00420## cis 135 ##STR00421## cis 136 ##STR00422## cis 137
##STR00423## cis 138 ##STR00424## cis 139 ##STR00425## 140
##STR00426## 141 ##STR00427## 142 ##STR00428## 143 ##STR00429## 144
##STR00430## cis/trans mix 145 ##STR00431## cis 146 ##STR00432##
147 ##STR00433## cis/trans mix 148 ##STR00434## cis 149
##STR00435## cis 150 ##STR00436## trans 151 ##STR00437## cis/trans
mix 152 ##STR00438## cis/trans mix 153 ##STR00439## diastereomer of
154 cis or trans unknown 154 ##STR00440## diastereomer of 153 cis
or trans unknown 155 ##STR00441## cis/trans mix 156 ##STR00442##
cis/trans mix 157 ##STR00443## cis/trans mix 158 ##STR00444##
cis/trans mix 159 ##STR00445## cis/trans mix 160 ##STR00446##
cis/trans mix 161 ##STR00447## trans 162 ##STR00448## cis 163
##STR00449## cis 164 ##STR00450## cis 165 ##STR00451## cis 166
##STR00452## cis 167 ##STR00453## cis 168 ##STR00454## cis 169
##STR00455## cis 170 ##STR00456## 171 ##STR00457## 172 ##STR00458##
173 ##STR00459## cis 174 ##STR00460## cis 175 ##STR00461## cis 176
##STR00462## cis 177 ##STR00463## cis 178 ##STR00464## cis 179
##STR00465## cis 180 ##STR00466## cis 181 ##STR00467## cis 182
##STR00468## cis 183 ##STR00469## cis 184 ##STR00470## 185
##STR00471## 186 ##STR00472## 187 ##STR00473## 188 ##STR00474##
cis/trans mix 189 ##STR00475## 190 ##STR00476## cis/trans mix 191
##STR00477## diastereomer of 192 cis or trans unknown 192
##STR00478## diastereomer of 191 cis or trans unknown 193
##STR00479## cis 194 ##STR00480## trans 195 ##STR00481## 196
##STR00482## cis/trans mix 197 ##STR00483## cis 198 ##STR00484##
cis/trans mix 199 ##STR00485## diastereomer of 200 cis or trans
unknown 200 ##STR00486## diastereomer of 199 cis or trans unknown
201 ##STR00487## cis 202 ##STR00488## 203 ##STR00489## cis 204
##STR00490## cis 205 ##STR00491## cis 206 ##STR00492## cis 207
##STR00493## cis 208 ##STR00494## 209 ##STR00495## 210 ##STR00496##
cis 211 ##STR00497## cis 212 ##STR00498## 213 ##STR00499## 214
##STR00500## 215 ##STR00501## 216 ##STR00502## 217 ##STR00503## 218
##STR00504## 219 ##STR00505## 220 ##STR00506## 221 ##STR00507## 222
##STR00508## 223 ##STR00509## 224 ##STR00510## 225 ##STR00511## 226
##STR00512## 227 ##STR00513## 228 ##STR00514## 229 ##STR00515## 230
##STR00516## 231 ##STR00517## 232 ##STR00518## 233 ##STR00519## 234
##STR00520## 235 ##STR00521## 236 ##STR00522## 237 ##STR00523## 238
##STR00524## 239 ##STR00525## 240 ##STR00526## cis 241 ##STR00527##
cis 242 ##STR00528## cis 243 ##STR00529## cis 244 ##STR00530## cis
245 ##STR00531## cis 246 ##STR00532## cis 247 ##STR00533## cis 248
##STR00534## cis 249 ##STR00535## cis
250 ##STR00536## cis 251 ##STR00537## cis 252 ##STR00538## cis 253
##STR00539## 254 ##STR00540## cis 255 ##STR00541## cis 256
##STR00542## cis 257 ##STR00543## cis 258 ##STR00544## cis 259
##STR00545## cis 260 ##STR00546## cis 261 ##STR00547## cis 262
##STR00548## cis 263 ##STR00549## cis 264 ##STR00550## cis 265
##STR00551## cis 266 ##STR00552## cis 267 ##STR00553## cis 268
##STR00554## cis 269 ##STR00555## cis 270 ##STR00556## cis 271
##STR00557## cis 272 ##STR00558## cis 273 ##STR00559## cis 274
##STR00560## cis 275 ##STR00561## cis 276 ##STR00562## cis 277
##STR00563## cis 278 ##STR00564## cis 279 ##STR00565## cis 280
##STR00566## cis 281 ##STR00567## cis 282 ##STR00568## cis/trans
mix 283 ##STR00569## cis 284 ##STR00570## cis 285 ##STR00571## cis
286 ##STR00572## cis 287 ##STR00573## cis 288 ##STR00574## cis 289
##STR00575## cis 290 ##STR00576## cis 291 ##STR00577## cis 292
##STR00578## trans 293 ##STR00579## cis 294 ##STR00580## cis 295
##STR00581## cis 296 ##STR00582## cis 297 ##STR00583## cis 298
##STR00584## cis 299 ##STR00585## cis 300 ##STR00586## cis 301
##STR00587## cis 302 ##STR00588## cis 303 ##STR00589## cis 304
##STR00590## cis 305 ##STR00591## cis 306 ##STR00592## cis 307
##STR00593## cis 308 ##STR00594## cis 309 ##STR00595## cis 310
##STR00596## cis 311 ##STR00597## cis 312 ##STR00598## cis 313
##STR00599## cis 314 ##STR00600## cis 315 ##STR00601## cis 316
##STR00602## cis 317 ##STR00603## cis 318 ##STR00604## cis 319
##STR00605## cis 320 ##STR00606## cis 321 ##STR00607## cis 322
##STR00608## cis 323 ##STR00609## cis 324 ##STR00610## cis 325
##STR00611## cis 326 ##STR00612## cis 327 ##STR00613## cis 328
##STR00614## cis 329 ##STR00615## cis 330 ##STR00616## cis 331
##STR00617## cis 332 ##STR00618## cis 333 ##STR00619## cis 334
##STR00620## cis 335 ##STR00621## cis 336 ##STR00622## cis 337
##STR00623## cis 338 ##STR00624## cis 339 ##STR00625## cis 340
##STR00626## cis 341 ##STR00627## cis 342 ##STR00628## cis 343
##STR00629## 344 ##STR00630## cis 345 ##STR00631## cis 346
##STR00632## cis 347 ##STR00633## cis 348 ##STR00634## cis 349
##STR00635## 350 ##STR00636## diastereomer of 351 cis or trans
unknown 351 ##STR00637## diastereomer of 350 cis or trans unknown
352 ##STR00638## cis/trans mix 353 ##STR00639## cis 354
##STR00640## cis 355 ##STR00641## cis 356 ##STR00642## cis 357
##STR00643## cis 358 ##STR00644## cis 359 ##STR00645## cis 360
##STR00646## cis 361 ##STR00647## cis 362 ##STR00648## cis 363
##STR00649## cis 364 ##STR00650## cis/trans mix 365 ##STR00651##
diastereomer of 16 cis or trans unknwon 366 ##STR00652## cis 367
##STR00653## cis/trans mix 368 ##STR00654## cis/trans mix 369
##STR00655## cis/trans mix 370 ##STR00656## cis 371 ##STR00657##
cis/trans mix 372 ##STR00658## cis 373 ##STR00659## 374
##STR00660##
375 ##STR00661## diastereomer of 376 cis or trans unknown 376
##STR00662## diastereomer of 375 cis or trans unknown 377
##STR00663## cis/trans mix 378 ##STR00664## 379 ##STR00665## cis
380 ##STR00666## trans 381 ##STR00667## cis/trans mix 382
##STR00668## diastereomer of 22 cis or trans unknown 383
##STR00669## diastereomer of 384 cis or trans unknown 384
##STR00670## diastereomer of 383 cis or trans unknwon 385
##STR00671## diastereomer of 386 cis or trans unknown 386
##STR00672## diastereomer of 385 cis or trans unknown 387
##STR00673## diastereomer of 388 cis or trans unknown 388
##STR00674## diastereomer of 387 cis or trans unknwon 389
##STR00675## trans 390 ##STR00676## cis 391 ##STR00677## 392
##STR00678## cis/trans mix 393 ##STR00679## 394 ##STR00680##
cis/trans mix 395 ##STR00681## 396 ##STR00682## cis 397
##STR00683## trans 398 ##STR00684## cis/trans mix 399 ##STR00685##
diastereomer of 400 cis or trans unknown 400 ##STR00686##
diastereomer of 399 cis or trans unknwon 401 ##STR00687##
diastereomer of 402 cis or trans unknwon 402 ##STR00688##
diastereomer of 401 cis or trans unknown 403 ##STR00689## cis/trans
mix 404 ##STR00690## diastereomer of 405 cis or trans unknown 405
##STR00691## diastereomer of 404 cis or trans unknown 406
##STR00692## cis or trans unknown 407 ##STR00693## trans 408
##STR00694## 409 ##STR00695## 410 ##STR00696## 411 ##STR00697## 412
##STR00698## cis/trans mix 413 ##STR00699## cis/trans mix 414
##STR00700## diastereomer of 415 cis or trans unknown 415
##STR00701## diastereomer of 414 cis or trans unknown 416
##STR00702## cis/trans mix 417 ##STR00703## 418 ##STR00704## cis
419 ##STR00705## cis 420 ##STR00706## cis 421 ##STR00707## cis 422
##STR00708## cis 423 ##STR00709## trans 424 ##STR00710##
diastereomer of 425 cis or trans unknown 425 ##STR00711##
diastereomer of 424 cis or trans unknown 426 ##STR00712## cis or
trans unknown 427 ##STR00713## trans 428 ##STR00714## cis 429
##STR00715## cis/trans mix 430 ##STR00716## cis 431 ##STR00717##
cis 432 ##STR00718## cis 433 ##STR00719## cis 434 ##STR00720## cis
435 ##STR00721## cis 436 ##STR00722## cis 437 ##STR00723## cis 438
##STR00724## cis 439 ##STR00725## cis 440 ##STR00726## cis 441
##STR00727## 442 ##STR00728## trans 443 ##STR00729## cis 444
##STR00730## cis 445 ##STR00731## cis 446 ##STR00732## cis 447
##STR00733## cis 448 ##STR00734## cis 449 ##STR00735## cis 450
##STR00736## cis or trans unknown 451 ##STR00737## cis 452
##STR00738## cis 453 ##STR00739## cis/trans mix 454 ##STR00740##
cis/trans mix 455 ##STR00741## cis/trans mix 456 ##STR00742## cis
457 ##STR00743## cis 458 ##STR00744## 459 ##STR00745## cis 460
##STR00746## cis 461 ##STR00747## cis 462 ##STR00748## cis 463
##STR00749## cis 464 ##STR00750## cis 465 ##STR00751## cis 466
##STR00752## cis 467 ##STR00753## cis 468 ##STR00754## cis 469
##STR00755## cis 470 ##STR00756## cis 471 ##STR00757## cis 472
##STR00758## cis 473 ##STR00759## cis 474 ##STR00760## cis 475
##STR00761## cis 476 ##STR00762## cis 477 ##STR00763## cis 478
##STR00764## 479 ##STR00765## cis 480 ##STR00766## cis 481
##STR00767## cis 482 ##STR00768## cis 483 ##STR00769## 484
##STR00770## cis 485 ##STR00771## diastereomer of 486 cis or trans
unknown 486 ##STR00772## diastereomer of 485 cis or trans unknown
487 ##STR00773## cis/trans mix 488 ##STR00774## diastereomer of 490
cis or trans unknown 489 ##STR00775## 490 ##STR00776## diastereomer
of 488 cis or trans unknown 491 ##STR00777## 492 ##STR00778##
cis/trans mix 493 ##STR00779## diastereomer of 494 cis or trans
unknown 494 ##STR00780## diastereomer of 493 cis or trans unknown
495 ##STR00781## trans 496 ##STR00782## cis/trans mix 497
##STR00783## diastereomer of 498 cis or trans unknown 498
##STR00784## diastereomer of 497 cis or trans unknown 499
##STR00785## trans 500 ##STR00786## trans
501 ##STR00787## cis 502 ##STR00788## trans 503 ##STR00789## trans
504 ##STR00790## cis 505 ##STR00791## cis 506 ##STR00792## cis 507
##STR00793## cis 508 ##STR00794## 509 ##STR00795## 510 ##STR00796##
511 ##STR00797## 512 ##STR00798## 513 ##STR00799## 514 ##STR00800##
515 ##STR00801## 516 ##STR00802## 517 ##STR00803## 518 ##STR00804##
519 ##STR00805## 520 ##STR00806## 521 ##STR00807## 522 ##STR00808##
523 ##STR00809## 524 ##STR00810## 525 ##STR00811## 526 ##STR00812##
527 ##STR00813## 528 ##STR00814## 529 ##STR00815## 530 ##STR00816##
diastereomer of 534 cis or trans unknown 531 ##STR00817## cis/trans
mix 532 ##STR00818## diastereomer of 533 cis or trans unknown 533
##STR00819## diastereomer of 532 cis or trans unknown 534
##STR00820## diastereomer of 530 cis or trans unknown 535
##STR00821## cis/trans mix 536 ##STR00822## 537 ##STR00823## 538
##STR00824## 539 ##STR00825## 540 ##STR00826## 541 ##STR00827## 542
##STR00828## 543 ##STR00829## 544 ##STR00830## 545 ##STR00831## 546
##STR00832## cis 547 ##STR00833## 548 ##STR00834## 549 ##STR00835##
550 ##STR00836## 551 ##STR00837## 552 ##STR00838## 553 ##STR00839##
554 ##STR00840## 555 ##STR00841## 556 ##STR00842## 557 ##STR00843##
558 ##STR00844## 559 ##STR00845## 560 ##STR00846## 561 ##STR00847##
562 ##STR00848## 563 ##STR00849## 564 ##STR00850## 565 ##STR00851##
cis 566 ##STR00852## cis 567 ##STR00853## trans 568 ##STR00854##
cis 569 ##STR00855## cis 570 ##STR00856## cis 571 ##STR00857## cis
572 ##STR00858## cis 573 ##STR00859## cis 574 ##STR00860## cis 575
##STR00861## cis 576 ##STR00862## trans 577 ##STR00863## trans 578
##STR00864## cis 579 ##STR00865## cis
TABLE-US-00072 TABLE 72 Ref. Ex Ex Data 1 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.44-2.38 (10H, m), 2.85 (3H, d, J = 4.8 Hz), 4.23
(1H, m), 4.53 (1H, s), 6.58 (1H, m), 7.27 (1H, m), 8.58 (1H, s),
8.78 (1H, m), 9.25 (1H, m), 11.79 (1H, s). MS: 409 (M + H)+ 2 --
MS: 313 (M + H)+ 3 -- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.52-2.46
(11H, m), 2.63-2.72 (2H, m), 4.49-4.53 (1H, m), 6.31-6.35 (1H, m),
7.42-7.45 (1H, m), 7.89-7.90 (1H, m), 10.75-10.77 (1H, m),
11.55-11.58 (1H, m), 12.10 (1H, br). MS: 353 (M + H)+ 4 -- 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.51-2.13 (8H, m), 2.18-2.47 (3H, m),
2.65-2.76 (2H, m), 4.02-4.13 (2H, m), 4.50-4.55 (1H, m), 6.34-6.39
(1H, m), 7.44-7.46 (1H, m), 7.90 (1H, s), 8.14-8.39 (1H, m),
10.77-10.78 (1H, m), 11.58 (1H, s). MS: 391 (M + H)+ 5 -- MS: 404
(M + H)+ 6 -- MS: 371 (M + H)+ 7 -- MS: 508 (M + H)+ 8 -- MS: 409
(M + H)+ 9 -- MS: 542 (M + Na)+ 10 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.38-2.77 (18H, m), 4.38-4.54 (1H, m), 6.29-6.35
(1H, m), 7.25-7.37 (1H, m), 7.42-7.45 (1H, m), 7.89-7.90 (1H, m),
10.75 (1H, br), 11.57 (1H, s). MS: 380 (M + H)+ 11 -- 1H-NMR (400
MHz, d6-DMSO).delta.: 1.46-2.29 (9H, m), 3.83 (3H, s), 4.10 (1H,
m), 4.56 (1H, s), 6.50 (1H, m), 7.18 (1H, m), 8.55 (1H, s), 9.27
(1H, m), 11.68 (1H, s). MS: 342 (M + H)+ 12 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.43-1.54 (2H, m), 1.58-1.73 (4H, m), 1.73-1.86
(4H, m), 2.05-2.12 (1H, m), 2.17 (3H, s), 2.21-2.29 (2H, m),
4.08-4.16 (1H, m), 4.56 (1H, s), 4.99 (2H, s), 6.48-6.55 (1H, m),
7.18-7.24 (1H, m), 8.63 (1H, s), 9.12 (1H, d, J = 7.8 Hz), 11.74
(1H, s). MS: 384 (M + H)+ 13 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.43-1.53 (2H, m), 1.57-1.74 (4H, m), 1.74-1.90 (4H, m), 1.80 (3H,
s), 2.04-2.12 (1H, m), 2.20-2.29 (2H, m), 4.06-4.14 (1H, m), 4.56
(1H, s), 6.45 (2H, brs), 6.47-6.52 (1H, m), 7.14-7.19 (1H, m), 8.76
(1H, s), 9.41 (1H, d, J = 8.0 Hz), 11.64 (1H, s). MS: 384 (M + H)+
14 -- MS: 369 (M + H)+ 15 -- MS: 383 (M - H)- 16 -- 1H-NMR (400
MHz, d6-DMSO).delta.: 1.57-1.63 (2H, m), 1.95-2.09 (3H, m),
2.17-2.24 (2H, m), 3.31-3.71 (6H, m), 4.62 (1H, s), 6.38-6.40 (1H,
m), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.80 (1H, s), 11.58
(1H, s). MS: 334 (M + H)+ 17 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.51-1.56 (2H, m), 1.63-1.74 (4H, m), 1.83-1.91 (4H, m), 2.09-2.13
(1H, m), 2.30-2.34 (2H, m), 4.22-4.25 (1H, m), 4.58 (1H, s), 6.62
(1H, d, J = 3.6 Hz), 7.31 (1H, d, J = 3.6 Hz), 8.50 (1H, d, J = 7.6
Hz), 8.66 (1H, s), 12.00 (1H, brs). MS: 399 (M + Na)+ 18 -- 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.49-2.48 (10H, m), 2.72-2.85 (2H, m),
4.61 (1H, s), 6.44-6.61 (1H, m), 7.64-7.71 (1H, m), 8.02-8.35 (4H,
m), 11.59-11.64 (1H, m), 12.51-12.53 (1H, m). MS: 324 (M + H)+ 19
-- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.39-1.48 (2H, m), 1.59-1.74
(6H, m), 1.79-1.85 (2H, m), 2.02-2.07 (1H, m), 2.16-2.20 (2H, m),
4.45-4.48 (3H, m), 4.97 (1H, d, J = 7.4 Hz), 7.13-7.19 (2H, m),
7.36-7.40 (2H, m), 8.06 (1H, s), 8.48 (1H, s), 8.89 (1H, t, J = 5.9
Hz), 9.62. MS: 436 (M + H)+ 20 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.50-1.56 (2H, m), 1.62-1.72 (4H, m), 1.77-1.88 (4H, m), 2.08-2.11
(1H, m), 2.24-2.28 (2H, m), 3.56 (1H, m), 4.15-4.20 (1H, m),
6.67-6.69 (1H, m), 7.36-7.38 (1H, m), 8.28 (1H, s), 9.40 (1H, br),
10.36-10.41 (1H, m), 11.55 (1H, s), 12.53 (1H, brs), 14.29 (1H,
br). MS: 343 (M - HCl + H)+ 21 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
0.86-1.37 (3H, m), 1.58-1.69 (2H, m), 2.20-2.24 (1H, m), 2.41-2.51
(2H, m), 2.77-2.80 (1H, m), 2.90 (1H, s), 3.03-3.05 (1H, m),
4.29-4.35 (2H, m), 6.63 (1H, s), 7.43 (1H, s), 7.87 (1H, s), 10.7
(1H, s), 11.6 (1H, s). MS: 299 (M + H)+ 22 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.68-1.93 (6H, m), 2.02-2.13 (3H, m), 2.40-2.47
(2H, m), 2.71-2.75 (2H, m), 4.04 (2H, d, J = 5.5 Hz), 4.50 (1H, s),
6.34-6.36 (1H, m), 7.45 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 8.16
(1H, t, J = 5.6 Hz), 10.77 (1H, s), 11.59 (1H, s). MS: 391 (M + H)+
23 -- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.71-1.89 (6H, m),
2.21-2.25 (3H, m), 2.53-2.56 (6H, m), 6.63 (1H, s), 7.46 (1H, t, J
= 3.2 Hz), 7.90 (1H, s), 10.77 (1H, s), 11.61 (1H, s). MS: 309 (M +
H)+ 24 -- MS: 342 (M + H)+ 25 -- MS: 312 (M + H)+ 26 -- 1H-NMR (400
MHz, d6-DMSO).delta.: 1.33 (6H, d, J = 6.2 Hz), 1.46-1.86 (10H, m),
2.06 (1H, brs), 2.22 (2H, brs), 4.54 (1H, s), 5.05 (1H, d, J = 8.8
Hz), 5.18-5.15 (1H, m), 8.12 (1H, s), 8.63 (1H, s), 9.16 (1H, d, J
= 8.8 Hz), 13.0 (1H, brs). MS: 371 (M + H)+ 27 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.41-1.45 (2H, m), 1.59-1.62 (2H, m), 1.65-1.70
(2H, m), 1.74-1.79 (2H, m), 1.88-1.92 (2H, m), 2.05-2.09 (1H, m),
2.18-2.21 (2H, m), 4.02-4.05 (1H, m), 4.32 (1H, s), 5.82 (2H, brs),
6.41-6.42 (1H, m), 7.09-7.11 (1H, m), 8.13 (1H, s), 8.96 (1H, d, J
= 8.1 Hz), 9.50 (1H, s), 11.23 (1H, brs). MS: 342 (M + H)+ 28 --
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.57 (2H, m), 1.57-1.78 (4H,
m), 1.78-1.97 (4H, m), 2.05-2.14 (1H, m), 2.26-2.34 (2H, m), 2.44
(3H, s), 4.17-4.24 (1H, m), 4.53 (1H, s), 6.56-6.61 (1H, m),
7.24-7.28 (1H, m), 8.58 (1H, s), 9.10 (1H, d, J = 7.8 Hz), 11.82
(1H, brs). MS: 366 (M + H)+ 29 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.49-2.32 (13H, m), 4.20-4.22 (1H, m), 4.55 (1H, s), 6.55-6.57 (1H,
m), 7.25-7.27 (1H, m), 8.49 (1H, s), 8.79 (1H, d, J = 8.0 Hz), 9.27
(1H, s), 11.73 (1H, brs). MS: 374 (M + Na)+ 30 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.47-1.52 (2H, m), 1.62-1.64 (2H, m), 1.68-1.73
(2H, m), 1.81-1.91 (4H, m), 2.09-2.11 (1H, m), 2.28-2.31 (2H, m),
2.67 (3H, s), 4.19-4.22 (1H, m), 4.53 (1H, s), 6.53-6.54 (1H, m),
7.22-7.24 (1H, m), 7.88 (1H, d, J = 7.8 Hz), 8.69 (1H, s), 11.61
(1H, brs). MS: 366 (M + H)+ 31 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.44-1.49 (2H, m), 1.62-1.64 (2H, m), 1.74-1.79 (2H, m), 1.98-2.03
(4H, m), 2.15-2.18 (1H, m), 3.00-3.03 (2H, m), 4.45 (1H, brs), 4.61
(1H, brs), 5.77 (2H, s), 6.35-6.37 (1H, m), 7.33-7.35 (1H, m), 8.14
(1H, s), 11.44 (1H, brs). MS: 324 (M + H)+ 32 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-2.60 (13H, m), 3.27 (3H, s), 3.37-3.49 (4H,
m), 4.44 (1H, m), 4.77 (1H, s), 6.66 (1H, m), 7.46 (1H, m), 8.71
(1H, s), 8.98 (1H, m), 10.92 (1H, s), 12.08 (1H, s). MS: 453 (M +
H)+ 33 -- MS: 409 (M + H)+ 34 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.42-1.51 (2H, m), 1.58-1.75 (4H, m), 1.76-1.95 (4H, m), 2.05-2.13
(1H, m), 2.25-2.32 (2H, m), 4.11-4.19 (1H, m), 4.50 (1H, brs),
6.49-6.54 (1H, m), 7.17-7.22 (1H, m), 7.24 (2H, s), 8.06 (1H, s),
9.70 (1H, d, J = 7.6 Hz), 11.57 (1H, s). MS: 383 (M + H)+ 35 --
1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-2.49 (10H, m), 2.72-2.80
(2H, m), 4.49-4.56 (2H, m), 4.60-4.67 (1H, m), 5.64-5.71 (1H, m),
6.34-6.39 (1H, m), 7.42-7.47 (1H, m), 7.89-7.92 (1H, m), 8.62 (1H,
s), 10.77-10.83 (1H, m), 11.55-11.61 (1H, m). MS: 407 (M + H)+ 36
-- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.32-1.87 (12H, m), 2.09 (1H,
m), 2.08 (2H, m), 4.18-4.22 (1H, m), 4.68 (1H, m), 6.70-6.71 (1H,
m), 7.09 (1H, s), 7.25 (1H, s), 7.37-7.39 (1H, m), 8.32 (1H, s),
10.32 (1H, m), 12.68 (1H, brs). MS: 313 (M - 3HCl + H)+ 37 -- MS:
328 (M + H)+ 38 -- MS: 378 (M + H)+ 39 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.54-1.63 (2H, m), 1.86-2.56 (10H, m), 2.77-2.85
(1H, m), 4.91 (1H, s), 6.64-6.66 (1H, m), 7.36-7.38 (1H, m), 8.50
(1H, s), 10.82 (1H, s), 11.93-11.95 (1H, m). MS: 387, 389 (M + H)+
40 -- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.50-1.53 (2H, m),
1.64-2.01 (8H, m), 2.11 (1H, s), 2.32 (2H, s), 4.21 (1H, d, J = 7.5
Hz), 4.56 (2H, s), 6.58 (1H, s), 7.26 (1H, s), 8.61 (1H, s), 9.86
(1H, brs), 11.77 (1H, s). MS: 350 (M - H)- 41 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.54-1.60 (2H, m), 1.68-1.77 (4H, m), 1.78-1.86
(2H, m), 1.90-1.98 (2H, m), 2.12-2.16 (1H, m), 2.25-2.30 (2H, m),
2.68 (2H, t, J = 6.0 Hz), 3.57 (2H, t, J = 6.0 Hz), 4.08 (1H, d, J
= 7.8 Hz), 6.46 (1H, dd, J = 2.0, 3.6 Hz), 7.04 (1H, br), 7.13 (1H,
dd, J = 2.6, 3.6 Hz), 7.80 (1H, br), 8.38 (1H, s), 10.17 (1H, d, J
= 8.2 Hz), 11.47 (1H, s). MS: 380 (M + H)+ 42 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.21 (3H, t, J = 7.2 Hz), 1.41-2.34 (13H, m),
3.33-3.42 (2H, m), 4.12-4.18 (1H, m), 4.50 (1H, s), 6.48-6.51 (1H,
m), 7.17-7.21 (1H, m), 8.02 (1H, brd, J = 7.6 Hz), 8.42 (1H, brt, J
= 5.6 Hz), 8.58 (1H, s), 11.51 (1H, brs). MS: 395 (M + H)+ 43 --
1H-NMR (400 MHz, d6-DMSO).delta.: 1.58-1.69 (2H, m), 1.86-1.96 (2H,
m), 2.04-2.11 (1H, m), 2.14-2.23 (2H, m), 2.34-2.44 (4H, m),
2.61-2.71 (2H, m), 4.38-4.42 (1H, m), 6.63-6.67 (1H, m), 7.25 (1H,
s), 7.35 (1H, br), 8.05 (1H, br), 10.58 (1H, s), 10.58 (1H, s),
11.94 (1H, s). MS: 389, 391 (M + H)+ 44 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.72-2.04 (9H, m), 2.29-2.91 (4H, m), 4.42-4.45
(1H, m), 6.37 (1H, d, J = 3.5 Hz), 7.44 (1H, d, J = 3.5 Hz), 7.90
(1H, s), 10.80 (1H, br, s), 11.58 (1H, s). MS: 327 (M + H)+ 45 --
MS: 366 (M + H)+ 46 -- MS: 388 (M + H)+ 47 -- MS: 406 (M + H)+ 48
-- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.84-1.97 (2H, m), 1.97-2.17
(4H, m), 2.19-2.34 (2H, m), 2.96 (3H, s), 4.12-4.24 (2H, m),
4.30-4.40 (1H, m), 6.44-6.51 (1H, m), 7.04 (1H, br), 7.08-7.15 (1H,
m), 7.81 (1H, br), 8.38 (1H, s), 10.22 (1H, d, J = 7.6 Hz), 11.47
(1H, s). MS: 364 (M + H)+ 49 -- MS: 386 (M + H)+ 50 -- 1H-NMR (400
MHz, d6-DMSO).delta.: 1.48-1.53 (2H, m), 1.62-1.65 (2H, m), 1.64
(6H, s), 1.69-1.74 (2H, m), 1.81-1.93 (4H, m), 2.08-2.12 (1H, m),
2.29-2.32 (2H, m), 4.19-4.23 (1H, m), 4.53 (1H, s), 6.07 (1H, s),
6.53-6.55 (1H, m), 7.22-7.24 (1H, m), 7.87-7.90 (1H, m), 8.72 (1H,
s), 11.62 (1H, brs). MS: 410 (M + H)+ 51 -- MS: 389 (M + H)+ 52 --
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.47 (9H, m), 3.17 (1H, m),
4.10 (1H, m), 4.58 (1H, s), 6.51 (1H, m), 7.21 (1H, m), 8.22 (1H,
s), 9.79 (1H, s), 9.90 (1H, m), 11.84 (1H, s). MS: 312 (M + H)+ 53
-- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.48-2.33 (8H, m), 3.90 (3H,
s), 4.15 (1H, m), 4.51 (1H, s), 6.48 (1H, m), 7.17 (1H, m), 7.90
(1H, s), 8.43 (1H, s), 8.46 (1H, m), 11.50 (1H, s). MS: 341 (M +
H)+ 54 -- MS: 410 (M + H)+ 55 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.37-1.48 (2H, m), 1.57-1.91 (8H, m), 2.04-2.08 (1H, m), 2.24-2.33
(2H, m), 3.71 (3H, s), 3.99-4.02 (1H, m), 4.50 (1H, s), 5.85-5.87
(1H, m), 6.34-6.38 (1H, m), 6.43-6.46 (1H, m), 7.14-7.17 (1H, m),
7.93-7.98 (1H, m), 8.20 (1H, s), 11.49 (1H, brs). MS: 368 (M + H)+
56 -- MS: 361 (M + H)+ 57 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.39-1.45 (2H, m), 1.59-1.61 (2H, m), 1.64-1.70 (2H, m), 1.73-1.79
(2H, m), 1.85-1.91 (5H, m), 2.05-2.08 (1H, m), 2.20-2.23 (2H, m),
4.01-4.04 (1H, m), 4.42-4.52 (1H, m), 6.44 (1H, d, J = 3.6 Hz),
7.12 (1H, d, J = 3.6 Hz), 8.15 (1H, s), 10.05 (1H, br), 11.38 (1H,
brs). MS: 326 (M - AcOH + H)+ 58 -- MS: 284 (M + H)+ 59 -- MS: 427
(M + Na)+, 403 (M - H)- 60 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.45-2.27 (7H, m), 3.12 (3H, s), 3.18 (3H, s), 4.07 (1H, m), 4.46
(1H, s), 6.44 (1H, m), 7.09 (1H, m), 8.58 (1H, s), 9.08 (1H, s),
10.56 (1H, m), 11.45 (1H, s). MS: 382.3 (M + H)+ 61 -- 1H-NMR (400
MHz, d6-DMSO).delta.: 1.45-2.69 (13H, m), 4.19 (1H, m), 4.53 (1H,
s), 6.54 (1H, m), 7.25 (1H, m), 8.43 (1H, s), 8.75 (1H, m), 11.68
(1H, s). MS: 367.3 (M + H), 365.0 (M - H)- 62 -- 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.39-1.45 (2H, m), 1.59-1.70 (4H, m), 1.75-1.81
(2H, m), 1.90-1.95 (2H, m), 2.06-2.09 (1H, m), 2.20-2.23 (2H, m),
3.35 (2H, m), 3.89 (2H, t, J = 9.6 Hz), 4.04-4.08 (1H, m), 4.43
(1H, br), 6.44 (1H, d, J = 3.6 Hz), 6.87 (1H, brs), 7.10 (1H, d, J
= 3.5 Hz), 8.21 (1H, s), 10.97 (1H, d, J = 7.8 Hz), 11.34 (1H,
brs). MS: 352 (M + H)+ 63 -- 1H-NMR (400 MHz, d6-DMSO).delta.:
1.43-1.48 (2H, m), 1.60-1.63 (2H, m), 1.66-1.72 (2H, m), 1.77-1.83
(2H, m), 1.87-1.92 (2H, m), 2.06-2.10 (1H, m), 2.22-2.26 (2H, m),
4.05 (2H, t, J = 9.0 Hz), 4.09-4.13 (1H, m), 4.32 (2H, t, J = 9.0
Hz), 4.47 (1H, s), 6.47-6.49 (1H, m), 7.15-7.17 (1H, m), 8.34 (1H,
s), 9.98 (1H, d, J = 7.8 Hz), 11.49 (1H, brs). MS: 353 (M + H)+ 64
-- 1H-NMR (400 MHz, d6-DMSO).delta.: 1.02-1.05 (4H, m), 1.37-1.41
(9H, m), 1.53-1.67 (5H, m), 1.74-1.85 (2H, m), 2.01-2.23 (5H, m),
4.11-4.18 (2H, m), 6.29-6.36 (1H, m), 7.09-7.13 (1H, m), 7.28-7.32
(1H, m), 7.64-7.65 (1H, m), 11.11 (1H, brs). MS: 413 (M + H)+ 65 1
MS: 431 (M + H)+ 66 1 MS: 341 (M + H)+ 67 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.81-2.02 (8H, m), 2.09-2.62 (5H, m), 4.15-4.20
(1H, m), 6.43-6.46 (1H, m), 7.09 (1H, br), 7.14-7.16 (1H, m), 7.86
(1H, br), 8.40 (1H, s), 10.25 (1H, d, J = 8.2 Hz), 11.50 (1H, s).
MS: 336 (M + H)+ 68 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.54-1.60
(2H, m), 1.86-1.97 (3H, m), 1.99-2.03 (2H, m), 2.08-2.15 (4H, m),
2.27-2.35 (2H, m), 4.27 (1H, d, J = 7.6 Hz), 6.50-6.52 (1H, m),
6.99 (1H, br), 7.14 (1H, t), 7.81 (1H, s), 8.38 (1H, s), 10.17 (1H,
d, J = 8.3 Hz), 11.48 (1H, s). MS: 336 (M + H)+ 69 1 MS: 534 (M +
H)+, 532 (M - H)- 70 1 MS: 376 (M + H)+ 71 1 MS: 402 (M + H)+
72 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.39-1.43 (2H, m), 1.62-1.72
(4H, m), 1.79-1.89 (4H, m), 2.02-2.09 (1H, m), 2.11-2.17 (2H, m),
2.75 (3H, d, J = 4.3 Hz), 4.09-4.16 (1H, m), 4.49 (1H, brs),
6.39-6.41 (1H, m), 7.11-7.15 (1H, m), 8.18-8.25 (1H, m), 8.30 (1H,
s), 9.87 (1H, d, J = 8.3 Hz), 11.42 (1H, brs). MS: 341 (M + H)+ 73
1 MS: 341 (M + H)+ 74 1 MS: 355 (M + H)+ 75 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.44-2.27 (9H, m), 2.76 (3H, d, J = 4.4 Hz), 4.23
(1H, m), 6.48 (1H, m), 7.14 (1H, m), 8.25 (1H, m), 8.32 (1H, s),
9.87 (1H, m), 11.45 (1H, s). MS: 343 (M + H)+ 76 1 MS: 355 (M + H)+
77 1 MS: 440 (M + H)+ 78 1 1H-NMR (400 MHz, d6-DMSO).delta.:
1.43-2.36 (8H, m), 1.63 (6H, s), 4.22 (1H, m), 4.54 (1H, s), 5.90
(1H, s), 6.55 (1H, m), 7.25 (1H, m), 8.50 (1H, s), 8.80 (1H, m),
11.72 (1H, s). MS: 410 (M + H)+ 79 1 MS: 382 (M + H)+, 380 (M - H)-
80 1 MS: 417 (M + Na)+, 395 (M + H)+ 81 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.44-1.48 (2H, m), 1.60-1.68 (4H, m), 1.76-1.85
(4H, m), 2.06-2.08 (1H, m), 2.29-2.31 (2H, m), 4.13-4.15 (1H, m),
4.53-4.54 (1H, m), 5.99 (1H, d, J = 7.0 Hz), 6.68 (1H, d, J = 3.6
Hz), 7.28 (1H, d, J = 3.6 Hz), 8.11 (1H, s), 11.86 (1H, brs). MS:
331 (M + Na)+ 82 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.40-1.43 (2H,
m), 1.64-1.69 (4H, m), 1.83-1.88 (4H, m), 2.05-2.07 (1H, m),
2.21-2.23 (2H, m), 4.25-4.27 (1H, m), 4.52 (1H, brs), 6.04 (1H, d,
J = 7.2 Hz), 6.68 (1H, d, J = 3.5 Hz), 7.28 (1H, d, J = 3.4 Hz),
8.10 (1H, s), 11.85 (1H, brs). MS: 309 (M + H)+ 83 1 1H-NMR (400
MHz, d6-DMSO).delta.: 1.50-1.55 (2H, m), 1.62-1.73 (4H, m),
1.79-1.89 (4H, m), 2.08-2.12 (1H, m), 2.28-2.32 (2H, m), 4.24-4.28
(1H, m), 6.68-6.71 (1H, m), 7.39-7.41 (1H, m), 8.42 (1H, s),
8.44-8.48 (1H, m), 12.48 (1H, brs). MS: 368 (M + H)+ 84 1 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.50-1.57 (2H, m), 1.81-1.87 (2H, m),
1.92-2.00 (5H, m), 2.04-2.09 (2H, m), 2.18-2.24 (2H, m), 3.62 (3H,
s), 4.30-4.33 (1H, m), 6.16 (1H, d, J = 7.1 Hz), 6.72 (1H, d, J =
3.4 Hz), 7.28 (1H, d, J = 3.3 Hz), 8.11 (1H, s), 11.85 (1H, brs).
MS: 373 (M + Na)+ 85 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.70-1.75
(2H, m), 1.78-1.91 (5H, m), 1.94-2.02 (2H, m), 2.04-2.12 (2H, m),
2.19-2.26 (2H, m), 3.60 (3H, s), 4.25-4.28 (1H, m), 6.19 (1H, d, J
= 7.1 Hz), 6.70-6.72 (1H, m), 7.27-7.29 (1H, m), 8.10 (1H, s),
11.85 (1H, brs). MS: 373 (M + Na)+ 86 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.48-1.53 (2H, m), 1.63-1.74 (4H, m), 1.81-1.91
(4H, m), 2.08-2.11 (1H, m), 2.21 (3H, s), 2.29-2.36 (4H, m),
2.39-2.42 (2H, m), 3.49-3.53 (2H, m), 3.66-3.70 (2H, m), 4.19-4.23
(1H, m), 4.49 (1H, s), 6.57-6.59 (1H, m), 7.27-7.29 (1H, m), 8.64
(1H, s), 8.83-8.86 (1H, m), 11.86 (1H, brs). MS: 478 (M + H)+ 87 1
1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-1.52 (2H, m), 1.61-1.81 (8H,
m), 2.05-2.08 (1H, m), 2.20-2.24 (2H, m), 4.09-4.12 (1H, m), 4.53
(1H, s), 6.63-6.65 (1H, m), 6.82-6.86 (1H, m), 7.30-7.32 (1H, m),
8.65 (1H, s), 10.52-10.56 (1H, m), 11.80 (1H, brs). MS: 352 (M +
H)+ 88 1 1H-NMR (400 MHz, d6-DMSO).delta.: 0.85-0.93 (1H, m), 1.34,
1.40 (9H, s), 1.47-1.53 (1H, m), 1.67-1.79 (1H, m), 1.85-1.92 (3H,
m), 1.99-2.06 (3H, m), 2.13-2.34 (4H, m), 4.21-4.25, 4.30-4.34 (1H,
m), 6.37-6.41, 6.54-6.56 (1H, m), 6.51-6.63, 6.57-6.59 (1H, m),
7.28-7.29 (1H, m), 8.06-8.32 (2H, m), 8.63, 8.64 (1H, s),
8.87-8.89, 8.99-9.01 (1H, m), 11.88 (1H, brs). MS: 516 (M + Na)+ 89
1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.31-1.36 (1H, m), 1.47-1.53
(3H, m), 1.59-1.64 (1H, m), 1.67-1.80 (2H, m), 1.89-2.00 (3H, m),
2.06-2.11 (1H, m), 2.16-2.20 (2H, m), 3.02-3.09 (2H, m), 4.27-4.44
(2H, m), 6.52-6.54, 6.61-6.63 (1H, m), 7.26-7.29 (1H, m), 8.10-8.31
(2H, m), 8.63 (1H, s), 8.92-8.95, 9.04-9.07 (1H, m), 11.86 (1H,
brs). MS: 431 (M + Na)+ 90 1 1H-NMR (400 MHz, d6-DMSO).delta.:
1.48-1.53 (2H, m), 1.62-1.73 (4H, m), 1.81-1.92 (4H, m), 2.09-2.12
(1H, m), 2.29-2.32 (2H, m), 3.46 (3H, s), 4.20-4.24 (1H, m), 4.54
(1H, s), 4.86 (2H, s), 6.54-6.56 (1H, m), 7.24-7.25 (1H, m),
7.84-7.86 (1H, m), 8.72 (1H, s), 11.65 (1H, s). MS: 396 (M + H)+ 91
1 1H-NMR (400 MHz, d6-DMSO).delta.: 0.74-0.88 (1H, m), 1.13-1.75
(7H, m), 2.10-2.30 (2H, m), 4.27-4.44 (1H, m), 6.55 (1H, brs), 6.56
(1H, d, J = 3.4 Hz), 7.11 (1H, m), 7.65 (1H, d, J = 3.4 Hz), 8.35
(1H, s), 9.86 (1H, d, J = 7.9 Hz), 11.43 (1H, brs). MS: 271 (M +
H)+ 92 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.75-2.33 (5H, m),
2.97-3.36 (5H, m), 3.73-3.88 (1H, m), 4.38-4.64 (1H, m), 6.63 (1H,
d, J = 3.4 Hz), 7.17 (1H, brs), 7.23 (1H, d, J = 3.4 Hz), 7.92 (1H,
brs), 8.44 (1H, s), 10.25 (1H, d, J = 7.8 Hz), 11.68 (1H, s). MS:
286 (M + H)+ 93 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.29-2.02 (5H,
m), 2.41 (1H, dd, J = 3.8, 13.8 Hz), 2.65-2.83 (4H, m), 4.05-4.20
(1H, m), 4.36 (1H, t, J = 5.1 Hz), 6.51-6.58 (1H, m), 6.88-7.94
(3H, m), 8.37 (1H, s), 9.99 (1H, d, J = 7.9 Hz), 11.46 (1H, brs).
MS: 286 (M + H)+ 94 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.12-1.65
(7H, m), 1.82-1.97 (1H, m), 2.25-2.34 (2H, m), 3.85-3.96 (1H, m),
6.57 (1H, d, J = 3.3 Hz), 7.12 (1H, d, J = 2.4 Hz), 6.78-7.92 (2H,
brs), 8.35 (1H, s), 9.57 (1H, d, J = 7.1 Hz), 11.5 (1H, brs). MS:
271 (M + H)+ 95 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.17-1.64 (10H,
m) 2.0-2.07 (1H, m), 2.18-2.22 (1H, m), 2.38-2.40 (1H, m),
3.18-3.23 (1H, m), 4.14 (1H, t, J = 7.8 Hz), 4.25 (2H, q, J = 7.0
Hz), 4.46 (1H, t, J = 4.8 Hz), 7.17 (1H, s), 6.70 (1H, s), 8.51
(1H, s), 8.78 (1H, d, J = 8.0 Hz), 11.7 (1H, s). MS: 330 (M + H)+
96 1 1HNMR (400 MHz, d6-DMSO).delta.: 1.38-1.86 (10H, m), 2.07 (1H,
brs), 2.19 (2H, brs), 2.29 (3H, s), 3.97 (1H, d, J = 8.0 Hz), 4.49
(1H, s), 6.14 (1H, s), 6.98 (1H, brs), 7.78 (1H, brs), 8.28 (1H,
s), 9.99 (1H, d, J = 8.0 Hz), 11.3 (1H, s). MS: 341 (M + H)+ 97 1
1HNMR (400 MHz, CDCl3).delta.: 1.35-2.67 (13H, m), 3.75 (1H, brs),
4.05-4.20 (1H, m), 5.00-5.12 (1H, brs), 6.45-6.48 (1H, m),
7.15-7.16 (1H, m), 7.95 (1H, d, J = 4.7 Hz), 10.0 (1H, brs).. MS:
302 (M + H)+ 98 1 1HNMR (400 MHz, d6-DMSO).delta.: 1.40-2.30 (13H,
m), 3.92-3.96 (1H, m), 4.44 (1H, s), 5.27-5.29 (1H, m), 6.51 (1H,
dd, J = 2.0, 3.2 Hz), 7.21 (1H, dd, J = 2.8, 3.2 Hz), 7.88 (1H, d,
J = 4.8 Hz), 11.3 (1H, s). MS: 302 (M + H)+ 99 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.13-1.40 (3H, m), 1.48-1.63 (3H, m), 1.93-2.00
(1H, m), 2.14-2.18 (1H, m), 2.35-2.38 (1H, m), 3.12-3.20 (1H, m),
3.41-3.47 (1H, m), 4.04-4.10 (1H, m), 4.38-4.41 (1H, m), 6.61-6.65
(1H, m), 6.81-7.03 (1H, br), 7.09-7.13 (1H, m), 7.61-7.86 (1H, br),
8.33 (1H, s), 9.64 (1H, d, J = 8.0 Hz), 11.45 (1H, brs). MS: 301 (M
+ H)+. 100 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.38-2.28 (12H, m),
2.87-2.98 (1H, m), 3.63 (3H, s), 4.45-4.57 (1H, m), 6.42-6.45 (1H,
m), 6.80-7.13 (1H, br), 7.18-7.22 (1H, m), 7.51-7.93 (1H, br), 8.34
(1H, s), 9.44 (1H, d, J = 8.0 Hz), 11.49 (1H, brs). MS: 357 (M +
H)+. 101 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.33 (3H, t, J = 8.0
Hz), 1.47-1.51 (2H, m), 1.61-1.72 (4H, m), 1.78-1.85 (4H, m),
2.07-2.10 (1H, m), 2.23-2.27 (2H, m), 4.09-4.12 (1H, m), 4.30 (2H,
q, J = 8.0 Hz), 4.56 (1H, brs), 6.48-6.50 (1H, m), 7.17-7.19 (1H,
m), 8.56 (1H, s), 9.28 (1H, d, J = 7.6 Hz), 11.69 (1H, brs). MS:
356 (M + H)+. 102 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.32 (3H, t,
J = 6.8 Hz), 1.43-1.50 (2H, m), 1.65-1.73 (4H, m), 1.78-1.90 (4H,
m), 2.06-2.10 (1H, m), 2.16-2.21 (2H, m), 4.19-4.23 (1H, m), 4.29
(2H, q, J = 6.8 Hz), 4.54 (1H, brs), 6.45-6.46 (1H, m), 7.18-7.20
(1H, m), 8.56 (1H, s), 9.26 (1H, d, J = 8.0 Hz), 11.68 (1H, brs).
MS: 356 (M + H)+. 103 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.38-1.48
(2H, m), 1.59-1.70 (4H, m), 1.73-1.86 (4H, m), 2.03-2.09 (1H, m),
2.11-2.16 (1H, m), 2.18-2.23 (1H, m), 3.258 (1.5H, s), 3.263 (1.5H,
s), 3.53 (1.5H, s), 3.54 (1.5H, s), 4.00-4.05 (0.5H, m), 4.10-4.15
(0.5H, m), 4.50 (0.5H, brs), 4.52 (0.5H, brs), 6.42-6.45 (0.5H, m),
6.46-6.48 (0.5H, m), 7.16-7.19 (1H, m), 7.89 (0.5H, d, J = 8.4 Hz),
7.94 (0.5H, d, J = 8.4 Hz), 8.15-8.16 (1H, m), 11.52 (1H, brs). MS:
371 (M + H)+. 104 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-2.24
(13H, m), 4.31-4.33 (1H, m), 4.52 (1H, s), 6.52-6.53 (1H, m),
7.25-7.27 (1H, m), 8.49 (1H, s), 8.76 (1H, d, J = 8.0 Hz), 9.25
(1H, s), 11.72 (1H, s). MS: 352 (M + H)+ 105 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.51-2.17 (13H, m), 3.07-3.08 (2H, m), 4.31-4.32
(1H, m), 4.40-4.42 (1H, m), 6.50-6.51 (1H, m), 7.24-7.25 (1H, m),
8.49 (1H, s), 8.84 (1H, d, J = 8.0 Hz), 9.25 (1H, s), 11.71 (1H,
s). MS: 366.3 (M + H)+ 106 1 1H-NMR (400 MHz, d6-DMSO).delta.:
1.13-2.19 (13H, m), 2.97-3.00 (2H, m), 3.82-3.83 (1H, m), 4.31-4.40
(1H, m), 6.57-6.58 (1H, m), 7.26-7.27 (1H, m), 8.48 (1H, s), 8.78
(1H, d, J = 8.0 Hz), 9.24-9.25 (1H, m), 11.70 (1H, s). MS: 366 (M +
H)+ 107 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.51-2.31 (13H, m),
4.17-4.18 (1H, m), 4.58 (1H, brs), 6.56 (1H, d, J = 3.4 Hz), 7.22
(1H, d, J = 2.7 Hz, 7.50-7.57 (5H, m), 8.06 (1H, s), 10.58 (1H, d,
J = 7.9 Hz), 11.82 (1H, brs). MS: 388 (M + H)+. 108 1 1H-NMR (400
MHz, d6-DMSO).delta.: 0.88-2.26 (13H, m), 4.10-4.11 (1H, m), 4.58
(1H, brs), 4.60 (2H, s), 4.82 (2H, s), 6.51-6.52 (1H, s), 7.17-7.18
(1H, s), 7.30-7.38 (5H, m), 10.52 (1H, d, J = 7.9 Hz), 11.76 (1H,
brs). MS: 432 (M + H)+ 109 1 1H-NMR (400 MHz, d6-DMSO).delta.:
1.48-2.25 (13H, m), 3.36 (3H, s), 4.10-4.12 (1H, m), 4.57 (1H, s),
4.69 (2H, s), 6.51-6.52 (1H, m), 7.16-7.18 (1H, m), 8.49 (1H, s),
10.51 (1H, d, J = 8.0 Hz), 11.76 (1H, brs). MS: 356 (M + H)+ 110 1
1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-2.25 (14H, m), 4.10 (1H, d,
J = 7.9 Hz), 5.48 (2H, s), 6.51-6.53 (1H, m), 6.92-6.99 (3H, m),
7.18 (1H, brs), 7.28-7.30 (2H, m), 8.65 (1H, s), 10.44 (1H, d, J =
7.9 Hz), 11.8 (1H, s). MS: 418 (M + H)+ 111 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-2.19 (13H, m), 4.21-4.23 (1H, m), 4.51 (1H,
s), 4.59 (2H, s), 4.80 (2H, s), 6.46-6.48 (1H, m), 7.17-7.18 (1H,
m), 7.29-7.37 (6H, m), 10.45 (1H, d, J = 8.0 Hz), 11.73 (1H, s).
MS: 432 (M + H)+ 112 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.23-2.33
(13H, m), 2.99-3.11 (2H, m), 4.21 (1H, brs), 4.40-4.41 (1H, m),
4.59 (2H, s), 4.79 (2H, s), 6.51 (1H, brs), 7.16-7.37 (6H, m), 8.51
(1H, s), 10.50 (1H, d, J = 8.0 Hz), 11.72 (1H, s). MS: 446 (M + H)+
113 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.47-2.33 (13H, m),
3.53-3.75 (2H, m), 4.16-4.17 (1H, m), 4.40 (1H, s), 4.87 (1H, s),
6.19-6.20 (1H, m), 6.82 (1H, s), 7.21-7.22 (1H, m), 9.80 (1H, d, J
= 8.0 Hz), 11.64 (1H, s). MS: 398 (M + H)+ 114 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.49-1.52 (2H, m), 1.62 (6H, s), 1.64-2.31 (11H,
m), 4.19-4.20 (1H, m), 4.54 (1H, s), 6.27 (1H, s), 6.53 (1H, brs),
7.20-7.22 (1H, m), 8.30 (1H, s), 9.80 (1H, d, J = 8.0 Hz), 11.64
(1H, brs). MS: 426 (M + H)+ 115 1 1H-NMR (400 MHz, d6-DMSO).delta.:
1.49-2.32 (13H, m), 2.82 (3H, d, J = 4.8 Hz), 4.27-4.28 (1H, m),
4.52 (1H, s), 6.55-6.57 (1H, m), 7.22-7.23 (1H, m), 8.83 (1H, m),
9.31-9.32 (1H, m), 9.82-9.83 (1H, m), 11.76 (1H, s). MS: 424.9 (M -
H)- 116 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.27-2.77 (24H, m),
3.75-3.77 (1H, m), 4.24-4.25 (1H, m), 4.53 (1H, s), 6.55-6.56 (1H,
m), 7.23-7.24 (1H, m), 8.38 (1H, s), 9.24 (1H, d, J = 8.0 Hz), 9.80
(1H, d, J = 7.6 Hz), 11.77 (1H, brs). MS: 508 (M + H)+ 117 1 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.55-1.61 (2H, m), 1.71-1.75 (2H, m),
1.81-2.05 (10H, m), 4.16-4.21 (1H, m), 6.40-6.43 (1H, m), 6.81-7.06
(1H, br), 7.10-7.13 (1H, m), 7.53-7.91 (1H, br), 8.37 (1H, s),
10.17 (1H, d, J = 8.0 Hz), 11.44 (1H, brs). MS: 311 (M + H)+. 118 1
1H-NMR (400 MHz, d6-DMSO).delta.: 1.64-1.74 (6H, m), 2.02-2.15 (9H,
m), 6.66-6.69 (1H, m), 6.96-7.13 (1H, br), 7.15-7.18 (1H, m),
7.66-7.93 (1H, br), 8.33 (1H, s), 9.70 (1H, brs), 11.45 (1H, brs).
MS: 311 (M + H)+. 119 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.37-1.43
(2H, m), 1.91-2.10 (11H, m), 3.77-3.81 (1H, m), 4.68-4.70 (1H, m),
6.67-6.70 (1H, m), 6.92-7.14 (1H, br), 7.16-7.19 (1H, m), 7.66-7.91
(1H, br), 8.33 (1H, s), 9.68 (1H, brs), 11.45 (1H, brs). MS: 349 (M
+ Na)+. 120 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.66 (6H, m),
1.88-1.95 (6H, m), 2.21-2.26 (2H, m), 4.63 (1H, brs), 6.63-6.66
(1H, m), 6.93-7.15 (1H, br), 7.17-7.20 (1H, m), 7.70-7.91 (1H, br),
8.34 (1H, s), 9.70 (1H, brs), 11.46 (1H, brs). MS: 349 (M + Na)+.
121 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.38-1.44 (2H, m),
1.63-1.71 (4H, m), 1.80-1.87 (4H, m), 2.02-2.07 (1H, m), 2.12-2.16
(2H, m), 4.11-4.15 (1H, m), 4.50 (1H, brs), 6.39-6.41 (1H, m),
6.90-7.05 (1H, br), 7.11-7.14 (1H, m), 7.70-7.83 (1H, br), 8.37
(1H, s), 10.09 (1H, d, J = 8.0 Hz), 11.45 (1H, brs). MS: 327 (M +
H)+ 122 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.44-1.50 (2H, m),
1.58-1.71 (4H, m), 1.76-1.86 (4H, m), 2.06-2.10 (1H, m), 2.21-2.25
(2H, m), 4.05-4.10 (1H, m), 4.54 (1H, brs), 6.51-6.53 (1H, m),
7.08-7.26 (2H, m), 7.88-8.03 (1H, br), 8.42 (1H, s), 10.43-10.51
(1H, m), 11.80 (1H, s). MS: 327 (M + H)+. 123 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.41-1.48 (0.8H, m), 1.49-1.56 (1.2H, m),
1.65-1.97 (8H, m), 2.08-2.16 (1H, m), 2.17-2.23 (0.8H, m),
2.23-2.28 (1.2H, m), 4.05-4.11 (0.6H, m), 4.15-4.20 (0.4H, m),
6.44-6.48 (1H, m), 6.87-7.11 (1H, br), 7.11-7.15 (1H, m), 7.66-7.91
(1H, br), 8.37 (0.4H, s), 8.38 (0.6H, s), 10.12 (0.4H, d, J = 8.4
Hz), 10.14 (0.6H, d, J = 8.4 Hz), 11.45 (1H, brs). MS: 341 (M +
H)+. 124 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.43-1.51 (1H, m),
1.68-1.96 (8H, m), 2.01-2.31 (3H, m), 2.33-2.40 (1H, m), 4.06-4.12
(0.5H, m), 4.21-4.28 (0.5H, m), 6.45-6.53 (1H, m), 6.88-7.20 (2H,
m), 7.65-7.95 (1H, br), 8.38 (0.5H, s), 8.39 (0.5H, s), 10.10
(0.5H, d, J = 8.4 Hz), 10.18 (0.5H, d, J = 8.4 Hz), 11.48 (1H,
brs). MS: 329 (M + H)+. 125 1 1H-NMR (400 MHz, d6-DMSO).delta.:
1.41-1.48 (2H, m), 1.69-1.78 (4H, m), 1.82-1.98 (4H, m), 2.08-2.13
(1H, m), 2.17-2.23 (2H, m), 3.15 (3H, s), 4.15-4.20 (1H, m),
6.44-6.47 (1H, m), 6.86-7.10 (1H, br), 7.11-7.15 (1H, m),
7.62-7.91 (1H, br), 8.37 (1H, s), 10.12 (1H, d, J = 8.4 Hz), 11.45
(1H, brs). MS: 341 (M + H)+. 126 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.49-1.56 (2H, m), 1.64-1.75 (4H, m), 1.77-1.95
(4H, m), 2.10-2.15 (1H, m), 2.23-2.28 (2H, m), 3.12 (3H, s),
4.05-4.11 (1H, m), 6.44-6.48 (1H, m), 6.89-7.10 (1H, br), 7.11-7.15
(1H, m), 7.61-7.93 (1H, br), 8.38 (1H, s), 10.14 (1H, d), 11.45
(1H, brs). MS: 341 (M + H)+. 127 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.68-1.76 (4H, m), 1.79-1.89 (4H, m), 2.01-2.09
(2H, m), 2.19-2.25 (1H, m), 2.32-2.38 (2H, m), 4.06-4.12 (1H, m),
6.45-.6.49 (1H, m), 6.91-7.18 (2H, m), 7.65-7.92 (1H, br), 8.39
(1H, s), 10.18 (1H, d, J = 8.4 Hz), 11.48 (1H, brs). MS: 351 (M +
Na)+. 128 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.06 (3H, t, J = 8.0
Hz), 1.53-1.59 (2H, m), 1.68-1.75 (4H, m), 1.80-1.94 (4H, m),
2.10-2.14 (1H, m), 2.24-2.28 (2H, m), 3.42 (2H, q, J = 8.0 Hz),
4.08-4.13 (1H, m), 6.51-6.53 (1H, m), 7.12-7.31 (2H, m), 7.83-8.03
(1H, br), 8.42 (1H, s), 10.43 (1H, d, J = 8.0 Hz), 11.74 (1H, brs).
MS: 355 (M + H)+. 129 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.53-2.20
(13H, m), 3.58-3.64 (3H, m), 4.19-4.29 (1H, m), 6.54-6.58 (1H, m),
7.19-7.47 (2H, m), 7.96-8.16 (1H, br), 8.46 (1H, s), 10.65-10.72
(1H, m), 11.98 (1H, brs). MS: 369 (M + H)+. 130 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.44-1.49 (2H, m), 1.82-1.94 (6H, m), 2.12-2.29
(5H, m), 4.22-4.26 (1H, m), 6.47-.6.50 (1H, m), 6.86-7.17 (2H, m),
7.66-7.93 (1H, br), 8.38 (1H, s), 10.10 (1H, d, J = 8.0 Hz), 11.47
(1H, brs). MS: 329 (M + H)+. 131 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.32-1.39 (1H, m), 1.63-1.90 (8H, m), 1.98-2.14
(2H, m), 2.30-2.37 (1H, m), 3.76-3.80 (1H, m), 4.18-4.23 (1H, m),
4.96-5.00 (1H, m), 6.34-.6.38 (1H, m), 6.61-7.09 (2H, m), 7.21-7.72
(1H, br), 8.23 (1H, s), 10.03 (1H, d, J = 8.0 Hz), 11.33 (1H, brs).
MS: 327 (M + H)+. 132 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.83
(7H, m), 1.87-2.09 (4H, m), 2.19-2.25 (1H, m), 3.88-3.92 (1H, m),
4.53-4.58 (1H, m), 4.97-5.00 (1H, m), 6.75-6.78 (1H, m), 6.80-7.14
(2H, m), 7.59-7.89 (1H, br), 8.35 (1H, s), 10.17 (1H, d, J = 8.0
Hz), 11.39 (1H, brs). MS: 327 (M + H)+. 133 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.17-1.57 (7H, m), 1.87-1.91 (1H, m), 2.27-2.30
(2H, m), 3.90 (1H, m), 6.57-6.58 (1H, m), 6.88-7.15 (1H, brs),
7.11-7.13 (1H, m), 7.60-7.90 (1H, brs), 8.35 (1H, s), 9.57 (1H, d,
J = 3.6 Hz), 11.45 (1H, s). MS: 271 (M + H)+ 134 1 1H-NMR (400 MHz,
d6-DMSO).delta.: 0.12-0.15 (2H, m), 0.40-0.44 (2H, m), 0.89-0.92
(2H, m), 1.49-1.72 (8H, m), 1.81-1.91 (4H, m), 2.10 (1H, s), 2.30
(1H, s), 4.12 (1H, s), 4.21 (1H, d, J = 7.5 Hz), 4.54 (1H, s),
6.53-6.57 (2H, brs), 6.55 (1H, s), 7.24 (1H, m), 7.89 (1H, d, J =
7.7 Hz), 8.72 (1H, s), 11.63 (1H, s). MS: 435 (M + H)+ 135 1 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.44-1.91 (15H, m), 2.10 (1H, s), 2.30
(2H, s), 2.70 (2H, d, J = 5.7 Hz), 3.58-3.63 (1H, m), 3.72-3.77
(1H, m), 3.88-3.91 (1H, m), 4.12 (2H, s), 4.21 (1H, d, J = 7.6 Hz),
4.54 (1H, s), 6.54 (1H, d, J = 1.7 Hz), 7.23-7.24 (1H, m), 7.89
(1H, d, J = 7.6 Hz), 8.72 (1H, s), 11.62 (1H, s). MS: 465 (M + H)+,
487 (M + Na)+ 136 1 1H-NMR (400 MHz, d6-DMSO).delta.: 1.24-1.33
(2H, m), 1.48-1.51 (2H, m), 1.64-1.72 (4H, m), 1.79-1.91 (6H, m),
2.10 (1H, s), 2.30 (2H, s), 2.66 (1H, brs), 2.72-2.77 (1H, m),
3.26-3.33 (2H, m), 3.81-3.85 (2H, m), 4.13 (2H, s), 4.21 (1H, d, J
= 7.5 Hz), 4.54 (1H, s), 6.54-6.55 (1H, m), 7.23-7.24 (1H, m), 7.90
(1H, d, J = 7.8 Hz), 8.71 (1H, s), 11.63 (1H, s). MS: 465 (M + H)+
137 1 1H-NMR (400 MHz, d6-DMSO).delta.: 0.90 (1H, m), 1.48-1.51
(2H, m), 1.63 (2H, s), 1.69-1.72 (2H, m), 1.82-1.91 (4H, m), 2.10
(1H, s), 2.30 (2H, s), 2.79-2.82 (2H, m), 3.25 (3H, s), 3.41-3.44
(2H, m), 4.11 (2H, s), 4.20 (1H, d, J = 7.5 Hz), 4.54 (1H, s), 6.54
(1H, m), 7.23-7.24 (1H, m), 7.89 (1H, d, J = 7.8 Hz), 8.71 (1H, s),
11.63 (1H, s). MS: 439 (M + H)+, 461 (M + Na)+ 138 1 1H-NMR (400
MHz, d6-DMSO).delta.: 1.48-1.52 (2H, m), 1.63 (2H, s), 1.69-1.72
(2H, m), 1.82-1.92 (4H, m), 2.10 (1H, s), 2.30 (2H, s), 2.70-2.73
(2H, m), 3.49-3.50 (2H, m), 4.12 (2H, s), 4.22 (1H, d, J = 7.5 Hz),
4.55 (2H, s), 6.55 (1H, s), 7.24 (1H, s), 7.89 (2H, d, J = 7.8 Hz),
8.72 (1H, s), 11.63 (1H, s). MS: 425 (M + H)+, 447 (M + Na)+ 139 2
MS: 343 (M + H)+ 140 2 MS: 343 (M + H)+ 141 2 MS: 364 (M + H)+ 142
2 MS: 300 (M + H)+ 143 2 MS: 388 (M + H)+ 144 3 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.47-2.46 (11H, m), 2.64-2.82 (2H, m), 4.47-4.69
(1H, m), 6.33-6.39 (1H, m), 7.41-7.50 (1H, m), 7.89-7.94 (1H, m),
10.77-10.83 (1H, m), 11.59 (1H, s). MS: 421 (M + H)+ 145 3 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.40-1.46 (2H, m), 1.58-1.68 (4H, m),
1.72-1.78 (2H, m), 1.83-1.89 (2H, m), 2.04-2.09 (1H, m), 2.29-2.33
(2H, m), 3.99-4.03 (1H, m), 4.52 (1H, brs), 5.74-5.77 (1H, m), 6.26
(1H, d, J = 15.7 Hz), 6.43-6.45 (1H, m), 7.16-7.18 (1H, m), 7.87
(1H, d, J = 15.7 Hz), 8.16 (1H, s), 11.47 (1H, brs), 12.12 (1H,
br). MS: 354 (M + H)+ 146 3 1H-NMR (400 MHz, d6-DMSO).delta.:
1.45-1.62 (4H, m), 1.69-1.78 (2H, m), 1.90-1.99 (2H, m), 2.09-2.14
(2H, m), 2.19-2.26 (2H, m), 2.77-2.88 (1H, m), 4.47-4.59 (1H, m),
6.43-6.47 (1H, m), 6.85-7.10 (1H, br), 7.20-7.23 (1H, m), 7.57-7.90
(1H, br), 8.34 (1H, s), 9.45 (1H, d, J = 8.0 Hz), 11.49 (1H, brs),
12.12 (1H, brs). MS: 343 (M + H)+. 147 3 MS: 328 (M + H)+ 148 3
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.55 (2H, m), 1.58-1.75 (4H,
m), 1.77-1.93 (4H, m), 2.05-2.13 (1H, m), 2.22-2.29 (2H, m),
4.09-4.16 (1H, m), 4.60 (1H, s), 6.61 (1H, d, J = 3.5 Hz), 7.27
(1H, d, J = 3.5 Hz), 8.63 (1H, s), 11.83-12.00 (1H, m), 12.08 (1H,
brs), 13.43 (1H, br). MS: 396 (M + H)+ 149 3 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-1.50 (2H, m), 1.61-1.71 (4H, m), 1.77-1.86
(4H, m), 2.06-2.10 (1H, m), 2.23-2.27 (2H, m), 4.06-4.11 (1H, m),
4.54 (1H, brs), 6.46-6.50 (1H, m), 7.15-7.18 (1H, m), 8.52 (1H, s),
9.50 (1H, brs), 11.61 (1H, brs), 12.36 (1H, brs). MS: 350 (M +
Na)+. 150 3 1H-NMR (400 MHz, d6-DMSO).delta.: 1.43-1.49 (2H, m),
1.65-1.73 (4H, m), 1.78-1.91 (4H, m), 2.05-2.10 (1H, m), 2.16-2.21
(2H, m), 4.18-4.24 (1H, m), 4.54 (1H, brs), 6.47-6.50 (1H, m),
7.20-7.22 (1H, m), 8.54 (1H, s), 9.65 (1H, d, J = 8.0 Hz), 11.76
(1H, brs), 12.69 (1H, brs). MS: 328 (M + H)+. 151 3 1H-NMR (400
MHz, d6-DMSO).delta.: 1.49-2.15 (13H, m), 4.12-4.20 (1H, m),
6.42-6.46 (1H, m), 6.87-7.15 (2H, m), 7.63-7.91 (1H, br), 8.37 (1H,
s), 10.14-10.23 (1H, m), 11.45 (1H, brs), 12.13 (1H, brs). MS: 355
(M + H)+. 152 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.50-2.75 (15H,
m), 3.21-3.72 (2H, m), 4.48-4.54 (1H, m), 6.33-6.39 (1H, m),
7.43-7.46 (1H, m), 7.75-8.01 (2H, m), 10.76-10.78 (1H, m), 11.58
(1H, s). MS: 405 (M + H)+ 153 4 1H-NMR (400 MHz, d6-DMSO).delta.:
1.69-1.77 (2H, m), 1.83-1.92 (4H, m), 2.03-2.12 (3H, m), 2.39-2.48
(2H, m), 2.70-2.75 (2H, m), 3.59 (2H, d, J = 5.6 Hz), 4.49 (1H, s),
6.34-6.36 (1H, m), 6.99 (1H, s), 7.12 (1H, s), 7.42-7.45 (2H, m),
7.90 (1H, s), 10.76 (1H, s), 11.57 (1H, s). MS: 409 (M + H)+ 154 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.50-1.57 (2H, m), 1.83-1.89 (2H,
m), 1.95-2.03 (3H, m), 2.20-2.28 (2H, m), 2.38-2.46 (2H, m),
2.63-2.70 (2H, m), 3.63 (2H, d, J = 5.8 Hz), 4.54 (1H, s),
6.39-6.40 (1H, m), 6.95-7.25 (3H, m), 7.45 (1H, t, J = 3.0 Hz),
7.90 (1H, s), 10.77 (1H, br), 11.57 (1H, s). MS: 409 (M + H)+ 155 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.57-2.73 (13H, m), 3.20-3.28
(3H, m), 4.36-4.39 (2H, m), 4.51-4.59 (1H, m), 6.30-6.38 (1H, m),
7.41-7.46 (1H, m), 7.89-7.90 (1H, m), 10.72-10.87 (1H, m),
11.53-11.61 (1H, m). MS: 405 (M + H)+ 156 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.20-1.56 (2H, m), 1.80-2.16 (7H, m), 2.31-2.45
(2H, m), 2.65-2.78 (2H, m), 3.54-3.60 (2H, m), 4.45-4.54 (1H, m),
6.27-6.37 (1H, m), 7.43-7.46 (1H, m), 7.83-7.94 (2H, m), 10.78 (1H,
s), 11.58 (1H, s). MS: 391 (M + H)+ 157 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.51-2.70 (17H, m), 3.71-3.84 (1H, m), 4.46-4.56
(1H, m), 6.29-6.39 (1H, m), 7.42-7.44 (1H, m), 7.89-7.91 (1H, m),
10.77-10.81 (1H, m), 11.55-11.59 (1H, m). MS: 417 (M + H)+ 158 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.40-2.87 (13H, m), 4.41-4.72
(1H, m), 6.28-6.42 (1H, m), 7.40-7.48 (1H, m), 7.86-7.93 (1H, m),
8.01-8.11 (1H, m), 8.20-8.32 (1H, m), 10.71-10.82 (1H, m),
11.54-11.63 (1H, m). MS: 420 (M + H)+ 159 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.49-2.22 (9H, m), 2.36-2.44 (2H, m), 2.63-2.74
(2H, m), 3.06-3.18 (2H, m), 3.36-3.44 (2H, m), 4.46-4.54 (1H, m),
4.61-4.68 (1H, m), 6.35-6.38 (1H, m), 7.24-7.55 (2H, m), 7.90 (1H,
s), 10.74-10.76 (1H, m), 11.57 (1H, s). MS: 396 (M + H)+ 160 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.35-1.99 (9H, m), 1.50-2.45
(11H, m), 2.63-2.74 (2H, m), 2.92-3.14 (4H, m), 4.46-4.53 (1H, m),
6.32-6.39 (1H, m), 6.78-9.86 (1H, m), 7.32-7.60 (2H, m), 7.90 (1H,
s), 10.73-10.79 (1H, m), 11.57 (1H, s). MS: 495 (M + H)+ 161 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.59-1.65 (2H, m), 1.85-1.95 (2H,
m), 2.05-2.11 (1H, m), 2.13-2.21 (2H, m), 2.35-2.47 (6H, m), 5.16
(1H, d, J = 8.7 Hz), 7.13 (1H, br), 7.91 (1H, br), 8.08 (1H, s),
8.47 (1H, s), 9.98 (1H, d, J = 8.7 Hz), 12.81 (1H, br). MS: 390,
392 (M + H)+ 162 4 MS: 479 (M + H)+ 163 4 MS: 465 (M + H)+ 164 4
MS: 508 (M + H)+ 165 4 MS: 492 (M + H)+ 166 4 MS: 508 (M + H)+ 167
4 MS: 488 (M + H)+ 168 4 MS: 513 (M + H)+ 169 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.78-1.89 (4H, m), 2.04-2.11 (1H, m), 2.22-2.25
(4H, m), 2.30-2.35 (2H, m), 2.51-2.56 (2H, m), 5.05 (1H, d, J = 8.7
Hz), 7.20 (1H, br), 7.95 (1H, br), 8.07 (1H, s), 8.49 (1H, s),
10.17 (1H, d, J = 8.7 Hz), 12.81 (1H, br). MS: 390, 392 (M + H)+
170 4 MS: 353 (M + H)+ 171 4 MS: 390 (M + H)+ 172 4 MS: 434 (M +
H)+ 173 4 MS: 417 (M + H)+ 174 4 MS: 369 (M + H)+ 175 4 MS: 369 (M
+ H)+ 176 4 MS: 355 (M + H)+ 177 4 MS: 433 (M + H)+ 178 4 MS: 423
(M + H)+ 179 4 MS: 433 (M + H)+ 180 4 MS: 419 (M + H)+ 181 4 MS:
558 (M + Na)+ 182 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.39-2.34
(12H, m), 3.09 (3H, s), 4.08 (2H, s), 4.44 (1H, s), 4.50 (1H, m),
5.00 (1H, m), 8.04 (1H, s), 9.11 (1H, s), 10.18 (1H, m), 11.11 (1H,
m), 12.80 (1H, s). MS: 424 (M + H)+ 183 4 MS: 434 (M + H)+. MS: 432
(M - H)- 184 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.43 (9H, s),
1.68-1.84 (2H, m), 1.84-2.13 (4H, m), 2.13-2.31 (2H, m), 4.04-4.17
(2H, m), 4.30-4.39 (1H, m), 6.44-6.49 (1H, m), 7.01 (1H, br),
7.06-7.12 (1H, m), 7.77 (1H, br), 8.37 (1H, s), 10.24 (1H, d, J =
7.6 Hz), 11.43 (1H, s). MS: 386 (M + H)+ 185 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.76-2.40 (8H, m), 3.95 (1H, d, J = 18.8 Hz), 4.05
(1H, d, J = 18.8 Hz), 4.13-4.24 (1H, m), 4.29-4.41 (1H, m),
4.44-4.55 (1H, m), 6.39-6.47 (1H, m), 7.04 (1H, br), 7.08-7.15 (1H,
m), 7.80 (1H, br), 8.38 (1H, s), 10.28 (1H, d, J = 7.6 Hz), 11.46
(1H, s). MS: 353 (M + H)+ 186 4 1H-NMR (400 MHz, d6-DMSO).delta.:
1.72-2.52 (8H, m), 3.94-4.09 (1H, m), 4.37-4.48 (1H, m), 4.58-4.73
(1H, m), 6.45-6.51 (1H, m), 7.02 (1H, br), 7.07-7.14 (1H, m),
7.42-7.56 (5H, m), 7.79 (1H, br), 8.37 (1H, s), 10.29 (1H, d, J =
7.7 Hz), 11.45 (1H, s). MS: 390 (M + H)+ 187 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.30-1.50 (11H, m), 1.67-2.22 (6H, m), 4.12 (2H,
brs), 5.40-5.55 (1H, m), 7.10 (1H, brs), 7.82 (1H, brs), 8.10 (1H,
s), 8.43 (1H, s), 9.28 (1H, d, J = 8.6 Hz), 12.8 (1H, brs). MS: 387
(M + H)+ 188 4 1H-NMR (400 MHz, d6-DMSO).delta.: 0.96-2.19 (13H,
m), 4.09-4.19 (1H, m), 6.42-6.43 (1H, m), 6.55-6.57 (1H, m),
7.11-7.14 (1H, m), 7.63-7.65 (1H, m), 7.86-7.89 (1H, m), 7.86-7.89
(1H, m), 8.20 (1H, s), 8.37 (1H, d, J = 2.8 Hz), 10.11-10.23 (1H,
m), 11.47 (1H, s), 12.16 (1H, s).. MS: 393 (M + H)+ 189 4 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.42-1.60 (4H, m), 1.70-1.83 (4H, m),
2.05-2.11 (2H, m), 2.19-2.26 (2H, m), 2.76-2.87 (1H, m), 4.54-4.66
(1H, m), 6.53-6.56 (1H, m), 6.71 (1H, brs), 6.88-7.10 (1H, br),
7.19-7.22 (1H, m), 7.35 (1H, brs), 7.60-7.85 (1H, br), 8.34 (1H,
s), 9.45 (1H, d, J = 8.0 Hz), 11.46 (1H, brs). MS: 364 (M + Na)+.
190 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.49-2.13 (13H, m),
4.10-4.21 (1H, m), 6.43-6.46 (1H, m), 6.73-6.78 (1H, m), 6.92-7.14
(3H, m), 7.61-7.95 (1H, br), 8.37-8.39 (1H, m), 10.11-10.18 (1H,
m), 11.46 (1H, brs). MS: 354 (M + H)+ 191 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.47-1.53 (2H, m), 1.78-1.96 (7H, m), 2.00-2.10
(4H, m), 4.16-4.21 (1H, m), 6.44-6.46 (1H, m), 6.76 (1H, brs),
6.88-7.13 (3H, m), 7.62-7.90 (1H, br), 8.37 (1H, s), 10.17 (1H, d,
J = 8.0 Hz), 11.45 (1H, brs). MS: 376 (M + Na)+. 192 4 1H-NMR (400
MHz, d6-DMSO).delta.: 1.69-1.98 (11H, m), 2.10-2.15 (2H, m),
4.10-4.15 (1H, m), 6.43-6.46 (1H, m), 6.75 (1H, brs), 6.90-7.09
(2H, m), 7.11-7.15 (1H, m), 7.66-7.93 (1H, br), 8.37 (1H, s), 10.13
(1H, d, J = 8.0 Hz), 11.46 (1H, brs). MS: 354.2 (M + H)+. 193 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.40-1.86 (10H, m), 2.05 (1H,
brs), 2.19 (2H, brs), 4.48 (1H, s), 4.94 (1H, d, J = 8.7 Hz), 7.09
(1H, brs), 7.83 (1H, brs), 8.04 (1H, s), 8.45 (1H, s), 9.97 (1H, d,
J = 8.7 Hz), 12.8 (1H, brs). MS: 328 (M + H)+ 194 4 1H-NMR (400
MHz, d6-DMSO).delta.: 1.40-1.89 (10H, m), 2.11 (1H, brs), 2.18 (2H,
brs), 3.15 (3H, s), 5.04 (1H, d, J = 8.8 Hz), 7.10 (1H, brs), 7.82
(1H, brs), 8.06 (1H, s), 8.46 (1H, s), 9.98 (1H, d, J = 8.8 Hz),
12.7 (1H, brs). MS: 342 (M + H)+ 195 4 1HNMR (400 MHz,
d6-DMSO).delta.: 1.40-1.65 (2H, m), 1.80-2.15 (6H, m), 3.90-4.10
(2H, m), 4.20 (1H, brs), 4.55 (1H, brs),
5.45-5.55 (1H, m), 7.18 (1H, brs), 7.81 (1H, brs), 8.11 (1H, s),
8.25 (1H, s), 9.25 (1H, d, J = 9.1 Hz), 12.8 (1H, brs). MS: 376 (M
+ Na)+ 196 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.2-2.1 (14H, m),
2.73 (1H, s), 2.89 (1H, s), 3.7-4.6 (4H, m), 6.4-6.5 (1H, m),
7.1-7.5 (1H, m), 7.9-8.0 (1H, m), 8.3-8.4 (1H, m), 10.1-10.2 (1H,
m), 11.46 (1H, s). MS: 497.2 (M + H)+. 197 4 MS: 385 (M + H)+ 198 4
1H-NMR (400 MHz, d6-DMSO).delta.: 1.52-2.23 (13H, m), 3.23-3.34
(3H, m), 4.12-4.47 (3H, m), 6.47-6.58 (1H, m), 6.94-7.14 (2H, m),
7.81 (1H, brs), 8.34-8.47 (1H, m), 10.12-10.27 (1H, m, J = 11.44
Hz), 11.44 (1H, s). MS: 393 (M + H)+. 199 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.56-2.31 (14H, m), 2.77 (3H, d, J = 4.4 Hz),
4.16-4.18 (1H, m), 6.43 (1H, s), 7.14-7.16 (1H, s), 8.31-8.40 (1H,
s), 9.96-9.98 (1H, s), 11.48 (1H, s). MS: 350 (M + H)+ 200 4 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.51-2.34 (14H, m), 2.74 (3H, d, J = 4.0
Hz), 4.2-4.3 (1H, m), 6.50-6.52 (1H, m), 7.13-7.15 (1H, m),
8.25-8.26 (1H, m), 9.92-9.95 (1H, m), 11.46 (1H, s). MS: 350 (M +
H)+ 201 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.47-1.54 (2H, m),
1.62-1.74 (4H, m), 1.81-1.92 (4H, m), 2.08-2.11 (1H, m), 2.28-2.31
(2H, m), 3.36-3.44 (2H, m), 3.48-3.76 (6H, m), 4.04, 4.12 (2H, s),
4.20-4.24 (1H, m), 4.40, 4.50 (1H, s), 6.58-6.61 (1H, m), 7.27-7.30
(1H, m), 8.65 (1H, s), 8.83-8.86 (1H, m), 11.90 (1H, brs). MS: 531
(M + H)+ 202 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.57-2.20 (8H, m),
2.42 (3H, s), 4.05-4.06 (2H, m), 4.26-4.27 (1H, m), 4.58 (2H, s),
6.66-6.67 (1H, m), 7.31-7.32 (1H, m), 8.43 (1H, d, J = 8.0 Hz),
8.57 (1H, s), 11.88 (1H, brs). MS: 392.2 (M + H)+ 203 4 1H-NMR (400
MHz, d6-DMSO).delta.: 1.31-1.50 (4H, m), 1.54-1.72 (8H, m),
1.72-1.89 (4H, m), 2.03-2.11 (1H, m), 2.16-2.25 (2H, m), 2.75-2.87
(4H, m), 3.98-4.06 (1H, m), 4.53 (1H, s), 6.41-6.47 (1H, m),
7.10-7.15 (1H, m), 8.27 (1H, s), 9.09 (1H, brs), 9.52 (1H, d, J =
6.8 Hz), 11.46 (1H, brs). MS: 410 (M + H)+ 204 4 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.38-1.81 (16H, m), 2.02-2.10 (1H, m), 2.14-2.22
(2H, m), 3.45-3.56 (4H, m), 3.93-4.01 (1H, m), 4.50 (1H, s),
6.44-6.48 (1H, m), 6.97 (1H, d, J = 8.4 Hz), 7.16-7.21 (1H, m),
7.80 (1H, s), 11.46 (1H, brs). MS: 395 (M + H)+ 205 4 1H-NMR (400
MHz, d6-DMSO).delta.: 0.93-1.88 (20H, m), 2.01-2.09 (1H, m),
2.12-2.22 (2H, m), 3.85-4.03 (2H, m), 4.48 (1H, s), 4.59 (2H, s),
6.42-6.47 (1H, m), 7.11 (1H, d, J = 8.0 Hz), 7.13-7.18 (1H, m),
7.94 (1H, s), 11.40 (1H, brs). MS: 424 (M + H)+ 206 4 1H-NMR (400
MHz, d6-DMSO).delta.: 1.04-1.92 (20H, m), 2.03-2.12 (1H, m),
2.15-2.27 (2H, m), 2.65-2.77 (1H, m), 3.98-4.08 (1H, m), 4.51 (1H,
s), 4.90-5.01 (1H, m), 6.40-6.47 (1H, m), 7.10-7.16 (1H, m), 8.27
(1H, s), 9.47 (1H, d, J = 8.1 Hz), 9.66-9.74 (1H, m), 11.47 (1H,
s). MS: 424 (M + H)+ 207 4 1H-NMR (400 MHz, d6-DMSO).delta.:
1.42-1.49 (2H, m), 1.58-1.72 (4H, m), 1.75-1.88 (4H, m), 1.92 (3H,
s), 2.04-2.10 (1H, m), 2.18-2.25 (2H, m), 4.03-4.08 (1H, m), 4.52
(1H, s), 6.44-6.48 (1H, m), 7.14-7.17 (1H, m), 8.42 (1H, s), 9.65
(1H, d, J = 8.0 Hz), 9.76 (1H, s), 9.99 (1H, brs), 11.52 (1H, brs).
MS: 384 (M + H)+ 208 4 1H-NMR (400 MHz, d6-DMSO).delta.: 1.88-2.47
(8H, m), 2.42 (3H, s), 3.98 (1H, d, J = 18.9 Hz), 4.08 (1H, d, J =
18.9 Hz), 4.20-4.26 (1H, m), 4.48-4.57 (2H, m), 6.56-6.61 (1H, m),
7.23-7.28 (1H, m), 8.58 (1H, s), 9.17 (1H, d, J = 7.6 Hz), 11.83
(1H, s). MS: 392 (M + H)+ 209 4 1H-NMR (400 MHz, d6-DMSO).delta.:
1.81-1.94 (4H, m), 2.11 (1H, m), 2.46-2.51 (3H, m), 4.13 (2H, s),
4.39 (1H, s), 4.71 (1H, s), 4.97 (1H, m), 6.26 (1H, s), 7.36-7.44
(1H, m), 7.94 (1H, s), 11.02 (1H, brs), 11.65 (1H, s). MS: 373 (M +
Na)+ 210 4 MS: 439 (M + H)+ 211 4 MS: 493 (M + H)+ 212 4 MS: 404 (M
+ H)+ 213 4 MS: 404 (M + H)+ 214 4 MS: 415 (M + H)+ 215 4 MS: 415
(M + H)+ 216 4 MS: 415 (M + H)+ 217 4 MS: 408 (M + H)+ 218 4 MS:
420 (M + H)+ 219 4 MS: 420 (M + H)+ 220 4 MS: 432 (M + H)+ 221 4
MS: 448 (M + H)+ 222 4 MS: 328 (M + H)+ 223 4 MS: 342 (M + H)+ 224
4 MS: 344 (M + H)+ 225 4 MS: 354 (M + H)+ 226 4 MS: 356 (M + H)+
227 4 MS: 358 (M + H)+ 228 4 MS: 370 (M + H)+ 229 4 MS: 371 (M +
H)+ 230 4 MS: 391 (M + H)+ 231 4 MS: 391 (M + H)+ 232 4 MS: 391 (M
+ H)+ 233 4 MS: 396 (M + H)+ 234 4 MS: 397 (M + H)+ 235 4 MS: 405
(M + H)+ 236 4 MS: 422 (M + H)+ 237 4 MS: 434 (M + H)+ 238 4 MS:
468 (M + H)+ 239 4 MS: 483 (M + H)+ 240 4 MS: 385 (M + H)+ 241 4
MS: 398 (M + H)+ 242 4 MS: 413 (M + H)+ 243 4 MS: 384 (M + H)+ 244
4 MS: 399 (M + H)+ 245 4 MS: 425 (M + H)+ 246 4 MS: 424 (M + H)+
247 4 MS: 450 (M + H)+ 248 4 MS: 411 (M + H)+ 249 4 MS: 415 (M +
H)+ 250 4 MS: 425 (M + H)+ 251 4 MS: 411 (M + H)+ 252 4 MS: 438 (M
+ H)+ 253 4 1H-NMR (400 MHz, d6-DMSO).delta.: 0.81 (3H, s), 0.91
(3H, s), 0.99 (3H, s), 0.87-1.31 (3H, m), 1.34-1.52 (3H, m),
2.33-2.49 (1H, m), 4.13-4.28 (1H, m), 6.42 (1H, d, J = 2.6 Hz),
6.72-7.94 (3H, m), 8.36 (1H, s), 10.09 (1H, d, J = 8.4 Hz), 11.46
(1H, brs). MS: 313 (M + H)+ 254 4 MS: 440 (M + H)+ 255 4 MS: 398 (M
+ H)+ 256 4 MS: 435 (M + H)+ 257 4 MS: 435 (M + H)+ 258 4 MS: 435
(M + H)+ 259 4 MS: 442 (M + H)+ 260 4 MS: 407 (M + H)+ 261 4 MS:
403 (M + H)+ 262 4 MS: 410 (M + H)+ 263 4 MS: 411 (M + H)+ 264 4
MS: 447 (M + H)+ 265 4 MS: 432 (M + H)+ 266 4 MS: 447 (M + H)+ 267
4 MS: 432 (M + H)+ 268 7 MS: 469 (M + H)+ 269 7 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-2.35 (10H, m), 3.39 (2H, m), 3.76-4.13 (5H,
m), 4.23 (1H, m), 4.54 (1H, s), 6.56 (1H, m), 7.26 (1H, m), 7.74
(1H, m), 8.80 (1H, s), 9.41 (1H, m), 11.69 (1H, s). MS: 479 (M +
H)+ 270 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-2.48 (14H, m),
3.41 (2H, m), 4.23 (1H, m), 4.55 (1H, s), 6.57 (1H, m), 7.26 (1H,
m), 7.72 (1H, m), 8.78 (1H, s), 9.30 (1H, m), 11.69 (1H, s). MS:
466 (M + H)+ 271 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.39-2.32
(12H, m), 3.45 (2H, m), 3.85 (2H, m), 4.01 (1H, m), 4.23 (1H, m),
4.56 (1H, s), 4.87 (1H, m), 6.56 (1H, m), 7.26 (1H, m), 7.72 (1H,
m), 8.71 (1H, s), 11.71 (1H, s). MS: 479 (M + H)+ 272 7 1H-NMR (400
MHz, d6-DMSO).delta.: 1.49-2.47 (14H, m), 3.67-3.78 (4H, m), 4.24
(1H, m), 4.56 (1H, s), 6.56 (1H, m), 7.25 (1H, m), 7.71 (1H, m),
8.71 (1H, s), 11.71 (1H, s). MS: 478 (M + H)+ 273 7 MS: 550 (M +
H)+ 274 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.38 (13H, m),
3.55 (4H, m), 3.99 (1H, m), 4.23 (1H, m), 4.51 (1H, s), 4.82 (2H,
m), 6.60 (1H, m), 7.27 (1H, m), 8.17 (1H, m), 8.65 (1H, m), 8.84
(1H, m), 11.88 (1H, s). MS: 469 (M + H)+ 275 7 MS: 469 (M + H)+ 276
7 MS: 556 (M + H)+ 277 7 MS: 505 (M + Na)+ 278 7 MS: 491 (M + Na)+
279 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.42 (9H, s), 1.44-2.38
(7H, m), 2.85 (2H, m), 3.89-4.05 (4H, m), 4.22 (1H, m), 4.38 (1H,
s), 6.60 (1H, m), 7.27 (1H, m), 8.31 (1H, m), 8.73 (1H, m), 8.89
(1H, m), 11.87 (1H, s). MS: 600 (M + Na)+ 280 7 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-1.51 (2H, m), 1.61-1.64 (2H, m), 1.67-1.73
(2H, m), 1.81-1.87 (2H, m), 1.93-1.99 (2H, m), 2.08-2.12 (1H, m),
2.32-2.36 (2H, m), 4.19-4.23 (1H, m), 4.46 (1H, s), 6.60 (1H, d, J
= 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz), 8.17-8.21 (2H, m), 8.64 (1H,
s), 8.88 (1H, d, J = 7.5 Hz), 11.88 (1H, brs). MS: 395 (M + H)+ 281
7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.47-1.53 (2H, m), 1.62-1.65
(2H, m), 1.67-1.74 (2H, m), 1.81-1.92 (4H, m), 2.08-2.12 (1H, m),
2.28-2.32 (2H, m), 3.06 (3H, s), 3.11 (3H, s), 4.19-4.23 (1H, m),
4.50 (1H, s), 6.59 (1H, d, J = 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz),
8.65 (1H, s), 8.88 (1H, d, J = 7.6 Hz), 11.89 (1H, brs). MS: 423 (M
+ H)+ 282 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.5-2.2 (14H, m),
2.98 (3H, s), 3.00 (3H, s), 4.11-4.18 (1H, m), 6.44-6.48 (1H, m),
7.11-7.12 (1H, m), 7.39-7.56 (1H, m), 7.70-7.73 (1H, m), 8.31 (1H,
s), 8.37-8.38 (1H, m), 10.16-10.18 (1H, m), 11.46 (1H, brs). MS:
382.3 (M + H)+. 283 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.48-1.54
(2H, m), 1.61-1.65 (2H, m), 1.68-1.74 (2H, m), 1.82-1.93 (4H, m),
2.08-2.12 (1H, m), 2.29-2.33 (2H, m), 3.56-3.63 (4H, m), 3.68-3.70
(4H, m), 4.20-4.24 (1H, m), 4.52 (1H, s), 6.59 (1H, d, J = 3.6 Hz),
7.29 (1H, d, J = 3.6 Hz), 8.64 (1H, s), 8.84 (1H, d, J = 7.8 Hz),
11.89 (1H, brs). MS: 487 (M + Na)+ 284 7 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.47-1.53 (2H, m), 1.62-1.65 (2H, m), 1.68-1.73
(2H, m), 1.81-1.92 (4H, m), 2.08-2.12 (1H, m), 2.28-2.33 (2H, m),
2.68-2.72 (2H, m), 2.75-2.79 (2H, m), 3.40-3.43 (2H, m), 3.59-3.62
(2H, m), 4.19-4.22 (1H, m), 4.51 (1H, brs), 6.57-6.60 (1H, m),
7.27-7.29 (1H, m), 8.64 (1H, s), 8.83-8.86 (1H, m), 11.89 (1H,
brs). MS: 464 (M + H)+ 285 7 1H-NMR (400 MHz, d6-DMSO).delta.:
1.48-1.54 (2H, m), 1.63-1.65 (2H, m), 1.69-1.74 (2H, m), 1.82-1.92
(4H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 2.86 (3H, s),
4.22-4.25 (1H, m), 4.55 (1H, brs), 6.57 (1H, d, J = 3.6 Hz), 7.27
(1H, d, J = 3.6 Hz), 7.71-7.74 (1H, m), 8.78 (1H, s), 9.38 (1H,
brs), 11.68 (1H, brs). MS: 409 (M + H)+ 286 7 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-1.51 (2H, m), 1.61-1.64 (2H, m), 1.67-1.73
(2H, m), 1.81-1.87 (2H, m), 1.93-1.99 (2H, m), 2.08-2.12 (1H, m),
2.32-2.36 (2H, m), 4.19-4.23 (1H, m), 4.46 (1H, s), 6.60 (1H, d, J
= 3.6 Hz), 7.28 (1H, d, J = 3.6 Hz), 8.17-8.21 (2H, m), 8.64 (1H,
s), 8.88 (1H, d, J = 7.5 Hz), 11.88 (1H, brs). MS: 395 (M + H)+ 287
7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.48-1.53 (2H, m), 1.63-1.80
(8H, m), 1.82-1.99 (6H, m), 2.09-2.12 (1H, m), 2.17 (3H, s),
2.30-2.33 (2H, m), 2.76-2.81 (2H, m), 3.73-3.79 (1H, m), 4.22-4.25
(1H, m), 4.53 (1H, s), 6.56-6.57 (1H, m), 7.25-7.27 (1H, m),
7.74-7.76 (1H, m), 8.80 (1H, s), 9.33-9.36 (1H, m), 11.68 (1H,
brs). MS: 492 (M + H)+ 288 7 1H-NMR (400 MHz, d6-DMSO).delta.:
1.49-1.55 (2H, m), 1.63-1.66 (2H, m), 1.69-1.75 (2H, m), 1.82-1.93
(4H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 3.67-3.73 (6H, m),
3.83-3.86 (2H, m), 4.22-4.26 (1H, m), 4.52 (1H, s), 6.55-6.57 (1H,
m), 7.24-7.26 (1H, m), 7.70-7.73 (1H, m), 8.72 (1H, s), 11.68 (1H,
brs). MS: 465 (M + H)+ 289 7 1H-NMR (400 MHz, d6-DMSO).delta.:
1.49-1.54 (2H, m), 1.63-1.65 (2H, m), 1.69-1.75 (2H, m), 1.82-1.93
(4H, m), 2.09-2.12 (1H, m), 2.30-2.33 (2H, m), 3.10 (3H, s), 3.25
(3H, s), 4.22-4.26 (1H, m), 4.52 (1H, s), 6.55-6.57 (1H, m),
7.24-7.26 (1H, m), 7.71-7.73 (1H, m), 8.72 (1H, s), 11.67 (1H,
brs). MS: 423 (M + H)+ 290 7 1H-NMR (400 MHz, d6-DMSO).delta.:
1.41-1.42 (9H, m), 1.48-1.57 (4H, m), 1.63-1.74 (4H, m), 1.78-1.92
(6H, m), 2.09-2.12 (1H, m), 2.30-2.32 (2H, m), 2.79-2.90 (1H, m),
3.33-3.39 (2H, m), 3.93-4.02 (2H, m), 4.22-4.26 (1H, m), 4.53 (1H,
s), 6.56-6.58 (1H, m), 7.25-7.27 (1H, m), 7.73-7.76 (1H, m), 8.79
(1H, s), 9.37-9.40 (1H, m), 11.68 (1H, brs). MS: 578 (M + H)+ 291 7
1H-NMR (400 MHz, d6-DMSO).delta.: 1.48-1.54 (2H, m), 1.63-1.65 (2H,
m), 1.69-1.74 (2H, m), 1.82-2.00 (6H, m), 2.09-2.12 (1H, m),
2.30-2.33 (2H, m), 3.33-3.62 (2H, m), 3.79-4.01 (2H, m), 4.22-4.25
(1H, m), 4.54, 4.55 (1H, m), 4.72-4.73 (1H, m), 5.00-5.01,
5.55-5.56 (1H, m), 6.55-6.57 (1H, m), 7.25-7.26 (1H, m), 7.71-7.74
(1H, m), 8.73, 8.74 (1H, s), 11.72 (1H, m). MS: 477 (M + H)+ 292 7
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.52 (2H, m), 1.67-1.75 (4H,
m), 1.87-1.93 (4H, m), 2.08-2.12 (1H, m), 2.23-2.26 (2H, m), 2.85
(3H, d, J = 4.7 Hz), 3.17 (1H, s), 4.33-4.37 (1H, m), 6.53-6.55
(1H, m), 7.27-7.29 (1H, m), 7.74-7.77 (1H, m), 8.78 (1H, s),
9.37-9.41 (1H, m), 11.72 (1H, brs). MS: 409 (M + H)+ 293 7 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.49-2.31 (13H, m), 3.28 (3H, s),
3.47-3.52 (4H, m), 4.22-4.23 (1H, m), 4.52 (1H, brs), 6.55-6.57
(1H, m), 7.25-7.26 (1H, m), 7.71-7.73 (1H, m), 8.78 (1H, s), 9.42
(1H, brs), 11.66 (1H, brs). MS: 453 (M + H)+ 294 7 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.08 (3H, d, J = 6.0 Hz), 1.49-2.32 (13H, m),
3.16-3.27 (2H, m), 3.84-3.86 (1H, m), 4.23-4.24 (1H, m), 4.52 (1H,
s), 4.82 (1H, d, J = 4.8 Hz), 6.55-6.57 (1H, m), 7.25-7.27 (1H, m),
7.72-7.74 (1H, m),
8.78 (1H, s), 9.26-9.27 (1H, m), 11.66 (1H, brs).. MS: 453 (M + H)+
295 7 1H-NMR (400 MHz, d6-DMSO).delta.: 1.02-2.31 (18H, m),
3.20-3.24 (4H, m), 3.83-3.84 (2H, m), 4.23-4.24 (1H, m), 4.52 (1H,
brs), 6.56-6.57 (1H, m), 7.24-7.26 (1H, m), 7.72-7.74 (1H, m), 8.78
(1H, s), 9.45-9.46 (1H, m), 11.66 (1H, brs). MS: 493 (M + H)+ 296 8
MS: 439 (M + H)+ 297 8 MS: 453 (M + H)+ 298 8 MS: 453 (M + H)+ 299
8 MS: 466 (M + H)+ 300 8 MS: 452 (M + H)+ 301 8 MS: 463 (M + H)+
302 8 MS: 479 (M + H)+ 303 8 MS: 488 (M + H)+ 304 8 MS: 460 (M +
H)+ 305 8 MS: 465 (M + H)+ 306 8 MS: 479 (M + H)+ 307 8 MS: 506 (M
+ H)+ 308 8 MS: 506 (M + H)+ 309 8 MS: 478 (M + H)+ 310 8 MS: 477
(M + H)+ 311 8 MS: 493 (M + H)+ 312 8 MS: 479 (M + H)+ 313 8 MS:
492 (M + H)+ 314 8 MS: 479 (M + H)+ 315 8 MS: 493 (M + H)+ 316 8
MS: 506 (M + H)+ 317 8 MS: 508 (M + H)+ 318 8 MS: 541 (M + H)+ 319
8 MS: 546 (M + H)+ 320 8 MS: 434 (M + H)+ 321 8 MS: 499 (M + H)+
322 8 MS: 423 (M + H)+ 323 8 MS: 352 (M + H)+ 324 8 MS: 452 (M +
H)+ 325 8 MS: 467 (M + H)+ 326 8 MS: 483 (M + H)+ 327 8 MS: 475 (M
+ H)+ 328 8 MS: 486 (M + H)+ 329 8 MS: 486 (M + H)+ 330 8 MS: 486
(M + H)+ 331 8 MS: 492 (M + H)+ 332 8 MS: 493 (M + H)+ 333 8 MS:
506 (M + H)+ 334 8 MS: 509 (M + H)+ 335 8 MS: 477 (M + H)+ 336 8
MS: 556 (M + H)+ 337 8 MS: 513 (M + H)+ 338 8 MS: 527 (M + H)+ 339
8 MS: 508 (M + H)+ 340 8 MS: 479 (M + H)+ 341 8 MS: 504 (M + H)+
342 8 MS: 449 (M + H)+ 343 8 1H-NMR (400 MHz, d6-DMSO).delta.:
1.92-2.32 (8H, m), 2.49 (3H, s), 3.58-4.57 (5H, m), 6.76-6.77 (1H,
m), 7.39-7.40 (1H, m), 8.69 (1H, s), 8.79-9.05 (3H, m), 12.20 (1H,
brs). MS: 325 (M + H)+ 344 10 MS: 542 (M + H)+ 345 10 1H-NMR (400
MHz, d6-DMSO).delta.: 1.43-2.39 (9H, m), 2.79 (6H, s), 2.81 (2H,
m), 3.57 (2H, m), 3.99 (1H, m), 4.21 (1H, m), 4.40 (1H, s), 6.59
(1H, m), 7.27 (1H, m), 8.64 (1H, s), 8.76 (1H, m), 8.90 (1H, m),
11.89 (1H, s). MS: 571 (M + Na)+ 346 10 MS: 585 (M + H)+ 347 10 MS:
535 (M + H)+ 348 13 1H-NMR (400 MHz, d6-DMSO).delta.: 1.30 (3H, t,
J = 7.1 Hz), 1.45-1.54 (2H, m), 1.58-1.75 (4H, m), 1.77-1.89 (4H,
m), 2.06-2.12 (1H, m), 2.23-2.29 (2H, m), 4.09-4.15 (1H, m), 4.30
(2H, q, J = 7.1 Hz), 4.58 (1H, s), 6.49-9.53 (1H, m), 7.10 (2H,
brs), 7.17-7.21 (1H, m), 8.90 (1H, s), 9.33 (1H, d, J = 7.8 Hz),
11.72 (1H, brs). MS: 442 (M + H)+ 349 13 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.43 (9H, s), 1.71-1.85 (2H, m), 1.80 (3H, s),
1.90-2.09 (4H, m), 2.17-2.32 (2H, m), 4.08-4.17 (2H, m), 4.38-4.46
(1H, m), 6.45 (2H, brs), 6.50-6.56 (1H, m), 7.12-7.17 (1H, m), 8.77
(1H, s), 9.51 (1H, d, J = 7.6 Hz), 11.64 (1H, s). MS: 443 (M + H)+
350 14 1H-NMR (400 MHz, d6-DMSO).delta.: 1.47-1.55 (2H, m),
1.79-1.82 (2H, m), 1.86-1.99 (5H, m), 2.02-3.15 (4H, m), 4.09 (2H,
d, J = 5.5 Hz), 4.17-4.23 (1H, m), 6.44-6.47 (1H, m), 7.00 (1H,
br), 7.11-7.14 (1H, m), 7.78 (1H, br), 8.28 (1H, t, J = 5.4 Hz),
8.38 (1H, s), 10.18 (1H, d, J = 8.2 Hz), 11.46 (1H, s). MS: 393 (M
+ H)+ 351 14 1H-NMR (400 MHz, d6-DMSO).delta.: 1.71-2.03 (11H, m),
2.13-2.17 (2H, m), 4.06 (2H, d, J = 5.5 Hz), 4.12-4.16 (1H, m),
6.43-6.46 (1H, m), 6.99 (1H, br), 7.11-7.15 (1H, m), 7.77 (1H, br),
8.21 (1H, d, J = 5.5 Hz), 8.37 (1H, s), 10.18 (1H, d), 11.46 (1H,
s). MS: 393 (M + H)+ 352 14 1H-NMR (400 MHz, d6-DMSO).delta.:
1.37-1.39 (9H, m), 1.43-1.48 (2H, m), 1.68-2.03 (8H, m), 2.05-2.19
(3H, m), 4.04-4.17 (1H, m), 6.36-6.56 (2H, m), 6.87-7.16 (2H, m),
7.76 (1H, br), 8.36-8.38 (1H, m), 10.11-10.15 (1H, m), 11.44 (1H,
m). MS: 426 (M + H)+ 353 14 1H-NMR (400 MHz, d6-DMSO).delta.:
1.14-2.21 (13H, m), 4.02-4.04 (1H, m), 4.36 (2H, brs), 4.48 (1H,
s), 6.43-6.33 (1H, m), 7.12-7.13 (1H, m), 8.28 (1H, s), 9.48 (1H,
s), 9.67 (1H, d, J = 8.0 Hz), 11.42 (1H, brs). MS: 342 (M + H)+ 354
14 MS: 366 (M + H)+ 355 14 MS: 418 (M + H)+ 356 14 MS: 418 (M + H)+
357 14 MS: 418 (M + H)+ 358 14 1H-NMR (400 MHz, d6-DMSO).delta.:
1.45-2.22 (8H, m), 3.70 (3H, s), 4.04 (1H, m), 4.53 (1H, s), 6.45
(1H, m), 7.15 (1H, m), 8.16 (1H, s), 9.41 (1H, s), 11.41 (1H, s),
11.51 (1H, s). MS: 357 (M + H)+ 359 14 MS: 355 (M + H)+, 353 (M -
H)- 360 14 1H-NMR (400 MHz, d6-DMSO).delta.: 1.09-2.23 (16H, m),
3.28 (2H, m), 4.48 (1H, s), 4.96 (1H, m), 8.05 (1H, s), 8.31 (1H,
m), 8.40 (1H, s), 9.73 (1H, m), 12.73 (1H, s). MS: 356 (M + H)+ 361
14 1H-NMR (400 MHz, d6-DMSO).delta.: 1.22-2.34 (13H, m), 4.29 (2H,
m), 4.51 (1H, s), 5.01 (1H, m), 8.08 (1H, s), 8.43 (1H, s), 8.99
(1H, m), 9.65 (1H, m), 12.86 (1H, s). MS: 367 (M + H)+ 362 14 MS:
377 (M - H)- 363 15 MS: 408 (M + Na)+, 384 (M - H)- 364 16 1H-NMR
(400 MHz, d6-DMSO).delta.: 0.80-2.84 (13H, m), 4.60-4.69 (1H, m),
7.43-7.47 (1H, m), 7.90-7.92 (1H, m), 8.91-8.94 (1H, m),
10.78-10.85 (1H, m), 11.55-11.65 (1H, m). MS: 402 (M + H)+ 365 16
1H-NMR (400 MHz, d6-DMSO).delta.: 1.90-1.97 (4H, m), 2.03-2.12 (5H,
m), 2.62-2.67 (2H, m), 2.74-2.79 (2H, m), 4.54 (1H, s), 6.34-6.35
(1H, m), 7.45 (1H, t, J = 3.1 Hz), 7.91 (1H, s), 10.86 (1H, s),
11.61 (1H, s). MS: 334 (M + H)+ 366 17 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.46-1.83 (10H, m), 2.07 (1H, brs), 2.29 (2H,
brs), 4.57 (1H, s), 4.67-4.77 (1H, m), 5.95-6.02 (1H, m), 8.245
(1H, s), 8.249 (1H, s), 13.1 (1H, brs). MS: 332 (M + Na)+ 367 18
1H-NMR (400 MHz, d6-DMSO).delta.: 1.52-1.61 (2H, m), 1.72-1.92 (3H,
m), 1.99-2.13 (4H, m), 2.22-2.41 (3H, m), 2.64-2.74 (2H, m),
2.80-2.93 (2H, m), 3.26-3.38 (2H, m), 4.57-4.64 (1H, m), 6.52-6.59
(1H, m), 7.58-7.63 (1H, m), 7.82-7.91 (2H, m), 7.96. MS: 395 (M +
H)+ 368 18 1H-NMR (400 MHz, d6-DMSO).delta.: 1.50-1.59 (2H, m),
1.72-1.99 (6H, m), 2.05-2.17 (2H, m), 2.24-2.36 (2H, m), 4.21-4.30
(1H, m), 6.52-6.66 (1H, m), 7.31-7.39 (1H, m), 7.62 (1H, br),
7.70-7.71 (1H, m), 8.00-8.39 (4H, m), 8.53-8.56 (1H, m), 9.10 (1H,
s), 11.08 (1H, br), 12.44 (1H, br), 14.38 (1H, br). MS: 326 (M +
H)+ 369 18 MS: 340 (M + H)+ 370 18 MS: 478 (M + H)+ 371 18 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.51-1.57 (1H, m), 1.71-1.79 (2H, m),
1.83-1.90 (2H, m), 1.96-2.02 (2H, m), 2.06-2.20 (4H, m), 2.33-2.46
(2H, m), 4.38-4.42 (1H, m), 6.60-6.62, 6.73-6.75 (1H, m), 7.41-7.45
(1H, m), 8.11-8.29 (3H, m), 8.44, 8.56 (1H, brs), 8.80 (1H, s),
9.31-9.34, 9.45-9.50 (1H, m), 12.45 (1H, brs). MS: 394 (M - 3HCl +
H)+ 372 18 1H-NMR (400 MHz, d6-DMSO).delta.: 1.52-1.57 (2H, m),
1.65-1.75 (4H, m), 1.84-1.92 (6H, m), 1.97-2.02 (2H, m), 2.10-2.14
(1H, m), 2.32-2.36 (2H, m), 2.99-3.09 (2H, m), 3.30-3.36 (2H, m),
4.09-4.16 (1H, m), 4.32-4.35 (1H, m), 6.72-6.75 (1H, m), 7.40-7.42
(1H, m), 8.29-8.41 (1H, m), 8.56-8.65 (1H, m), 8.74-8.79 (1H, m),
8.82 (1H, s), 9.66-9.68 (1H, m), 12.37 (1H, brs). MS: 478 (M - 2HCl
+ H)+ 373 18 1H-NMR (400 MHz, d6-DMSO).delta.: 1.93-2.24 (6H, m),
2.46-2.61 (2H, m), 3.95-4.09 (2H, m), 4.42-4.54 (1H, m), 6.68-6.76
(1H, m), 7.34-7.41 (1H, m), 7.78 (1H, brs), 8.51 (1H, brs), 8.63
(1H, s), 9.11-9.51 (2H, m), 11.25 (1H, d, J = 7.3 Hz), 12.69 (1H,
s), 14.76 (1H, br). MS: 286 (M + H - 2HCl)+ 374 18 1H-NMR (400 MHz,
d6-DMSO).delta.: 2.02-2.20 (4H, m), 2.24-2.36 (2H, m), 2.43-2.61
(2H, m), 2.47 (3H, s), 4.01-4.11 (2H, m), 4.53-4.62 (1H, m),
6.67-6.73 (1H, m), 7.37-7.42 (1H, m), 8.74 (1H, s), 9.00-9.10 (1H,
m), 9.18-9.29 (1H, m), 9.45 (1H, d, J = 7.6 Hz), 12.34 (1H, brs).
MS: 325 (M + H - 2HCl)+ 375 18 1H-NMR (400 MHz, d6-DMSO).delta.:
1.34-2.15 (15H, m), 4.02-4.11 (1H, m), 6.43 (1H, d, J = 2.9 Hz),
6.56 (1H, d, J = 2.9 Hz), 7.11-7.12 (1H, m), 7.63-7.65 (1H, m),
8.37 (1H, s), 10.11 (1H, d, J = 8.0 Hz), 11.43 (1H, brs). MS: 326
(M + H)+. 376 18 1H-NMR (400 MHz, d6-DMSO).delta.: 1.38-2.08 (15H,
m), 4.09-4.11 (1H, m), 6.39 (1H, d, J = 3.5 Hz), 6.56 (1H, d, J =
3.5 Hz), 7.11-7.12 (1H, m), 7.64-7.65 (1H, m), 8.35 (1H, s), 10.09
(1H, d, J = 8.2 Hz), 11.44 (1H, brs). MS: 326 (M + H)+. 377 18
1H-NMR (400 MHz, d6-DMSO).delta.: 1.15-2.51 (15H, m), 4.28-4.33
(1H, m), 6.53-6.59 (1H, m), 6.75-6.79 (1H, m), 7.32-7.34 (1H, m),
8.06-8.12 (3H, m), 8.24-8.25 (1H, m), 12.09-12.14 (1H, m). MS: 308
(M + H)+ 378 19 MS: 286 (M + H)+ 379 19 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.48-1.51 (2H, m), 1.63 (1H, brs), 1.68-1.71 (2H,
m), 1.80-1.89 (4H, m), 2.09 (1H, brs), 2.25 (1H, brs), 4.10-4.13
(1H, m), 4.56 (1H, m), 4.75 (2H, d, J = 5.6 Hz), 4.87 (1H, t, J =
5.6 Hz), 6.50-6.52 (1H, m), 7.11-7.18 (1H, m), 8.47 (1H, s), 10.50
(1H, d, J = 8.0 Hz), 11.77 (1H, brs). MS: 342 (M + H)+ 380 19
1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-2.19 (13H, m), 4.21-4.23
(1H, m), 4.51 (1H, s), 4.74-4.76 (2H, d, J = 6.0 Hz), 4.83 (1H, t,
J = 6.9 Hz), 6.46-6.48 (1H, m), 7.17-7.19 (1H, m), 8.47 (1H, s),
10.46 (1H, d, J = 8.0 Hz), 11.74 (1H, s). MS: 342 (M + H)+ 381 19
1H-NMR (400 MHz, d6-DMSO).delta.: 1.23-2.32 (13H, m), 3.00-3.07
(2H, m), 4.21 (1H, brs), 4.43 (1H, brs), 4.75 (2H, brs), 6.46-6.49
(1H, m), 6.55 (1H, s), 7.16-7.17 (1H, m), 8.46 (1H, s), 10.54 (1H,
d, J = 8.0 Hz), 11.75 (1H, brs). MS: 356 (M + H)+ 382 22 MS: 391 (M
+ H)+ 383 22 1H-NMR (400 MHz, d6-DMSO).delta.: 1.77-1.87 (2H, m),
1.92-2.08 (6H, m), 2.10-2.15 (1H, m), 2.65-2.73 (4H, m), 3.21 (3H,
s), 4.36 (2H, s), 4.51 (1H, s), 6.35-6.38 (1H, m), 7.45 (1H, t, J =
2.9 Hz), 7.91 (1H, s), 10.84 (1H, s), 11.60 (1H, s). MS: 405 (M +
H)+ 384 22 1H-NMR (400 MHz, d6-DMSO).delta.: 1.59-1.67 (2H, m),
1.82-2.07 (3H, m), 2.16-2.30 (4H, m), 2.35-2.43 (2H, m), 2.69-2.73
(2H, m), 3.28 (3H, s), 4.39 (2H, s), 4.59 (1H, s), 6.31-6.35 (1H,
m), 7.43 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.77 (1H, br), 11.56
(1H, s). MS: 406 (M + H)+ 385 22 MS: 340 (M + H)+ 386 22 MS: 340 (M
+ H)+ 387 22 1H-NMR (400 MHz, d6-DMSO).delta.: 1.48-1.53 (4H, m),
1.58-1.64 (2H, m), 1.70-1.75 (2H, m), 1.93-1.96 (1H, m), 2.05-2.11
(2H, m), 2.16-2.20 (2H, m), 3.06-3.08 (2H, m), 4.27-4.30 (1H, m),
4.41-4.45 (1H, m), 6.52-6.54 (1H, m), 7.26-7.28 (1H, m), 8.11-8.12
(1H, m), 8.29-8.31 (1H, m), 8.63 (1H, s), 9.03-9.06 (1H, m), 11.86
(1H, brs). MS: 409 (M + H)+ 388 22 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.31-1.35 (2H, m), 1.47-1.49 (2H, m), 1.75-1.80
(2H, m), 1.85-2.00 (5H, m), 2.16-2.19 (2H, m), 3.01-3.03 (2H, m),
4.33-4.41 (2H, m), 6.61-6.63 (1H, m), 7.27-7.28 (1H, m), 8.14-8.16
(1H, m), 8.19-8.20 (1H, m), 8.63 (1H, s), 8.92-8.95 (1H, m), 11.87
(1H, brs). MS: 409 (M + H)+ 389 22 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.41-1.46 (2H, m), 1.69-1.79 (4H, m), 1.96-2.08
(3H, m), 2.31-2.37 (2H, m), 2.67-2.70 (2H, m), 4.48 (1H, s), 4.57
(1H, s), 6.3 (1H, d, J = 3.4 Hz), 7.45-7.45 (1H, m), 7.89 (1H, s),
10.75 (1H, s), 11.57 (1H, s). MS: 325 (M + H)+ 390 22 1H-NMR (400
MHz, d6-DMSO).delta.: 1.44-1.49 (2H, m), 1.63-1.79 (4H, m),
1.92-1.98 (2H, m), 2.14-2.34 (3H, m), 2.78-2.81 (1H, m), 4.37 (1H,
s), 4.39 (1H, s), 6.33-6.35 (1H, m), 6.55 (1H, s), 7.43 (1H, t, J =
2.9 Hz), 7.89 (1H, s), 10.75 (1H, s), 11.56 (1H, s). MS: 325 (M +
H)+ 391 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.57-1.63 (2H, m),
1.75-2.11 (8H, m), 2.44-2.59 (4H, m), 4.55 (1H, s), 6.34 (1H, dd, J
= 1.4 Hz, 3.3 Hz), 7.43 (1H, t, J = 2.9 Hz), 7.89 (1H, s), 10.74
(1H, s), 11.56 (1H, s). MS: 309 (M + H)+ 392 23 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.42-3.57 (13H, m), 4.37-4.61 (2H, m), 3.29-3.36
(1H, m), 7.42-7.46 (1H, m), 7.90 (1H, s), 10.75-10.77 (1H, m),
11.56 (1H, s). MS: 325 (M + H)+ 393 23 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.54-1.68 (12H, m), 1.86-1.91 (3H, m), 3.71 (2H,
s), 6.65 (1H, dd, J = 1.8 Hz, 3.5 Hz), 7.39 (1H, t, J = 3.1 Hz),
7.91 (1H, s), 10.86 (1H, s), 11.52 (1H, s). MS: 323 (M + H)+ 394 23
1H-NMR (400 MHz, d6-DMSO).delta.: 1.51-1.59 (2H, m), 2.03-2.14 (5H,
m), 2.33-2.52 (4H, m), 2.63-2.68 (2H, m), 3.90 (1H, s), 4.76 (1H,
d, J = 3.1 Hz), 6.64-6.65 (1H, m), 7.47 (1H, t, J = 3.1 Hz), 7.90
(1H, s), 10.78 (1H, s), 11.61 (1H, s. MS: 325 (M + H)+ 395 23
1H-NMR (400 MHz, d6-DMSO).delta.: 1.56-1.79 (5H, m), 2.31-2.55 (9H,
m), 4.75 (1H, s), 6.61 (1H, s), 7.48 (1H, t, J = 3.1 Hz), 7.91 (1H,
s), 10.78 (1H, s), 11.61 (1H, s). MS: 325 (M + H)+ 396 23 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.51-1.60 (2H, m), 1.71-1.84 (4H, m),
1.95-2.02 (2H, m), 2.20-2.25 (1H, m), 2.39-2.45 (2H, m), 2.79-2.84
(2H, m), 3.11 (3H, s), 4.42 (1H, s), 6.35-6.38 (1H, m), 7.44 (1H,
t, J = 3.1 Hz), 7.90 (1H, s), 10.76 (1H, s), 11.57 (1H, s). MS: 338
(M + H)+ 397 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.43-1.50 (2H,
m),
1.74-1.77 (2H, m), 1.83-1.88 (2H, m), 2.02-2.15 (3H, m), 2.72-2.37
(2H, m), 2.75-2.79 (2H, m), 3.19 (3H, s), 4.50 (1H, s), 6.34 (1H,
dd, J = 1.7 Hz, 3.6 Hz), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s),
10.77 (1H, s), 11.56 (1H, s). MS: 339 (M + H)+ 398 23 1H-NMR (400
MHz, d6-DMSO).delta.: 1.53-1.60 (2H, m), 1.85-1.92 (2H, m),
1.97-2.09 (3H, m), 2.18-2.26 (2H, m), 2.38-2.45 (2H, m), 2.65-2.71
(2H, m), 3.64 (3H, s), 4.54 (1H, s), 6.30-6.31 (1H, m), 7.43 (1H,
t, J = 3.0 Hz), 7.90 (1H, s), 10.78 (1H, s), 11.57 (1H, s). MS: 367
(M + H)+ 399 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.17 (3H, t, J =
7.1 Hz), 1.69-1.93 (6H, m), 2.03-2.11 (2H, m), 2.37-2.47 (2H, m),
2.71-2.75 (2H, m), 3.73 (2H, d, J = 5.8 Hz), 4.06 (2H, q, J = 7.1
Hz), 4.49 (1H, s), 6.34-6.36 (1H, m), 7.44 (1H, t, J = 3.0 Hz),
7.81 (1H, t, J = 5.8 Hz), 7.90 (1H, s), 10.75 (1H, s), 11.57 (1H,
s). MS: 438 (M + H)+ 400 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.2
(3H, t, J = 7.1 Hz), 1.50-1.58 (2H, m), 1.84-1.88 (2H, m),
1.95-2.03 (3H, m), 2.18-2.26 (2H, m), 2.38-2.46 (2H, m), 2.63-2.70
(2H, m), 3.8 (2H, d, J = 5.8 Hz), 4.09 (2H, q, J = 7.1 Hz), 4.55
(1H, s), 6.36-6.38 (1H, m), 7.45 (1H, t, J = 3.0 Hz), 7.90 (1H, s),
8.07 (1H, t, J = 6.1 Hz), 10.78 (1H, s), 11.58 (1H, s). MS: 438 (M
+ H)+ 401 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.67-1.73 (2H, m),
1.78-1.82 (2H, m), 1.84-1.91 (2H, m), 2.00-2.10 (3H, m), 2.37-2.44
(2H, m), 2.68-2.72 (2H, m), 4.48 (1H, s), 6.34-6.35 (1H, m), 6.70
(1H, s), 6.91 (1H, s), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s),
10.75 (1H, s), 11.56 (1H, s). MS: 352 (M + H)+ 402 23 1H-NMR (400
MHz, d6-DMSO).delta.: 1.45-1.55 (2H, m), 1.81-1.85 (2H, m),
1.93-2.00 (3H, m), 2.16-2.21 (2H, m), 2.38-2.45 (2H, m), 2.61-2.66
(2H, m), 4.53 (1H, s), 6.38-6.39 (1H, m), 6.80 (1H, s), 7.15 (1H,
s), 7.44 (1H, t, J = 3.0 Hz), 7.90 (1H, s), 10.76 (1H, s), 11.56
(1H, s). MS: 352 (M + H)+ 403 23 1H-NMR (400 MHz, d6-DMSO).delta.:
1.35-1.40 (9H, m), 1.45-2.13 (7H, m), 2.25-2.40 (4H, m), 2.64-2.77
(2H, m), 4.41-4.49 (1H, m), 6.27-6..34 (1H, m), 6.39-6.58 (1H, m),
7.42-7.47 (1H, m), 7.89 (1H, s), 10.75-10.76 (1H, m), 11.54-11.59
(1H, m). MS: 424 (M + H)+ 404 23 1H-NMR (400 MHz, d6-DMSO).delta.:
1.57-1.63 (2H, m), 1.74-1.85 (4H, m), 1.95-2.02 (2H, m), 2.21-2.26
(1H, m), 2.42-2.48 (2H, m), 2.65 (2H, t, J = 6.0 Hz), 2.79-2.83
(2H, m), 3.55 (2H, t, J = 6.0 Hz), 4.44 (1H, s), 6.38-6.40 (1H, m),
7.46 (1H, t, J = 3.0 Hz), 7.92 (1H, s), 10.83 (1H, s), 11.65 (1H,
s). MS: 378 (M + H)+ 405 23 1H-NMR (400 MHz, d6-DMSO).delta.:
1.44-1.52 (2H, m), 1.75-1.81 (2H, m), 1.86-1.92 (2H, m), 2.08-2.17
(3H, m), 2.31-2.37 (2H, m), 2.71 (2H, t, J = 6.0 Hz), 2.75-2.79
(2H, m), 3.65 (2H, t, J = 6.0 Hz), 4.53 (1H, s), 6.38 (1H, s), 7.45
(1H, t, J = 3.0 Hz), 7.91 (1H, s), 10.82 (1H, s), 11.62 (1H, s).
MS: 378 (M + H)+ 406 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.58-1.67
(2H, m), 2.06-2.11 (1H, m), 2.30-2.59 (6H, m), 2.66-2.78 (4H, m),
4.68 (1H, s), 6.34-6.36 (1H, m), 7.44 (1H, t, J = 3.1 Hz), 7.90
(1H, s), 10.79 (1H, s), 11.58 (1H, s). MS: 387, 389 (M + H)+ 407 23
1H-NMR (400 MHz, d6-DMSO).delta.: 1.59-1.69 (2H, m), 2.07-2.14 (1H,
m), 2.36-2.47 (6H, m), 2.65-2.72 (2H, m), 2.86-2.92 (2H, m), 4.98
(1H, s), 7.99 (1H, s), 8.35 (1H, s), 10.98 (1H, s), 13.00 (1H, s).
MS: 388, 390 (M + H)+ 408 23 1H-NMR (400 MHz, d6-DMSO).delta.:
1.17-2.47 (9H, m), 2.93-3.00 (1H, m), 4.36-4.42 (1H, m), 6.54-6.57
(1H, m), 7.42-7.44 (1H, m), 7.88 (1H, s), 10.77 (1H, brs), 11.58
(1H, brs). MS: 269 (M + H)+ 409 23 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.20-1.86 (7H, m), 2.32-2.42 (1H, m), 3.05-3.17
(1H, m), 4.71-4.84 (1H, m), 6.49-6.55 (1H, m), 6.91 (1H, s),
7.40-7.46 (1H, m), 7.90 (1H, s), 10.77 (1H, brs), 11.56 (1H, brs).
MS: 269 (M + H)+ 410 23 1H-NMR (400 MHz, d6-DMSO).delta.: 1.01 (3H,
d, J = 7.2 Hz), 1.24 (3H, s), 1.30 (3H, s), 1.88-2.09 (3H, m),
2.29-2.52 (4H, m), 4.81-4.92 (1H, m), 6.44-6.49 (1H, m), 7.43-7.47
(1H, m), 7.92 (1H, s), 10.92 (1H, brs), 11.64 (1H, brs). MS: 311 (M
+ H)+ 411 23 1H-NMR (400 MHz, d6-DMSO).delta.: 0.78 (3H, s), 0.91
(3H, s), 1.14 (3H, s), 1.21-1.31 (1H, m), 1.63-1.73 (1H, m),
1.80-1.88 (2H, m), 1.97-2.11 (2H, m), 2.75 (1H, dd, J = 5.3, 12.5
Hz), 4.80 (1H, ddd, J = 2.4, 5.3, 12.0 Hz), 6.45 (1H, dd, J = 1.7,
3.6 Hz), 7.40-7.43 (1H, m), 7.91 (1H, s), 10.89 (1H, brs), 11.58
(1H, brs). MS: 311 (M + H)+ 412 23 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.15-3.14 (13H, m), 4.41-4.60 (1H, m), 6.35-6.40
(1H, m), 7.43-7.47 (1H, m), 7.90-7.92 (1H, m), 10.80-10.87 (1H, m),
11.62 (1H, brs). MS: 327 (M + H)+ 413 24 MS: 330 (M + H)+ 414 24
1H-NMR (400 MHz, d6-DMSO).delta.: 1.46 (2H, d, J = 12.3 Hz), 1.63
(2H, s), 1.72 (2H, d, J = 12.1 Hz), 1.92 (2H, d, J = 12.1 Hz), 1.99
(1H, s), 2.39 (2H, d, J = 12.3 Hz), 2.96 (2H, s), 4.34 (1H, s),
4.67 (1H, s), 7.97 (1H, s), 8.31 (1H, s), 10.9 (1H, s), 13.0 (1H,
s). MS: 348 (M + Na)+ 415 24 1H-NMR (400 MHz, d6-DMSO).delta.: 1.42
(2H, d, J = 12.5 Hz), 1.68 (2H, s), 1.72 (2H, d, J = 12.0 Hz), 2.00
(2H, d, J = 12.0 Hz), 2.08 (1H, s), 2.39 (2H, d, J = 12.5 Hz), 2.79
(2H, s), 4.49 (1H, s), 4.88 (1H, s), 7.97 (1H, s), 8.32 (1H, s),
10.9 (1H, brs), 13.0 (1H, brs). MS: 348 (M + Na)+ 416 25 1HNMR (400
MHz, d6-DMSO).delta.: 1.38-2.18 (11H, m), 3.33-3.40 (1H, m), 4.47
(1H, s), 4.92-5.05 (1H, m), 7.05 (1H, br), 7.82 (1H, br), 8.05 (1H,
s), 8.45 (1H, s), 9.97 (1H, d, J = 9.2 Hz), 11.5 (1H, s), 12.8 (1H,
br). MS: 328 (M + H)+ 417 25 1HNMR (400 MHz, d6-DMSO).delta.: 1.32
(3H, t, J = 7.1 Hz), 1.56 (2H, t, J = 10.7 Hz), 1.80-1.83 (2H, m),
1.92-2.08 (4H, m), 3.20 (2H, brs), 3.57 (2H, s), 4.28 (2H, q, J =
7.1 Hz), 5.30-5.45 (1H, brs), 7.20-7.24 (1H, m), 7.32 (2H, dd, J =
7.2, 7.8 Hz), 7.39 (2H, d, J = 7.2 Hz), 8.14 (1H, s), 8.48 (1H, d,
J = 8.8 Hz), 8.60 (1H, s), 13.0 (1H, brs). MS: 406 (M + H)+ 418 25
1HNMR (400 MHz, d6-DMSO).delta.: 1.11 (6H, t, J = 6.8 Hz),
1.50-2.31 (13H, m), 3.46-3.68 (4H, m), 4.11-4.12 (1H, m), 4.57 (1H,
s), 6.65-6.66 (1H, m), 6.74 (1H, s), 7.38-7.39 (1H, m), 8.54 (1H,
s), 8.88 (1H, d, J = 8.0 Hz), 9.30 (1H, s). MS: 454 (M + H)+ 419 26
1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-1.52 (2H, m), 1.64-1.66 (2H,
m), 1.78-1.84 (2H, m), 2.01-2.06 (2H, m), 2.18-2.27 (3H, m),
3.10-3.12 (2H, m), 4.40 (1H, s), 4.76 (1H, br), 6.53-6.55 (1H, m),
7.61-7.63 (1H, m), 8.56-8.59 (1H, s), 12.09 (1H, brs), 13.14 (1H,
brs). MS: 442 (M + Na)+ 420 26 1H-NMR (400 MHz, d6-DMSO).delta.:
1.39 (3H, t, J = 7.1 Hz), 1.48-1.53 (2H, m), 1.62-1.65 (2H, m),
1.69-1.74 (2H, m), 1.81-1.93 (4H, m), 2.09-2.12 (1H, m), 2.29-2.33
(2H, m), 4.22-4.26 (1H, m), 4.47 (2H, q, J = 7.1 Hz), 4.54 (1H,
brs), 6.56-6.58 (1H, m), 7.26-7.27 (1H, m), 7.80-7.83 (1H, m), 8.71
(1H, s), 11.71 (1H, brs). MS: 424 (M + H)+ 421 26 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.48-2.31 (13H, m), 4.24 (1H, m), 4.52 (1H, s),
6.55 (1H, m), 7.23 (1H, m), 7.86 (1H, m), 8.75 (1H, s), 9.67 (1H,
s), 11.63 (1H, s). MS: 352 (M + H)+ 422 26 1HNMR (400 MHz,
d6-DMSO).delta.: 1.34 (3H, t, J = 7.1 Hz), 1.45-1.84 (10H, m), 2.06
(1H, brs), 2.22 (2H, brs), 4.31 (2H, q, J = 7.1 Hz), 4.53 (1H, s),
5.04 (1H, d, J = 8.7 Hz), 8.12 (1H, s), 8.64 (1H, s), 9.16 (1H, d,
J = 8.7 Hz), 12.8 (1H, brs). MS: 357 (M + H)+ 423 26 1HNMR (400
MHz, d6-DMSO).delta.: 1.32 (3H, t, J = 7.1 Hz), 1.42-1.90 (10H, m),
2.15 (1H, brs), 2.22 (2H, brs), 3.15 (3H, s), 4.31 (2H, q, J = 7.1
Hz), 5.12 (1H, d, J = 8.7 Hz), 8.14 (1H, s), 8.64 (1H, s), 9.14
(1H, d, J = 8.7 Hz), 13.0 (1H, brs). MS: 371 (M + H)+ 424 26 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.40-1.67 (10H, m), 1.88-1.94 (1H, m),
2.02 (2H, brs), 3..03 (2H, d, J = 5.5 Hz), 4.37 (1H, t, J = 5.5
Hz), 5.05 (1H, d, J = 8.9 Hz), 7.04 (1H, brs), 7.82 (1H, brs), 8.03
(1H, s), 8.45 (1H, s), 10.0 (1H, d, J = 8..9 Hz), 12.7 (1H, brs).
MS: 342 (M + H)+ 425 26 1H-NMR (400 MHz, d6-DMSO).delta.: 1.22-1.84
(10H, m), 1.94 (1H, brs), 2.06 (2H, brs), 2.98 (2H, d, J = 5.7 Hz),
4.36 (1H, t, J = 5.7 Hz), 5.06 (1H, d, J = 8.7 Hz), 7.10 (1H, brs),
7.82 (1H, brs), 8.04 (1H, s), 8.45 (1H, s), 10.0 (1H, d, J = 8.7
Hz), 12.7 (1H, brs). MS: 342 (M + H)+ 426 26 MS: 337 (M + H)+ 427
27 1H-NMR (400 MHz, d6-DMSO).delta.: 1.36-1.41 (2H, m), 1.64-1.70
(4H, m), 1.80-1.93 (4H, m), 2.04-2.07 (1H, m), 2.11-2.14 (2H, m),
4.13-4.16 (1H, m), 4.44 (1H, s), 5.82 (2H, brs), 6.37-6.38 (1H, m),
7.09-7.11 (1H, m), 8.13 (1H, s), 8.97 (1H, d, J = 8.2 Hz), 9.54
(1H, s), 11.23 (1H, brs). MS: 342 (M + H)+ 428 28 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.39 (3H, t, J = 7.2 Hz), 1.46-1.54 (2H, m),
1.58-1.77 (4H, m), 1.80-1.90 (2H, m), 1.97-2.14 (3H, m), 2.28-2.35
(2H, m), 4.18-4.25 (1H, m), 4.42 (1H, s), 4.43 (2H, q, J = 7.2 Hz),
6.60 (1H, d, J = 3.5 Hz), 7.29 (1H, d, J = 3.5 Hz), 8.65 (1H, s),
9.04 (1H, d, J = 7.7 Hz), 11.91 (1H, brs). MS: 424 (M + H)+ 429 28
1H-NMR (400 MHz, d6-DMSO).delta.: 1.30-1.36 (3H, m), 1.63-1.72 (2H,
m), 1.93-2.04 (2H, m), 2.07-2.49 (6H, m), 2.75-2.84 (3H, m),
4.37-4.45 (2H, m), 4.61-4.68 (1H, m), 6.36-6.41 (1H, m), 7.43-7.47
(1H, m), 7.91 (1H, s), 10.82 (1H, s), 11.58-11.61 (1H, m). MS: 449
(M + H)+ 430 28 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.29 (13H,
m), 3.42 (3H, s), 4.21-4.22 (1H, m), 4.46 (1H, s), 4.65 (2H, s),
6.58-6.59 (1H, m), 7.26-7.27 (1H, m), 8.60 (1H, s), 9.04 (1H, d, J
= 8.0 Hz), 11.84 (1H, s). MS: 396.3 (M + H)+ 431 32 1H-NMR (400
MHz, d6-DMSO).delta.: 1.45-2.39 (20H, m), 2.60 (1H, s), 2.69 (1H,
m), 3.22 (3H, s), 3.69 (1H, m), 4.44 (1H, m), 4.77 (1H, s), 6.64
(1H, m), 7.45 (1H, m), 8.74 (1H, m), 8.78 (1H, m), 10.83 (1H, s),
12.05 (1H, s). MS: 507 (M + H)+ 432 32 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-2.67 (18H, m), 3.12 (2H, m), 4.02 (2H, m),
4.44 (1H, m), 4.77 (1H, s), 6.66 (1H, m), 7.46 (1H, m), 8.73 (1H,
s), 9.21 (1H, m), 10.94 (1H, m), 12.07 (1H, m). MS: 549 (M + Na)+
433 32 MS: 543 (M + Na)+ 434 32 MS: 505 (M - H)- 435 32 MS: 467 (M
+ H)+ 436 32 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.69 (21H, m),
3.89 (1H, m), 4.42 (1H, m), 4.76 (1H, s), 6.65 (1H, m), 7.45 (1H,
m), 8.74 (1H, s), 9.02 (1H, m), 10.88 (1H, s), 12.05 (1H, s). MS:
513 (M + H)+ 437 32 1H-NMR (400 MHz, d6-DMSO).delta.: 0.85-2.61
(21H, m), 3.63-3.79 (2H, m), 4.35 (1H, m), 4.44 (1H, m), 4.76 (1H,
s), 6.65 (1H, m), 7.46 (1H, m), 8.72 (1H, s), 8.74 (1H, s), 10.86
(1H, s), 12.07 (1H, s). MS: 493 (M + H)+ 438 32 MS: 464 (M + H)+
439 32 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.50 (2H, m),
1.65-1.68 (2H, m), 1.77-2.04 (6H, m), 2.17-2.21 (1H, m), 2.33-2.40
(2H, m), 2.59-2.64 (2H, m), 3.35-3.48 (1H, m), 3.77-3.88 (3H, m),
4.46-4.48 (1H, m), 4.67-4.69 (1H, m), 4.75-4.77 (1H, m), 4.89, 5.18
(1H, m), 6.64-6.65 (1H, m), 7.44-7.46 (1H, m), 8.74, 8.78 (1H, m),
11.03-11.19 (1H, m), 12.10 (1H, brs). MS: 499 (M + N)+ 440 32
1H-NMR (400 MHz, d6-DMSO).delta.: 1.44-1.49 (2H, m), 1.65-1.68 (2H,
m), 1.77-1.83 (2H, m), 1.99-2.05 (2H, m), 2.17-2.21 (1H, m),
2.35-2.40 (2H, m), 2.58-2.62 (2H, m), 4.45 (1H, s), 4.75-4.77 (1H,
m), 6.65-6.67 (1H, m), 7.45-7.47 (1H, m), 8.03 (1H, brs), 8.39 (1H,
brs), 8.74 (1H, s), 10.82 (1H, brs), 12.08 (1H, brs). MS: 417 (M +
Na)+ 441 32 1H-NMR (400 MHz, d6-DMSO).delta.: 0.77-3.54 (22H, m),
4.84 (1H, brs), 6.82-6.86 (1H, m), 7.49-7.53 (1H, m), 8.64 (1H, s),
8.87-8.93 (1H, m), 12.12 (1H, brs). MS: 453 (M + H)+ 442 32 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.39-1.44 (2H, m), 1.71-1.73 (2H, m),
1.78-1.83 (2H, m), 2.04-2.09 (2H, m), 2.11-2.15 (1H, m), 2.38-2.44
(2H, m), 2.49-2.51 (2H, m), 4.56 (1H, s), 4.88-4.89 (1H, m),
6.60-6..62 (1H, m), 7.45-7.47 (1H, m), 8.01 (1H, brs), 8.36 (1H,
brs), 8.74 (1H, s), 10.85-10.90 (1H, m), 12.07 (1H, brs). MS: 417
(M + Na)+ 443 32 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.39 (13H,
m), 3.16 (2H, d, J = 5.2 Hz), 3.50 (2H, q, J = 5.6 Hz), 4.07 (1H,
q, J = 5.6 Hz), 4.76 (1H, brs), 4.78 (1H, t, J = 5.2 Hz), 6.65-6.66
(1H, m), 7.45-7.47 (1H, m), 8.71 (1H, s), 8.88-8.90 (1H, m), 10.89
(1H, s), 12.07 (1H, brs). MS: 439 (M + H)+ 444 32 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.46-2.37 (13H, m), 2.94 (3H, s), 3.12 (3H, s),
4.46-4.47 (1H, m), 4.75 (1H, brs), 6.63-6.64 (1H, m), 7.45-7.46
(1H, m), 8.78 (1H, s), 11.36 (1H, s), 12.16 (1H, s). MS: 423.3 (M +
H)+ 445 32 1H-NMR (400 MHz, d6-DMSO).delta.: 1.15-2.45 (13H, m),
2.49-2.51 (6H, m), 4.21 (4H, brs), 4.76 (1H, brs), 6.55-6.55 (1H,
m), 7.45-7.46 (1H, m), 8.56 (1H, s), 8.72 (1H, s), 8.83-8.87 (1H,
m), 11.44 (1H, s), 12.07 (1H, brs). MS: 466.3 (M + H)+ 446 32
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.39 (11H, m), 2.49-2.45 (m,
3H), 2.60 (2H, brs), 3.16-3.20 (2H, m), 3.81-3.82 (1H, m), 4.45
(1H, s), 4.76 (1H, brs), 4.85 (1H, d, J = 4.8 Hz), 6.65-6.67 (1H,
m), 7.45-7.46 (1H, m), 8.72 (1H, s), 8.82-8.82 (1H, m), 10.90 (1H,
s), 12.07 (1H, brs). MS: 453 (M + Na)+ 447 32 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.04-2.38 (17H, m), 3.46-3.70 (5H, m), 4.35-4.36
(1H, m), 4.45 (1H, q), 4.57-4.59 (1H, m), 4.76 (1H, brs), 6.65-6.66
(1H, m), 7.45-7.46 (1H, m), 8.72 (1H, s), 8.82 (1H, d, J = 8.0 Hz),
10.88 (1H, s), 12.06 (1H, brs). MS: 515 (M + H)+ 448 32 1H-NMR (400
MHz, d6-DMSO).delta.: 1.45-2.60 (17H, m), 3.45-4.00 (6H, m), 4.47
(1H, s), 4.76 (1H, brs), 6.56-6.57 (1H, m), 7.45-7.46 (1H, m), 8.71
(1H, s), 10.93 (1H, brs), 12.07 (1H, brs). MS477 (M - H)- 449 32
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.39 (17H, m), 3.43-3.99
(5H, m), 4.34-4.54 (1H, m), 4.76 (1H, brs), 6.65-6.66 (1H, m),
7.45-7.46 (1H, m), 8.73 (1H, s), 9.02 (1H, d, J = 8.0 Hz), 10.91
(1H, brs), 12.07 (1H, brs). MS: 477 (M - H)- 450 32 1H-NMR (400
MHz, d6-DMSO).delta.: 1.56-1.59 (2H, m), 2.03-2.08 (3H, m),
2.22-2.25 (2H, m), 2.46-2.57 (6H, m), 3.28 (3H, s), 3.39-3.40 (2H,
m), 3.48-3.49 (2H, m), 5.04 (1H, s), 6.78 (1H, s), 7.46 (1H, s),
8.73 (1H, s), 8.95 (1H, m), 10.99 (1H, s), 12.05 (1H, s). MS: 462
(M + H)+, 484 (M + Na)+ 451 32 1H-NMR (400 MHz, d6-DMSO).delta.:
1.36-2.37 (17H, m), 3.43-3.60 (7H, m), 4.48 (1H, brs), 4.75 (1H,
brs), 6.64 (1H, brs), 7.45 (1h, brs), 8.81-8.83 (1H, m), 11.45 (1H,
brs), 12.11 (1H, brs). MS: 506 (M + H)+ 452 32 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.45-2.39 (18H, m),
3.42-4.01 (6H, m), 4.47 (1H, s), 4.76 (1H, brs), 6.56-6.57 (1H, m),
7.45-7.46 (1H, m), 8.71 (1H, s), 8.95-8.96 (1H, m), 10.93 (1H,
brs), 12.07 (1H, brs). MS: 515 (M + Na)+ 453 32 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.56 (2H, m), 1.75-1.77 (1H, m), 1.88-1.95 (4H,
m), 2.04-2.12 (4H, m), 2.29-2.33 (2H, m), 3.28 (3H, s), 3.38-3.42
(2H, m), 3.47-3.49 (2H, m), 3.59 and 3.65 (total 3H, eachs), 4.90
and 4.96 (total 1H, eachs), 6.66-6.77 (1H, m), 7.44-7.47 (1H, m),
8.71 and 8.72 (total 1H, eachs), 8.97 (1H, m), 11.00 (1H, s), 12.07
(1H, s). MS: 517 (M + Na)+ 454 32 1H-NMR (400 MHz, d6-DMSO).delta.:
52-1.55 (3H, m), 1.74-1.84 (5H, m), 2.04-2.07 (2H, m), 2.25 (1H,
s), 2.64 (2H, s), 3.13 (3H, s), 3.28 (3H, s), 3.39-3.42 (2H, m),
3.47-3.50 (2H, m), 4.81 (1H, s), 6.68 (1H, dd, J = 1.9, 3.3 Hz),
7.40 (1H, t, J = 3.0 Hz), 8.71 (1H, s), 8.94 (1H, t, J = 5.8 Hz),
11.02 (1H, s), 12.06 (1H, s). MS: 467 (M + H)+, 489 (M + Na)+ 455
32 1H-NMR (400 MHz, d6-DMSO).delta.: 1.27-1.32 (2H, m), 1.45-1.55
(4H, m), 1.68-1.71 (2H, m), 1.84-1.91 (2H, m), 2.00 (1H, s),
2.09-2.17 (2H, m), 3.03 and 3.13 (total 2H, eachd, J = 5.5 and 5.5
Hz), 3.28 (3H, s), 3.39-3.42 (2H, m), 3.47-3.50 (2H, m), 4.30 and
4.47 (total 1H, eacht, J = 5.5 and 5.5 Hz), 4.85 and 4.87 (total
1H, eachs), 6.60 and 6.65 (total 1H, eachm), 7.46 (1H, t, J = 3.0
Hz), 8.71 and 8.72 (total 1H, s), 8.97 (1H, m), 10.96 and 10.97
(total 1H, s), 12.07 (1H, s). MS: 467 (M + H)+, 489 (M + Na)+ 456
33 MS: 646 (M + H)+ 457 33 MS: 506 (M + H)+ 458 33 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.01 (3H, d, J = 7.6 Hz), 1.24 (3H, s), 1.30 (3H,
s), 1.88-2.83 (7H, m), 4.80-4.90 (1H, m), 6.45-6.48 (1H, m),
7.43-7.46 (1H, m), 7.92 (1H, s), 10.91 (1H, brs), 11.63 (1H, brs).
MS: 311 (M + H)+ 459 33 MS: 465 (M + H)+ 460 33 MS: 497 (M + H)+
461 33 MS: 509 (M + H)+ 462 33 MS: 509 (M + H)+ 463 33 MS: 478 (M +
H)+ 464 33 MS: 465 (M + H)+ 465 33 MS: 463 (M + H)+ 466 33 MS: 434
(M + H)+ 467 33 MS: 499 (M + H)+ 468 33 MS: 541 (M + H)+ 469 33 MS:
477 (M + H)+ 470 33 MS: 449 (M + H)+ 471 33 MS: 546 (M + H)+ 472 33
MS: 506 (M + H)+ 473 33 MS: 453 (M + H)+ 474 33 MS: 504 (M + H)+
475 33 MS: 453 (M + H)+ 476 34 1H-NMR (400 MHz, d6-DMSO).delta.:
1.75-1.90 (4H, m), 2.00-2.10 (2H, m), 2.14-2.28 (3H, m), 2.37-2.54
(4H, m), 4.21-4.27 (1H, m), 6.36 (1H, d, J = 6.8 Hz), 6.73-6.78
(1H, m), 7.27-7.31 (1H, m), 8.11 (1H, s), 11.86 (1H, brs). MS: 427
(M + Na)+ 477 35 MS: 314 (M + H)+ 478 35 MS: 393 (M + H)+ 479 35
MS: 382 (M + H)+ 480 35 1H-NMR (400 MHz, d6-DMSO).delta.: 1.39-1.46
(2H, m), 1.56-1.87 (8H, m), 2.07 (1H, m), 2.18 (3H, s), 2.25 (2H,
m), 4.03 (1H, m), 4.47 (1H, s), 4.77 (1H, d, J = 7.2 Hz), 6.38 (1H,
d, J = 3.6 Hz), 7.13 (1H, d, J = 3.6 Hz), 7.71 (1H, s), 8.32 (1H,
s), 11.156 (1H, s). MS: 298 (M + H)+ 481 35 MS: 378 (M + Na)+ 482
35 MS: 420 (M + Na)+ 483 35 1H-NMR (400 MHz, d6-DMSO).delta.:
1.22-2.24 (13H, m), 3.20-3.40 (2H, m), 4.42-4.65 (2H, m), 6.44-6.48
(1H, m), 6.82-7.09 (1H, br), 7.16-7.19 (1H, m), 7.56-7.84 (1H, br),
8.34 (1H, s), 9.45 (1H, d, J = 8.0 Hz), 11.48 (1H, brs). MS: 329 (M
+ H)+. 484 35 1H-NMR (400 MHz, d6-DMSO).delta.: 1.47-1.51 (2H, m),
1.61-1.63 (2H, m), 1.68-1.73 (2H, m), 1.81-1.87 (2H, m), 1.91-1.96
(2H, m), 2.08-2.12 (1H, m), 2.28-2.31 (2H, m), 4.19-4.23 (1H, m),
4.46 (1H, brs), 4.66-4.68 (2H, m), 5.68-5.71 (1H, m), 6.58-6.60
(1H, m), 7.25-7.26 (1H, m), 8.60 (1H, s), 9.07 (1H, d, J = 7.8 Hz),
11.83 (1H, brs). MS: 382 (M + H)+ 485 35 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.31-1.35 (2H, m), 1.47-1.50 (2H, m), 1.61-1.98
(7H, m), 2.07-2.12 (2H, m), 2.96-2.99 (2H, m), 4.11-4.16 (1H, m),
4.35-4.39 (1H, m), 6.42-6.46 (1H, m), 6.80-7.09 (1H, br), 7.10-7.13
(1H, m), 7.52-7.88 (1H, br), 8.36 (1H, s), 10.13 (1H, d, J = 8.0
Hz), 11.43 (1H, brs). MS: (M + H)+. 486 35 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.43-1.70 (8H, m), 1.89-1.96 (3H, m), 2.05-2.10
(2H, m), 3.03-3.08 (2H, m), 4.08-4.15 (1H, m), 4.39-4.44 (1H, m),
6.40-6.44 (1H, m), 6.95-7.19 (2H, m), 7.68-7.96 (1H, br), 8.38 (1H,
s), 10.27 (1H, d, J = 8.0 Hz), 11.55 (1H, brs). MS: 341 (M + H)+.
487 35 1H-NMR (400 MHz, d6-DMSO).delta.: 1.34-1.44 (2H, m),
1.58-1.72 (4H, m), 1.80-1.90 (2H, m), 2.00-2.11 (3H, m), 2.33-2.44
(2H, m), 4.18-4.28 (3H, m), 6.59-6.60, (1H, m), 6.90-6.98 (1H, m),
7.20 (1H, brs), 7.33 (1H, brs), 7.38-7.39 (1H, m), 7.46 (1H, brs),
8.19 (1H, s), 8.61 (3H, br), 12.63 (1H, brs). MS: 313 (M - 3HCl +
H)+ 488 39 1H-NMR (400 MHz, d6-DMSO).delta.: 1.85-2.25 (8H, m),
2.37-2.41 (1H, m), 2.53-2.57 (2H, m), 2.91-2.96 (1H, m), 3.11-3.18
(1H, m), 4.74 (1H, s), 6.55-6.59 (1H, m), 7.37 (1H, t, J = 2.7 Hz),
8.51-8.52 (1H, m), 10.89 (1H, s), 11.94 (1H, s). MS: 387, 389 (M +
H)+ 489 39 1H-NMR (400 MHz, d6-DMSO).delta.: 1.10-1.28 (2H, m),
1.36-2.38 (7H, m), 2.54 (1H, brs), 5.02-5.08 (1H, m), 6.72-6.74
(1H, m), 7.35-7.37 (1H, m), 8.47 (1H, s), 10.9 (1H, brs), 12.0 (1H,
s). MS: 269 (M + H)+ 490 39 1H-NMR (400 MHz, d6-DMSO).delta.:
1.54-1.64 (2H, m), 2.10-2.63 (9H, m), 2.75-2.83 (2H, m), 4.91 (1H,
s), 6.64-6.66 (1H, m), 7.37 (1H, t, J = 3.0 Hz), 8.50 (1H, s),
10.81 (1H, s), 11.93 (1H, s). MS: 387, 389 (M + H)+ 491 39 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.55-1.60 (2H, m), 1.77-1.80 (2H, m),
1.90-2.02 (4H, m), 2.06-2.13 (2H, m), 2.32-2.36 (2H, m), 2.52-2.57
(2H, m), 4.75-4.77 (1H, m), 6.53-6.56 (1H, m), 7.35-7.38 (1H, m),
8.50 (1H, s), 10.78 (1H, brs), 11.92 (1H, brs). MS: 309 (M + H)+.
492 40 1H-NMR (400 MHz, d6-DMSO).delta.: 1.38-1.48 (2H, m),
1.64-1.81 (4H, m), 1.93-2.05 (2H, m), 2.11-2.19 (1H, m), 2.37-2.57
(4H, m), 4.44 (0.34H, brs), 4.56-4.59 (1H, m), 4.70 (0.66H, brs),
6.50-6.52 (0.66H, m), 6.54-6.56 (0.34H, m), 7.36-7.38 (1H, m), 8.50
(0.66H, s), 8.51 (0.34H, s), 10.78 (1H, brs), 11.92 (1H, brs). MS:
325 (M + H)+. 493 40 MS: 325 (M + H)+. 494 40 1HNMR (400 MHz,
d6-DMSO).delta.: 0.88 (3H, d, J = 6.9 Hz), 1.72-1.92 (2H, m),
2.15-2.26 (1H, m), 3.55-3.70 (4H, m), 5.30-5.40 (1H, m), 7.01 (1H,
d, J = 9.2 Hz), 7.15 (1H, brs), 7.76 (1H, d, J = 9.2 Hz), 7.90 (1H,
brs), 8.09 (1H, s), 8.39 (1H, s), 8.48 (1H, s), 9.89 (1H, d, J =
9.0 Hz), 12.9 (1H, brs). MS: 420 (M + H)+ 495 41 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.43-1.52 (2H, m), 1.76-1.91 (6H, m), 2.10-2.16
(1H, m), 2.27-2.33 (3H, m), 2.68 (2H, t, J = 6 Hz), 3.59 (2H, t, J
= 6 Hz), 4.76-4.85 (1H, m), 6.09 (1H, d, J = 7.3 Hz), 8.25-8.27
(3H, m), 13.21 (1H, br). MS: 363 (M + H)+ 496 41 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.00-1.59 (13H, m), 2.64-2.75 (2H, m), 3.54-3.69
(2H, m), 4.63-4.76 (1H, m), 6.55-6.64 (1H, m), 7.35-7.39 (1H, m),
8.50 (1H, s), 10.79-10.83 (1H, m), 11.91 (1H, s). MS: 378 (M + H)+
497 41 1H-NMR (400 MHz, d6-DMSO).delta.: 1.54-1.62 (2H, m),
1.73-1.86 (4H, m), 1.96-2.27 (4H, m), 2.54-2.61 (3H, m), 2.67 (2H,
t, J = 6.0 Hz), 3.57 (2H, t, J = 6.0 Hz), 4.63 (1H, s), 6.56-6.59
(1H, m), 7.36-7.39 (1H, m), 8.49-8.51 (1H, m), 10.83 (1H, s), 11.93
(1H, s). MS: 378 (M + H)+ 498 41 1H-NMR (400 MHz, d6-DMSO).delta.:
1.41-1.49 (2H, m), 1.77-1.82 (2H, m), 1.84-1.89 (2H, m), 2.15-2.22
(4H, m), 2.41-2.48 (3H, m), 2.71 (2H, t, J = 6.0 Hz), 3.66 (2H, t,
J = 6.0 Hz), 4.76 (1H, s), 6.61-6.63 (1H, m), 7.36-7.37 (1H, m),
8.50 (1H, s), 10.79 (1H, s), 11.92 (1H, s). MS: 378 (M + H)+ 499 41
1H-NMR (400 MHz, d6-DMSO).delta.: 1.42-1.49 (2H, m), 1.73-1.80 (4H,
m), 1.83-1.89 (2H, m), 1.97-2.03 (2H, m), 2.09-2.13 (1H, m),
2.18-2.23 (2H, m), 2.68 (2H, t, J = 6.0 Hz), 3.61 (2H, t, J = 6.0
Hz), 4.17-4.21 (1H, m), 6.48 (1H, dd, J = 1.9, 3.5 Hz), 6.99 (1H,
br), 7.12 (1H, dd, J = 2.5, 3.5 Hz), 7.79 (1H, br), 8.37 (1H, s),
10.11 (1H, d, J = 8.3 Hz), 11.46 (1H, s). MS: 390 (M + H)+ 500 41
1H-NMR (400 MHz, d6-DMSO).delta.: 1.42-1.48 (2H, m), 1.71-1.90 (7H,
m), 2.10-2.20 (4H, m), 2.68 (2H, t, J = 5.9 Hz), 3.59 (2H, t, J =
5.9 Hz), 5.07 (1H, d, J = 8.7 Hz), 7.12 (1H, br), 7.86 (1H, br),
8.05 (1H, s), 8.45 (1H, s), 9.97 (1H, d, J = 8.7 Hz), 12.78 (1H,
br). MS: 381 (M + H)+ 501 41 1H-NMR (400 MHz, d6-DMSO).delta.:
1.53-1.60 (2H, m), 1.70-1.79 (6H, m), 1.87-1.95 (2H, m), 2.08-2.15
(1H, m), 2.21-2.27 (2H, m), 2.69 (2H, t, J = 6 Hz), 3.58 (2H, t, J
= 6 Hz), 4.99 (1H, d, J = 8.6 Hz), 7.18 (1H, br), 7.89 (1H, br),
8.06 (1H, s), 8.46 (1H, s), 10.05 (1H, d, J = 8.6 Hz), 12.79 (1H,
br). MS: 381 (M + H)+ 502 41 1H-NMR (400 MHz, d6-DMSO).delta.:
1.43-1.51 (2H, m), 1.77-1.80 (2H, m), 1.83-1.90 (2H, m), 2.03-2.09
(2H, m), 2.12-2.17 (1H, m), 2.33-2.40 (3H, m), 2.70 (2H, t, J = 6.0
Hz), 2.89-2.93 (2H, m), 3.61 (2H, t, J = 6.0 Hz), 4.87 (1H, s),
7.98 (1H, s), 10.94 (1H, s), 12.95 (1H, br). MS: 379 (M + H)+ 503
41 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.52 (2H, m), 1.79-1.84
(2H, m), 1.87-1.95 (2H, m), 2.06-2.10 (2H, m), 2.14-2.19 (1H, m),
2.28-2.38 (2H, m), 2.95-3.02 (2H, m), 4.48 (2H, s), 4.82 (1H, s),
7.98 (1H, s), 8.33 (1H, s), 10.95 (1H, s), 12.99 (1H, br). MS: 356
(M + H)+ 504 43 1H-NMR (400 MHz, d6-DMSO).delta.: 1.83-1.90 (2H,
m), 1.93-1.99 (2H, m), 2.08-2.13 (1H, m), 2.23-2.29 (5H, m),
2.32-2.36 (3H, m), 4.27 (1H, d, J = 7.8 Hz), 6.6 (1H, d, J = 1.9
Hz), 7.3 (1H, t, J = 2.3 Hz), 7.53 (1H, br), 8.16 (1H, br), 8.47
(1H, s), 10.94 (1H, s), 12.11 (1H, s). MS: 389, 391 (M + H)+ 505 43
1H-NMR (400 MHz, d6-DMSO).delta.: 1.22-2.33 (10H, m), 4.12 (1H, m),
6.44 (1H, m), 7.03 (1H, m), 7.14 (1H, m), 7.64 (1H, m), 8.39 (1H,
s), 10.25 (1H, m), 11.48 (1H, s). MS: 345 (M + H)+ 506 43 1H-NMR
(400 MHz, d6-DMSO).delta.: 1.68-2.38 (13H, m), 4.98-5.02 (1H, m),
7.08 (1H, brs), 7.90 (1H, brs), 8.06 (1H, s), 8.47 (1H, s), 10.4
(1H, d, J = 8.6 Hz), 12.7 (1H, brs). MS: 330 (M + H)+ 507 45 MS:
366 (M + H)+ 508 46 MS: 388 (M + H)+ 509 46 MS: 387 (M + H)+ 510 46
MS: 397 (M + H)+ 511 46 MS: 363 (M + H)+ 512 46 MS: 405 (M + H)+
513 46 MS: 749 (M + H)+ 514 46 MS: 381 (M + H)+ 515 46 MS: 314 (M +
H)+ 516 46 MS: 328 (M + H)+ 517 46 MS: 356 (M + H)+ 518 46 MS: 368
(M + H)+ 519 46 MS: 370 (M + H)+ 520 46 MS: 377 (M + H)+ 521 46 MS:
379 (M + H)+ 522 46 MS: 382 (M + H)+ 523 46 MS: 394 (M + H)+ 524 46
MS: 378 (M + H)+ 525 46 MS: 378 (M + H)+ 526 46 MS: 393 (M + H)+
527 46 MS: 426 (M + H)+ 528 46 MS: 342 (M + H)+ 529 46 MS: 384 (M +
H)+ 530 47 MS: 368 (M + H)+ 531 47 MS: 354 (M + H)+ 532 47 MS: 354
(M + H)+ 533 47 MS: 354 (M + H)+ 534 47 MS: 368 (M + H)+ 535 47
1H-NMR (400 MHz, d6-DMSO).delta.: 1.13-1.27 (1H, m), 1.43-1.52 (2H,
m), 1.62-1.73 (4H, m), 1.78-1.91 (5H, m), 2.07-2.42 (6H, m),
3.54-3.67 (5H, m), 4.00-4.13 (1H, m), 4.53 (1H, brs), 6.35-6.43
(1H, m), 7.18-7.20 (1H, m), 7.70 (1H, s), 7.82 (1H, m), 11.64 (1H,
brs). MS: 383 (M + H)+ 536 49 MS: 440 (M + H)+ 537 47 1H-NMR (400
MHz, d6-DMSO).delta.: 1.58-2.42 (8H, m), 3.04-3.66 (4H, m),
4.19-4.38 (1H, m), 6.37-6.54 (1H, m), 6.87-7.96 (8H, m), 8.36 (1H,
s), 10.08-10.26 (1H, m), 11.42 (1H, brs). MS: 376 (M + H)+ 538 49
MS: 421 (M + H)+ 539 49 MS: 408 (M + H)+ 540 49 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.47-2.22 (9H, m), 4.59 (1H, m), 4.83 (2H, m),
6.59 (1H, m), 6.98 (1H, m), 7.20 (1H, m), 7.73 (1H, m), 8.33 (1H,
m), 8.37 (1H, m), 9.34 (1H, m), 11.53 (1H, s). MS: 389 (M + H)+ 541
49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.49-2.36 (7H, m), 4.63 (1H,
m), 4.91 (2H, m), 6.61 (1H, m), 6.98 (1H, m), 7.21 (1H, m), 7.77
(1H, m), 8.32 (1H, m), 9.15 (2H, m), 9.39 (1H, m), 11.54 (1H, s).
MS: 409 (M + H)+ 542 49 MS: 442, 444 543 49 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.41-2.33 (8H, m), 4.61 (1H, m), 4.86 (2H, m),
6.60 (1H, m), 6.95 (1H, m), 7.21 (1H, m), 7.32 (1H, m), 7.74 (1H,
m), 7.88 (1H, m), 8.32 (1H, m), 9.34 (1H, m), 11.53 (1H, s). MS:
389 (M + H)+ 544 49 MS: 394 (M + H)+ 545 49 MS: 389 (M + H)+ 546 49
1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-1.51 (2H, m), 1.59-1.62 (2H,
m), 1.66-1.71 (2H, m), 1.81-1.92 (4H, m), 2.07-2.10 (1H, m),
2.28-2.31 (2H, m), 3.69-3.87 (8H, m), 4.20-4.24 (1H, m), 4.47 (1H,
s), 6.59-6.61 (1H, m), 6.96 (1H, d, J = 9.0 Hz), 7.28-7.29 (1H, m),
7.91 (1H, dd, J = 2.4, 9.1 Hz), 8.52-8.53 (1H, m), 8.66 (1H, s),
8.86-8.89 (1H, m), 11.90 (1H, brs). MS: 566 (M + H)+ 547 49 MS: 405
(M + H)+ 548 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.75-1.87 (2H,
m), 1.98-2.14 (2H, m), 2.14-2.33 (4H, m), 4.25-4.35 (1H, m),
4.50-4.83 (2H, m), 6.38-6.45 (1H, m), 6.85 (1H, d, J = 9.0 Hz),
7.03-7.10 (1H, m), 7.05 (1H, br), 7.83 (1H, br), 7.85 (1H, dd, J =
9.0, 2.2 Hz), 8.38 (1H, s), 8.51 (1H, d, J = 2.2 Hz), 10.36 (1H, d,
J = 7.7 Hz), 11.43 (1H, s) MS: 388 (M + H)+
549 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.75-1.87 (2H, m),
1.98-2.14 (2H, m), 2.14-2.33 (4H, m), 4.25-4.35 (1H, m), 4.50-4.83
(2H, m), 6.38-6.45 (1H, m), 6.85 (1H, d, J = 9.0 Hz), 7.03-7.10
(1H, m), 7.05 (1H, br), 7.83 (1H, br), 7.85 (1H, dd, J = 9.0, 2.2
Hz), 8.38 (1H, s), 8.51 (1H, d, J = 2.2 Hz), 10.36 (1H, d, J = 7.7
Hz), 11.43 (1H, s). MS: 388 (M + H)+ 550 49 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.83-1.94 (2H, m), 2.01-2.18 (2H, m), 2.18-2.36
(4H, m), 4.27-4.38 (1H, m), 4.46-5.09 (2H, m), 6.38-6.45 (1H, m),
6.87 (1H, d, J = 9.5 Hz), 7.04-7.11 (1H, m), 7.05 (1H, br), 7.83
(1H, br), 8.24 (1H, dd, J = 9.5, 2.8 Hz), 8.39 (1H, s), 9.01 (1H,
d, J = 2.8 Hz), 10.38 (1H, d, J = 7.7 Hz), 11.45 (1H, s). MS: 408
(M + H)+ 551 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.69-1.84 (2H,
m), 1.99-2.14 (2H, m), 2.14-2.36 (4H, m), 4.24-4.34 (1H, m),
4.54-4.75 (2H, m), 6.38-6.44 (1H, m), 6.88 (1H, d, J = 8.9 Hz),
7.02-7.07 (1H, m), 7.06 (1H, br), 7.79 (1H, dd, J = 8.9, 2.5 Hz),
7.80 (1H, br), 8.38 (1H, s), 8.42-8.45 (1H, m), 10.35 (1H, d, J =
7.7 Hz), 11.42 (1H, s). MS: 431 (M + H)+ 552 49 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.83-1.95 (2H, m), 2.05-2.21 (2H, m), 2.21-2.41
(4H, m), 2.45 (3H, s), 4.42-4.52 (1H, m), 4.58-4.85 (2H, m),
6.54-6.60 (1H, m), 6.89 (1H, d, J = 8.9 Hz), 7.17-7.22 (1H, m),
7.87 (1H, dd, J = 8.9, 2.4 Hz), 8.53 (1H, dd, J = 2.4, 0.4 Hz),
8.59 (1H, s), 9.26 (1H, d, J = 7.6 Hz), 11.79 (1H, s). MS: 427 (M +
H)+ 553 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.80-2.00 (4H, m),
2.11-2.22 (2H, m), 2.29-2.42 (2H, m), 4.28-4.40 (3H, m), 6.42-6.48
(1H, m), 6.89 (1H, dd, J = 8.0, 4.6 Hz), 7.04 (1H, br), 7.05-7.10
(1H, m), 7.74 (1H, br), 8.21 (1H, dd, J = 8.0, 1.7 Hz), 8.37 (1H,
s), 8.42 (1H, dd, J = 4.6, 1.7 Hz), 10.27 (1H, d, J = 7.7 Hz),
11.41 (1H, s). MS: 408 (M + H)+ 554 49 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.55-1.65 (2H, m), 2.02-2.25 (6H, m), 4.38-4.44
(2H, m), 5.55-5.65 (1H, m), 7.10 (1H, brs), 7.82 (1H, brs), 8.05
(1H, s), 8.11 (1H, s), 8.42 (1H, s), 9.18 (1H, d, J = 8.5 Hz), 12.9
(1H, brs). MS: 395 (M + H)+ 555 49 1H-NMR (400 MHz,
d6-DMSO).delta.: 1.60-1.67 (2H, m), 1.96-2.06 (4H, m), 2.16-2.21
(2H, m), 4.50-4.60 (2H, m), 4.99 (1H, brs), 6.59 (1H, s), 7.00 (1H,
brs), 7.20 (1H, s), 7.80 (1H, brs), 8.22 (1H, d, J = 1.9 Hz), 8.34
(1H, s), 8.55 (1H, d, J = 1.9 Hz), 9.43 (1H, d, J = 8.5 Hz), 11.5
(1H, s). MS: 422 (M + H)+ 556 49 1H-NMR (400 MHz, d6-DMSO).delta.:
1.22-2.03 (8H, m), 4.58-4.67 (5H, m), 5.38 (1H, brs), 6.58-6.59
(1H, m), 6.97 (1H, brs), 7.19-7.25 (2H, m), 7.44-7.46 (1H, m), 7.75
(1H, brs), 8.31 (1H, s), 9.30 (1H, d, J = 8.0 Hz), 11.54 (1H, s).
MS: 394 (M + H)+ 557 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.30-2.15
(8H, m), 4.34 (2H, brs), 4.55-4.56 (1H, m), 6.57-6.58 (1H, m), 6.95
(1H, brs), 7.18-7.20 (1H, m), 7.86 (1H, brs), 8.00 (1H, s), 8.34
(1H, s), 9.39 (1H, d, J = 8.0 Hz), 11.55 (1H, brs). MS: 394 (M +
H)+ 558 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.56-2.56 (8H, m),
3.69 (3H, s), 4.66-4.85 (3H, m), 6.66 (1H, s), 7.25-7.35 (2H, m),
7.85-7.94 (1H, m), 8.35-8.43 (1H, m), 9.33-9.45 (1H, m), 11.53 (1H,
m). MS: 422 (M + H)+ 559 49 1H-NMR (400 MHz, d6-DMSO).delta.:
1.23-2.32 (8H, m), 4.60-4.80 (3H, m), 6.61 (1H, s), 7.24-7.36 (2H,
m), 7.85-8.40 (6H, m), 9.27-9.37 (1H, m), 11.53 (1H, brs). MS: 405
(M - H)- 560 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.96-1.98 (2H,
m), 2.15-2.20 (2H, m), 2.31-2.37 (2H, m), 2.51-2.58 (2H, m), 4.33
(1H, m), 5.00 (2H, s), 5.96 (1H, s), 6.94-6.97 (1H, m), 7.37 (1H,
t, J = 3.0 Hz), 7.90 (1H, s), 8.14 (1H, dd, J = 1.8, 7.7 Hz), 8.47
(1H, dd, J = 2.0, 4.8 Hz), 10.95 (1H, s), 11.60 (1H, s). MS: 386 (M
+ H)+ 561 49 1H-NMR (400 MHz, d6-DMSO).delta.: 1.71-1.73 (2H, m),
1.98-1.99 (2H, m), 2.13 (2H, m), 2.43-2.54 (4H, m), 4.81 (2H, s),
5.10 (1H, brs), 7.07 (1H, d, J = 4.9 Hz), 7.44 (1H, s), 7.90 (1H,
s), 8.41 (1H, d, J = 5.1 Hz), 10.97 (1H, s), 11.52 (1H, s). MS: 386
(M + H)+, 408 (M + Na)+ 562 49 1H-NMR (400 MHz, d6-DMSO).delta.:
1.94-1.96 (2H, m), 2.15 (2H, m), 2.26-2.32 (2H, m), 2.47-2.54 (2H,
m), 4.04 (1H, m), 4.77 (1H, s), 5.59 (1H, brs), 7.06 (1H, d, J =
5.2 Hz), 7.32 (1H, brs), 7.48 (1H, s), 7.88 (1H, s), 8.39 (1H, d, J
= 5.0 Hz), 10.92 (1H, s), 11.58 (1H, s). MS: 386 (M + H)+ 563 49
1H-NMR (400 MHz, d6-DMSO).delta.: 1.97-1.99 (2H, m), 2.16 (2H,
brs), 2.28-2.35 (2H, m), 2.46-2.54 (2H, m), 4.03 (1H, m), 4.83 (2H,
s), 5.70 (1H, s), 7.70 (1H, d, J = 9.0 Hz), 7.33 (1H, s), 7.88 (1H,
s), 7.98 (1H, dd, J = 2.4, 9.0 Hz), 8.60 (1H, d, J = 2.4 Hz), 10.94
(1H, s), 11.60 (1H, s). MS: 386 (M + H)+ 564 50 MS: 394 (M + H)-
565 50 1H-NMR (400 MHz, d6-DMSO).delta.: 1.46-2.22 (13H, m), 2.59
(3H, s), 4.09 (1H, m), 4.55 (1H, s), 6.49 (1H, m), 7.16 (1H, m),
8.58 (1H, s), 10.67 (1H, m), 11.71 (1H, s). MS: 326.2 (M + H)+ 566
50 MS: 410 (M + H)+ 567 50 1H-NMR (400 MHz, d6-DMSO).delta.:
1.43-1.50 (4H, m), 1.63 (6H, s), 1.65-1.74 (3H, m), 1.87-1.94 (3H,
m), 2.03-2.11 (1H, m), 2.21-2.24 (2H, m), 4.30-4.34 (1H, m), 4.53
(1H, s), 6.06 (1H, s), 6.49-6.51 (1H, m), 7.23-7.25 (1H, m),
7.84-7.87 (1H, m), 8.71 (1H, s), 11.63 (1H, brs). MS: 410 (M + H)+
568 53 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.33 (7H, m), 3.80
(3H, s), 4.07 (1H, m), 4.46 (1H, m), 6.07 (2H, s), 6.43 (1H, m),
7.11 (1H, m), 8.13 (1H, s), 8.84 (1H, m), 11.31 (1H, s). MS: 356 (M
+ H)+ 569 53 1H-NMR (400 MHz, d6-DMSO).delta.: 1.40-2.45 (13H, m),
4.11 (1H, m), 4.44 (1H, s), 6.45 (1H, m), 7.14 (1H, m), 7.86 (1H,
s), 8.32 (1H, s), 8.60 (1H, m), 10.77 (1H, s), 11.41 (1H, s). MS:
327 (M + H)+ 570 53 1H-NMR (400 MHz, d6-DMSO).delta.: 1.47-2.25
(7H, m), 2.31 (3H, s), 3.96 (3H, s), 4.10 (1H, m), 4.50 (1H, s),
6.46 (1H, m), 7.13 (1H, m), 8.16 (1H, s), 9.12 (1H, m), 11.39 (1H,
s). MS: 328 (M + H)+ 571 53 1H-NMR (400 MHz, d6-DMSO).delta.:
1.29-2.27 (12H, m), 2.31 (3H, s), 4.09 (1H, m), 4.32-4.37 (2H, m),
6.44 (1H, m), 7.12 (1H, m), 8.11 (1H, s), 9.33 (1H, m), 10.88 (1H,
s), 11.32 (1H, s). MS: 341 (M + H)+ 572 54 MS: 398 (M + H)+ 573 54
MS: 366 (M + H)+ 574 54 MS: 439 (M - H)+ 575 54 MS: 384 (M + H)+
576 54 MS: 440 (M - H)- 577 54 MS: 384 (M + H)+ 578 55 1H-NMR (400
MHz, d6-DMSO).delta.: 1.36-1.42 (2H, m), 1.57-1.69 (4H, m),
1.73-1.79 (2H, m), 1.93-1.99 (2H, m), 2.05-2.09 (1H, m), 2.27-2.31
(2H, m), 4.00-4.04 (1H, m), 4.48 (1H, s), 6.11 (1H, d, J = 16.1
Hz), 6.10-6.13 (1H, m), 6.42-6.44 (1H, m), 7.16-7.18 (1H, m), 7.91
(1H, d, J = 16.1 Hz), 8.21 (1H, s), 11.53 (1H, brs). MS: 335 (M +
H)+ 579 61 1H-NMR (400 MHz, d6-DMSO).delta.: 1.45-2.69 (13H, m),
4.19 (1H, m), 4.53 (1H, s), 6.54 (1H, m), 7.25 (1H, m), 8.43 (1H,
s), 8.75 (1H, m), 11.68 (1H, s), MS: 367 (M + H)+, 365 (M - H)-
* * * * *